Methods and compositions for nucleoside triphosphate and ribonucleic acid production

ABSTRACT

Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.

RELATED APPLICATION

This application is a continuation of international application number PCT/US2018/055353 filed Oct. 11, 2018, which claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application No. 62/571,071, filed Oct. 11, 2017, each of which is incorporated by reference herein in its entirety.

BACKGROUND

Ribonucleic acid (RNA) comprises repeating units of ribonucleotides and plays a role in key cellular processes, including gene expression and protein synthesis. Thus, RNA is an attractive target for modulating fundamental processes of the cell, for example, RNA vaccines that induce a cellular immune response. Low-cost production of RNA on a commercial scale (e.g., grams to kilograms), however, is challenging due in part to the cost of the starting material (e.g., nucleoside triphosphates (NTPs)) and reaction components (e.g., DNA template and polymerase). Providing high-quality RNA at commercially relevant scales requires cost efficient production of both NTPs and RNA.

SUMMARY

Provided herein are systems, methods, compositions (e.g., cells, cell lysates, reagents, and reaction mixtures), and kits for low-cost production (biosynthesis) of NTPs and/or RNAs, using biosynthetic pathways developed to utilize low-cost substrates (e.g., cellular RNA, nucleobases, nucleosides, nucleoside monophosphates (NMPs), and/or nucleoside diphosphates (NDPs)), recombinant and/or endogenous enzymes (e.g., kinases and/or polymerases), and energy sources (e.g., NTPs, polyphosphate, and/or pyrophosphate). The production of NTPs and/or RNA, in some embodiments, is achieved using in vitro and/or cell-free lysate systems designed to minimize (e.g., reduce, inhibit, and/or remove) undesired enzymatic activities, thus increasing efficiency of the process and yield of the desired end product.

The biosynthetic pathways described herein typically utilize polyphosphate kinase and polyphosphate as an alternative to endogenous pathway enzymes and phosphate sources.

Thus, some aspects of the present disclosure provide methods and compositions for producing NTPs that comprise incubating in a reaction mixture NDPs (e.g., ADP, CDP, GDP, and/or UDP), a polyphosphate kinase (e.g., PPK2), and a polyphosphate (e.g., hexametaphosphate) under conditions suitable for the production of NTPs. As shown in FIG. 2A, PPK transfers a phosphate from polyphosphate to ADP, CDP, GDP, and UDP, resulting in production of ATP, CTP, GDP, and UTP. In some embodiments, this reaction mixture further comprises a NDP kinase (e.g., ndk).

Other aspects of the present disclosure provide systems, methods, compositions, and kits for producing NTPs that comprise incubating in a reaction mixture NMPs (e.g., 5′-NMPs, such as 5′-AMP, 5′-GMP, 5′-GMP, and/or 5′-UMP), a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture further comprises a NMP kinase or a NDP kinase (e.g., ndk). In some embodiments, the reaction mixture further comprises a NMP kinase (e.g., adk, cmk, gmk, and/or pyrH) and a NDP kinase (e.g., ndk).

Still other aspects of the present disclosure provide systems, methods, compositions, and kits for producing NTPs that comprise incubating in a reaction mixture nucleosides (e.g., adenosine, cytidine, guanosine, and/or uridine), a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, or a NDP kinase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and a NDP kinase.

Further aspects of the present disclosure provide systems, methods, compositions, and kits for producing NTPs that comprise incubating in a reaction mixture nucleobases (e.g., adenine, cytosine, guanine, and/or uracil), a phosphoribosyltransferase, a phosphoribosylpyrophosphate, a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, or a NDP kinase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and a NDP kinase.

In some embodiments, the starting material (e.g., NMPs, NDPs, and/or nucleosides) for the biosynthesis of NTPs is produced from cellular RNA. Thus, some aspects of the present disclosure provide systems, methods, compositions, and kits for producing NTPs that comprise (a) incubating in a reaction mixture cellular RNA (e.g., obtained from unicellular or multicellular organisms), a polynucleotide phosphorylase (PNPase), and inorganic phosphate under conditions suitable for the production of nucleoside diphosphates (NDPs); (b) eliminating the PNPase (and optionally eliminating other undesired enzymatic activities); and (c) incubating in the resulting reaction mixture the NDPs, a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture of step (c) further comprises a NDP kinase. Alternatively, the methods may comprise (a) incubating in a reaction mixture cellular ribonucleic acid (RNA), a PNPase, inorganic phosphate, a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of nucleoside diphosphates (optionally wherein the reaction mixture further comprises a NDP kinase); (b) eliminating the PNPase; and (c) incubating the reaction mixture under conditions suitable for the production of NTPs. In some embodiments, the required pathway enzymes (e.g., polyphosphate kinase and/or NDP kinase) can withstand the elimination conditions (e.g., exposure to high temperature or a chemical inhibitor) such that they retain their activity (for example, at least 50% of their activity) following exposure to the conditions used to eliminate (e.g., reduce, inhibit and/or remove) the PNPase.

Other aspects of the present disclosure provide systems, methods, compositions, and kits for producing NTPs that comprise (a) incubating in a first reaction mixture cellular RNA and a ribonuclease (RNase, for example RNase R or Nuclease P1) under conditions suitable for the production of NMPs (e.g., 5′-NMPs); (b) eliminating the RNase (and optionally v other undesired enzymatic activities); and (c) incubating in the resulting reaction mixture the NMPs, a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture of step (c) further comprises a NMP kinase, a NDP kinase, or both a NMP kinase and a NDP kinase. Alternatively, the methods may comprise (a) incubating in a reaction mixture cellular RNA, a RNase, a polyphosphate kinase, and a polyphosphate under conditions suitable for the production of NMPs (e.g., 5′-NMPs); (b) eliminating the RNase; and (c) incubating the reaction mixture under conditions suitable for the production of NTPs.

The NTPs produced herein are used, in some embodiments, for the production of RNA (e.g., mRNA or double-stranded RNA). This may be achieved, for example, by adding DNA template and polymerase (e.g., T7 RNA polymerase) to any of the reaction mixtures used for the production of NTP, as described herein. Alternatively, the NTPs may be isolated and combined with DNA template and polymerase in a separate reaction mixture to produce RNA. Thus, the present disclosure also provides methods and compositions for the production of RNA.

In any of the biosynthetic pathways described herein the nucleobases, nucleosides, NMPs, NDPs, or NTPs, when used as the starting substrate, may be chemically synthesized, a product of fermentation, or produced by other means.

The polyphosphate kinase used in the systems, reaction mixtures, and methods described herein may be selected from any of the polyphosphate kinases listed in Table 2 or 12. In some embodiments, the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

The polyphosphate may be any polyphosphate that serves as a substrate for a pathway enzymes. In some embodiments, the polyphosphate is hexametaphosphate.

In embodiments where cellular RNA is used, the cellular RNA comprises, for example, ribosomal RNA, messenger RNA, and/or transfer RNA. The cellular RNA may be from a unicellular organism (e.g., bacteria or yeast) or a multicellular organism (e.g., plants).

Enzymes of the biosynthetic pathways useful in the present disclosure may be obtained from (isolated and/or purified) a (at least one) cell lysate prepared from, for example, cells (e.g., engineered cells) that express enzymes of the pathway (e.g., nucleases (such as RNases and/or PNPases), polyphosphate kinases, NMP kinases, NDP kinase, and/or polymerases). Exemplary methods for preparing these cell lysates are described herein. Alternatively, the reaction mixture may comprise a cell lysate (a single cell lysate or a mixture of cell lysates) prepared from cells (e.g., engineered cells) that express enzymes of the pathway. That is, a complete reaction may be performed in a cell lysate or a mixture of cell lysates containing recombinant enzymes and/or endogenous enzymes of the pathway as well as other reaction components (e.g., polyphosphate) required for the production of NTPs. In some embodiments, a (at least one) purified pathway enzyme is added to a reaction mixture.

For reaction mixtures that include cell lysate(s) or enzymes obtained from cell lysate(s), it may be advantageous to eliminate undesired native enzymatic activities using any of the elimination methods described herein. Undesired native enzymatic activities include, for example, phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases. In some embodiments, native enzymatic activity is eliminated via genetic modification, enzyme secretion from a cell, localization (e.g., periplasmic targeting), and/or protease targeting. In other embodiments, native enzymatic activity is eliminated via temperature, pH, salt, detergent, alcohol or other solvents, and/or chemical inhibitors. In yet other embodiments, native enzymatic activity is eliminated via separation, precipitation, filtration, capture, and/or chromatography.

The details of several embodiments of the invention are set forth in the accompanying Examples, Figures and the Detailed Description. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows biosynthetic pathways for the production of nucleoside triphosphates (NTPs), and downstream ribonucleic acid (RNA) using nucleotide starting materials. FIG. 1B shows examples of high-energy phosphate strategies where polyphosphate is fed to the reaction mixture. FIG. 1C shows examples of additional high-energy phosphate strategies.

FIG. 2A shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using nucleoside diphosphates (NDPs) as the starting materials. FIG. 2B shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using 5′ nucleoside monophosphates (5′-NMPs) as the starting materials. FIG. 2C shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using nucleosides as the starting materials. FIG. 2D shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using nucleobases as the starting materials. FIG. 2E shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using nucleobases and ribose as the starting materials.

FIG. 3A shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using cellular RNA as the starting material. In this pathway, a polynucleotide phosphorylase is used to degrade cellular RNA into NDPs. FIG. 3B shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using cellular RNA as the starting material. In this pathway, a ribonuclease is used to degrade cellular RNA into NMPs.

FIG. 4A shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using only polyphosphate kinases. FIG. 4B shows a biosynthetic pathway for the production of NTPs, and downstream RNA, using both polyphosphate kinases (e.g., PPK2) and ATP/ADP-dependent kinases (e.g., NMP kinases such as adk, cmk, gmk, and/or pyrH, and/or NDP kinases such as ndk).

FIG. 5 shows a biosynthetic pathway for the production of RNA starting from 5′-NMPs.

FIG. 6 shows a biosynthetic pathway for the production of RNA starting from cellular RNA. The schematic shows an example in which the template, the kinase, and the polymerase are added during a RNA production reaction.

FIG. 7 shows a biosynthetic pathway for the production of RNA starting from cellular RNA. The schematic shows an example in which the template may be added during the depolymerization phase or the RNA production phase, the kinase may be added during the depolymerization phase or the RNA production phase, and the polymerase may added during the depolymerization phase or the RNA production phase.

FIG. 8A shows a graph of acid-soluble nucleotides (mM) produced over time during depolymerization of RNA from E. coli lysates using overexpressed RNase R. Acid-soluble nucleotides were measured by UV absorbance.

FIG. 8B shows an agarose gel of RNA products produced in reactions comprising RNA polymerase and NMPs produced by depolymerization (−NMPs) or purified NMPs (+NMPs, 4 mM each). Abbreviations: −2 log: 2-log DNA ladder (New England Biolabs), NMPs: equimolar mix of 5-NMPs, RNA Pol: thermostable T7 RNA polymerase, Template 1: Linear DNA template, Template 2: Plasmid DNA template.

FIG. 9A shows a graph of acid-soluble nucleotides (mM) produced over time during depolymerization of purified RNA using 1 mg/mL purified RNase R. Acid-soluble nucleotides were measured by UV absorbance.

FIG. 9B shows an agarose gel of RNA products produced in reactions comprising RNA polymerase and NMPs produced by depolymerization of purified RNA. As a negative control, reaction were performed in the absence of RNA polymerase. Abbreviations: −2 log: 2-log DNA ladder (New England Biolabs), NMPs: equimolar mix of 5′-nucleoside monophosphates, RNA Pol: thermostable T7 RNA polymerase, Template 1: Linear DNA template, Template 2: Plasmid DNA template.

FIG. 10 shows an agarose gel of RNA products produced by cell-free RNA synthesis using a wild-type polymerase (W) or a thermostable polymerase mutant (T) at 37° C. Abbreviations: −2 log: 2-log DNA ladder (New England Biolabs), W: wild-type T7 RNA polymerase (New England Biolabs), T: thermostable T7 RNA polymerase, Template 1: Linear DNA template, Template 2: Plasmid DNA template.

FIG. 11A shows a plot of the response factor (calculated as ratio of area of the dsRNA of interest to that of a commercially-available dsRNA internal standard) of the reactions comprising either DgPPK2 as a sole kinase or the 5-enzyme lysate system.

FIG. 11B shows HPLC chromatograms of the dsRNA product produced in reactions comprising DgPPK2 lysate, 5-enzyme lysate system, and the negative controls without T7 RNA polymerase.

FIG. 12A shows a graph of acid-soluble nucleotides (mM) produced over time during depolymerization of various sources of RNA using purified RNase R or Nuclease P1. Acid-soluble nucleotides were measured by UV absorbance.

FIG. 12B shows a graph of the percent of available 5′-NMPs produced over time during depolymerization of RNA from E. coli or yeast using Nuclease P1. Percent of available 5′-NMPs was determined by LC-MS.

FIG. 13 shows nucleomic profile plots for RNA depolymerization across different temperatures of the lysate from GL17-109. Cumulative concentrations of the 20 analytes are shown. Nucleosides are shown in a white-speckled pattern, and were minimally produced. Data for 50° C. was collected but is not shown.

FIG. 14 is a schematic of an enzymatic pathway for production of ATP from pyrophosphate through the cyclical phosphorylation of acetate. The meaning of the abbreviations is as follows: AcK1=first acetate kinase, AcK2=second acetate kinase, PP_(i)=inorganic pyrophosphate, P_(i)=inorganic phosphate, ATP=adenosine triphosphate, ADP=adenosine diphosphate, and Acetyl-P=acetyl-phosphate.

FIG. 15A-15B is a schematic of an enzymatic pathway for production of ATP from citrate. FIG. 15A presents the three enzymatic reactions for ATP production from citrate and pyrophosphate. FIG. 15B presents the overall chemical reaction. The meaning of the abbreviations is as follows: PP_(i)=inorganic pyrophosphate, PEP=phosphoenolpyruvate, CO₂=carbon dioxide, P_(i)=inorganic phosphate, ATP=adenosine triphosphate, and AMP=adenosine monophosphate.

FIG. 16 is a schematic of an enzymatic pathway for production of ATP from sulfite. The meaning of the abbreviations is as follows: ATP=adenosine triphosphate, AMP=adenosine monophosphate, APS=adenosine 5′-phosphosulfate, and PP_(i)=inorganic pyrophosphate.

FIG. 17 is a graph showing that cell-free synthesis of dsRNA produces similar product titers regardless of nucleotide source.

FIG. 18 is a graph showing that cell-free synthesis of dsRNA results in comparable product titers with wild-type and thermostable mutant RNA polymerases at mesophilic reaction temperature.

FIG. 19 is a graph showing that cell-free synthesis of NTPs results in similar NTP titers regardless of nucleotide source after a 1 hour incubation at 48° C. For each source of nucleotides (cellular RNA, purified NMPs, or purified NDPs), a quantity of substrate sufficient to provide approximately 4 mM of each nucleotide was added to the reaction. For example, reactions with NDPs comprised 4 mM each ADP, CDP, GDP, and UDP.

DETAILED DESCRIPTION

The present disclosure provides, in some aspects, biosynthetic pathways for the production of NTPs and/or RNA that utilize cost-effective reaction components, such as cellular RNA substrates or monomeric substrates such as nucleobases, nucleosides, NMPs, or NDPs, recombinant and/or purified pathway enzymes (e.g., phosphoribosyltransferases, nucleoside phosphorylases, ribokinases, phosphopentomutaes, nucleases, polyphosphate kinases, NMP kinases, NDP kinases, nucleoside kinases, RNA polymerases), sources of high energy phosphate (e.g., polyphosphate), and/or DNA templates.

Reaction Components

Cellular RNA. Cellular RNA includes, for example, messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA) obtained from cellular material (biomass). Cellular RNA may be obtained from any source of cellular material including, but not limited to, unicellular organisms (e.g., bacteria and yeast) and multicellular organisms (e.g., plants and animals), either from fermentation or from a process waste stream, for example, cellular RNA obtained from a lysate expressing an enzyme (e.g., a kinase).

Nucleobases. A nucleobase is a nitrogenous base component of a nucleoside or nucleotide. Nucleobases function as fundamental units of the genetic code. Nucleobases include adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U). Nucleobases include modified nucleobases including, but not limited to, pseudouridine (Ψ), dihydrouridine (D), and 7-methylguanosine (m⁷G).

Nucleosides. A nucleoside is a nucleobase linked to a five-carbon sugar (e.g., a ribose). Examples of nucleosides include adenosine, cytidine, guanosine, thymidine and uridine.

Nucleotides. A nucleotide includes a nucleoside and a phosphate group. A nucleoside having one phosphate group is a nucleoside monophosphate (NMP), which include adenosine monophosphate (AMP), cytidine monophosphate (CMP), guanosine monophosphate (GMP), thymidine monophosphate (TMP), and uridine monophosphate (UMP). A nucleoside having two phosphate groups is a nucleoside diphosphate (NDP), which include adenosine diphosphate (ADP), cytidine diphosphate (CDP), guanosine diphosphate (GDP), thymidine diphosphate (TDP), and uridine diphosphate (UDP). A nucleoside having three phosphate groups is a nucleoside triphosphate (NTP), which include adenosine triphosphate (ATP), cytidine triphosphate (CTP), guanosine triphosphate (GTP), thymidine triphosphate (TTP), and uridine triphosphate (UTP).

Phosphoribosyltransferases. Phosphoribosyltransferases, such as adenine phosphoribosyltransferase (APRTase), is involved in the nucleotide salvage pathway in cells, which provides an alternative to nucleotide biosynthesis. APRTase catalyzes the following reaction in the purine nucleotide salvage pathway: Adenine+Phosphoribosyl Pyrophosphate (PRPP)→Adenosine 5′ monophosphate (AMP)+Pyrophosphate (PPi).

Ribokinases. Ribokinase is an enzyme that transfers phosphate from a high-energy phosphate source (e.g., ATP or polyphosphate) to D-ribose forming D-ribose-5-phosphate. Examples include the rbsK gene product of E. coli and the QT17_05185 gene product of Thermus sp. 2.9.

Phosphopentomutases. Phosphopentomutase is an enzyme that transfers phosphate within a ribose-phosphate molecule. Specifically, phosphoribomutase catalyzes the reversible interconversion of D-ribose-1-phosphate and D-ribose-5-phosphate. Examples include the deoB gene product of E. coli and the TM0167 gene product of Thermotoga maritima.

Nucleoside phosphorylases. Nucleoside phosphorylases are enzymes that catalyze the following reversible reaction—nucleobase+D-ribose-1-phosphate←→nucleoside+inorganic phosphate. Purine nucleoside phosphorylase catalyze such a reaction with purine nucleobases (e.g., adenine, guanine) and purine nucleosides (e.g., adenosine, guanosine). Pyrimidine nucleoside phosphorylases catalyze such a reaction with pyrimidine nucleobases (e.g., cytosine, uracil) and pyrimidine nucleosides (e.g, cytidine, uridine). Examples of nucleoside phosphorylases include the deoD, xapA, and udp gene products of E. coli, as well as the TtPNPI, TtPNPII, and TtPyNP, enzymes of Thermus thermophilus HB27.

Polynucleotide Phosphorylases. Polynucleotide phosphorylase (PNPase) is a bifunctional enzyme with a phosphorolytic 3′ to 5′ exoribonuclease activity and a 3′-terminal oligonucleotide polymerase activity. PNPase is capable of catalyzing the degradation of RNA into nucleoside 5′ diphosphates (NDPs) using inorganic phosphate as a co-substrate. Use of high concentrations of inorganic phosphate while employing PNPase to degrade RNA may simultaneously drive PNPase activity while reducing potential NDP yield loss due to phosphatase activities that might be present in the reaction mixture, as inorganic phosphate is known to inhibit such undesirable activities. In some embodiments, a PNPase is used, optionally in conjunction with one or more helicases, to catalyze degradation of RNA into NDPs. Adding a helicase may improve PNPase-meditated depolymerization of cellular RNA by improving accessibility of structured RNA.

Nucleases. Nucleases are enzymes that cleave the phosphodiester bonds in the backbone of DNA (DNases) or RNA (RNases). Thus, ribonucleases (RNases) are capable of catalyzing the degradation of RNA into nucleoside monophosphates (NMPs). Non-limiting examples of enzymes that may be used to depolymerize RNA, as provided herein, are provided in Table 1. In some embodiments, more than one nuclease is used in a reaction mixture to depolymerize RNA. In some embodiments, 2, 3, 4, or 5 different nucleases are used in a reaction mixture.

TABLE 1 Examples of Enzymes for RNA Depolymerization Enzyme Organism EC # UniProt Reference Nuclease P1 Penicillium citrinum 3.1.30.1 P24289 1, 2, 3 (P1 Nuclease) RNase II Escherichia coli 3.1.13.1 P30850 4, 5 RNase III Escherichia coli 3.1.26.3 P0A7Y0 6, 7, 8 RNase R Pseudomonas putida 3.1.13.— R9V9M9  9 or P21499 Escherichia coli RNase JI Bacillus subtilis 3.1.4.1 Q45493 10, 11 NucA Serratia marcescens 3.1.30.2 P13717 12, 13, 14 RNase T Escherichia coli 3.1.27.3 P30014 15, 16, 17 RNase E Escherichia coli 3.1.26.12 P21513 18, 19 PNPase Escherichia coli 2.7.7.8 P05055 55

Kinases. Kinases, generally, are enzymes that catalyze the transfer of phosphate groups from a high-energy phosphate-donating molecule (e.g., ATP, GTP, UTP, CTP, or polyphosphate containing n phosphate groups in the polymer) to specific substrates/molecules. This process produces a phosphorylated substrate and a dephosphorylated form of the high-energy phosphate-donating molecule (e.g., ADP, GDP, UDP, CDP, or polyphosphate containing n−1 phosphate groups in the polymer). Non-limiting examples of kinases for use as provided herein include NMP kinases, NDP kinases, nucleoside kinases, and polyphosphate kinases.

Polyphosphate Kinases. A polyphosphate kinase is an enzyme that catalyzes the transfer of phosphate group(s) from high-energy, phosphate-donating molecules, such as polyphosphate (PolyP_(n)), to specific substrates/molecules. This process is referred to as phosphorylation, where the substrate gains a phosphate group and the high-energy, phosphate-donating molecule donates a phosphate group. This transesterification produces a phosphorylated substrate and a phosphate-donating molecule lacking the donated phosphate group, such as PolyP_(n-1). The polyphosphate kinases of the present disclosure, in some embodiments, convert nucleosides to NMPs, NMPs to NDPs, and/or NDPs to NTPs. Non-limiting examples of polyphosphate kinases are provided in Table 2. In some embodiments, more than one polyphosphate kinase is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different polyphosphate kinases are used in a reaction mixture.

TABLE 2 Examples of Polyphosphate Kinases Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles PPK2 Deinococcus WP_011531362.1 SEQ ID 20 geothermalis NO: 1 DSM 11300 PPK2 Meiothermus ADD29239.1 SEQ ID 20 ruber NO: 2 DSM 1279 PPK2 Meiothermus WP_013159015.1 SEQ ID 20 silvanus NO: 3 DSM 9946 PPK2 Thermo- NP_682498.1 SEQ ID 20 synechococcus NO: 4 elongatus BP-1 PPK2 Anaerolinea WP_013558940 SEQ ID thermophila NO: 5 UNI-1 PPK2 Caldilinea WP_014433181 SEQ ID aerophila NO: 6 DSM 14535 PPK2 Chlorobaculum NP_661973.1 SEQ ID tepidum NO: 7 TLS PPK2 Oceanithermus WP_013458618 SEQ ID profundus NO: 8 DSM 14977 PPK2 Roseiflexus WP_012120763 SEQ ID castenholzii NO: 9 DSM 13941 PPK2 Roseiflexus WP_011956376 SEQ ID sp. RS-1 NO: 10 PPK2 Truepera WP_013178933 SEQ ID radiovictrix NO: 11 DSM 17093 Solvent-tolerant organisms PPK1 Pseudomonas AFO50238.1 42 putida I7BEV8 DOT-T1E PPK1 Escherichia AAC75554.1 coli P0A7B1 K-12 PPK1 Clostridium NP_347259.1 43 acetobutylicum Q97LE0 ATCC 824 Acidophiles PPK1 Thermosynechococcus elongatus WP_011056068 PPK1 Acidithiobacillus ferrooxidans WP_064219446 PPK1 Acidithiobacillus thiooxidans WP_031572361 PPK1 Bacillus acidicola WP_066264350 PPK1 Acetobacter aceti GAN58028 PPK2 Acetobacter aceti WP_077811826.1 PPK2 Acidithiobacillus thiooxidans WP_051690689.1 PPK2 Acidithiobacillus ferrooxidans WP_064219816.1 Alkaliphiles PPK1 Thioalkalivibrio denitrificans WP_077277945.1 Psychrophiles PPK1 Psychromonas ingrahamii WP_041766473.1 PPK2 Psychrobacter arcticus WP_083756052.1 PPK2 Psychroserpens jangbogonensis WP_033960485.1 PPK2 Cryobacterium psychrotolerans WP_092324020.1 PPK2 Nocardioides psychrotolerans WP_091116082.1 PPK2 Pseudomonas psychrophila WP_019411115.1

Nucleoside Kinases. Nucleoside kinases catalyze a phosphoryl transfer from a high-energy phosphate-donating molecule (e.g., a nucleotide triphosphate) to an R—OH acceptor, which is typically the 5′-hydroxyl group of the sugar moiety of the nucleoside (e.g., adenosine, guanosine, cytidine, uridine). This process converts a nucleoside to a NMP (e.g., AMP, CMP, GMP, UMP). In some embodiments, the nucleoside kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to adenosine to produce adenosine monophosphate (AMP). In some embodiments, the nucleoside kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to cytidine to produce cytidine monophosphate (CMP). In some embodiments, the nucleoside kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to guanosine to produce guanosine monophosphate (GMP). In some embodiments, the nucleoside kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to uridine to produce uridine monophosphate (UMP). Non-limiting examples of nucleoside kinases are provided in Table 3. In some embodiments, more than one nucleoside kinase is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different nucleoside kinases are used in a reaction mixture.

TABLE 3 Examples of Nucleoside Kinases GenBank # Enzyme Organism UniProt # Reference Thermophiles Nucleoside Thermoplasma CAC12009.1 21 kinase acidophilum Q9HJT3 Nucleoside Methanocaldococcus AAB98396.1 22 kinase jannaschii Q57849 Nucleoside Burkholderia ABC38537.1 23 kinase thailandensis AIP24308.1 Q2SZE4 Uridine- Thermus BAD70401.1 24 cytidine thermophilus Q5SKR5 kinase (Y93H mutant) Uridine kinase Caldilinea aerophila WP_014432899.1 Uridine kinase Geobacillus WP_043905564.1 stearothermophilus Uridine kinase Meiothermus ruber WP_013014613.1

NMP Kinases. A nucleoside monophosphate kinase (NMP kinase) is an enzyme that catalyzes the transfer of the terminal phosphoryl group from a nucleoside triphosphate (NTP), usually ATP, to the phosphoryl group on a nucleoside monophosphate (e.g., AMP, CMP, GMP, UMP). This process converts a NMP to a NDP (e.g., ADP, CDP, GDP, UDP). In some embodiments, the NMP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to AMP to produce adenosine diphosphate (ADP). In some embodiments, the NMP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to CMP to produce cytidine diphosphate (CDP). In some embodiments, the NMP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to GMP to produce guanosine diphosphate (GDP). In some embodiments, the NMP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to UMP to produce uridine diphosphate (UDP). Non-limiting examples of NMP kinases are provided in Table 4. In some embodiments, more than one NMP kinases is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different NMP kinases are used in a reaction mixture.

TABLE 4A Examples of AMP kinase enzymes Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles Adk Thermus thermophilus Q72I25 SEQ ID 25, 26 NO: 12 Adk Pyrococcus furiosus Q8U207 27 Solvent-tolerant organisms Adk Pseudomonas putida AFO48764.1 42 DOT-T1E I7CAA9 Adk Escherichia coli BAE76253.1 44 K-12 W3110 P69441 Adk1 Aspergillus niger CAK45139.1 45 CBS 513.88 A2QPN9 Adk1 Saccharomyces cerevisiae AAC33143.1 46 ATCC 204508/S288c P07170 Adk Clostridium acetobutylicum AAK81051.1 43 ATCC 824 Q97EJ9 Adk Halobacterium salinarum AAG19963.1 32 ATCC 700922 Q9HPA7 Acidophiles Adk Acidithiobacillus thiooxidans WP_024894015.1 Adk Acidithiobacillus ferrooxidans WP_064218420.1 Adk Acetobacter aceti WP_077811596.1 Adk Bacillus acidicola WP_066267988.1 Adk Sulfolobus solfataricus WP_009991241.1 Alkaliphiles Adk Thioalkalivibrio WP_019570706.1 Adk Amphibacillus xylanus WP_015008883.1 Psychrophiles Adk Colwellia psychrerythraea WP_033093471.1 28 (Vibrio psychroerythus) Q47XA8 Adk Psychromonas ingrahamii WP_011769361 A1STI3 Adk Pseudoalteromonas haloplanktis CAI86283 29 Q3IKQ1 Adk Psychrobacter arcticus WP_011280822 30 Adk Pseudomonas syringae WP_004406317.1 31 Q4ZWV2 Halophiles Adk Halobacterium halobium WP_010903261.1 32 Q9HPA7

TABLE 4B Examples of CMP kinase enzymes Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles Cmk Thermus thermophilus Q5SL35 SEQ ID 33 NO: 13 Cmk Pyrococcus furiosus Q8U2L4 27 Solvent-tolerant organisms Cmk Pseudomonas putida AFO48857.1 42 DOT-T1E I7BXE2 Cmk Escherichia coli AAC73996.1 47 K-12 MG1655 P0A6I0 Cmk Clostridium acetobutylicum AAK79812.1 43 ATCC 824 Q97I08 Cmk Halobacterium salinarum AAG19965.1 34 ATCC 700922 Q9HPA5 Acidophiles Cmk Bacillus acidicola WP_066270173 Cmk Acetobacter aceti WP_010667744 Cmk Acidithiobacillus thiooxidans WP_024892761.1 Cmk Acidithiobacillus ferrooxidans WP_064220349.1 Cmk Metallosphaera sedula WP_011921264.1 Alkaliphiles Cmk Amphibacillus xylanus WP_015009966.1 Cmk Thioalkalivibrio denitrificans WP_077278466.1 Psychrophiles Cmk Colwellia psychrerythraea WP_011043148.1 28 (Vibrio psychroerythus) Q482G4 Cmk Pseudoalteromonas haloplanktis CAI86499.1 29 Q3ILA1 Cmk Psychrobacter arcticus AAZ19343.1 30 Q4FRL5 Cmk Psychromonas ingrahamii ABM04716 A1SZ01 Cmk Pseudomonas syringae YP_236713 31 Q4ZQ97 Halophiles Cmk Halobacterium salinarum Q9HPA5 34

TABLE 4C Examples of UMP kinase enzymes Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles PyrH Pyrococcus furiosus Q8U122 SEQ ID 35, 36 NO: 14 PyrH Thermus thermophilus P43891 33 Solvent-tolerant organisms PyrH Pseudomonas putida AFO48412.1 42 DOT-T1E I7BW46 PyrH Escherichia coli CAA55388.1 48 K-12 MG1655 P0A7E9 An13g00440 Aspergillus niger CAK41445.1 45 CBS 513.88 A2R195 URA6 Saccharomyces cerevisiae AAA35194.1 49 ATCC 204508/S288c P15700 PyrH Clostridium acetobutylicum AAK79754.1 43 ATCC 824 Q97I64 PyrH Halobacterium salinarum AAG20182.1 34 ATCC 700922 Q9HNN8 Acidophiles PyrH Picrophilus torridus WP_048059653 PyrH Metallosphaera sedula WP_012021705 PyrH Ferroplasma WP_009886950.1 PyrH Thermoplasma acidophilum WP_010900913 PyrH Sulfolobus solfataricus WP_009992427 37 PyrH Acetobacter aceti WP_042788648 Alkaliphiles PyrH Thioalkalivibrio WP_081759172.1 sp. HK1 PyrH Amphibacillus xylanus WP_015010200.1 Psychrophiles PyrH Colwellia psychrerythraea WP_011042391.1 28 (Vibrio psychroerythus) Q485G8 PyrH Pseudoalteromonas haloplanktis CR954246.1 29 Q3IIX6 PyrH Psychrobacter arcticus AAZ19383.1 30 Q4FRH5 PyrH Psychromonas ingrahamii ABM04676.1 A1SYW1 PyrH Pseudomonas syringae YP_234434 31 Q4ZWS6 Halophiles PyrH Halobacterium salinarum WP_010903483.1 34 Q9HNN8

TABLE 4D Examples of GMP kinase enzymes Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles Gmk Thermotoga maritima Q9X215 SEQ ID 38 NO: 15 Gmk Thermus thermophilus Q5SI18 33 Solvent-tolerant organisms Gmk Pseudomonas putida AFO49847.1 42 DOT-T1E I7C087 Gmk Escherichia coli AAB88711.1 50 K-12 P60546 An08g00300 Aspergillus niger CAK45182.1 45 CBS 513.88 A2QPV2 GUK1 Saccharomyces cerevisiae AAA34657.1 51 ATCC 204508/S288c P15454 Gmk Clostridium acetobutylicum AAK79684.1 43 ATCC 824 Q97ID0 Acidophiles Gmk Acidithiobacillus ferrooxidans WP_064219869.1 Gmk Acidithiobacillus thiooxidans WP_010637919.1 Gmk Bacillus acidicola WP_066264774.1 Gmk Acetobacter aceti WP_018308252.1 Alkaliphiles Gmk Amphibacillus xylanus WP_015010280.1 Gmk Thioalkalivibrio sulfidiphilus WP_018953989.1 Psychrophiles Gmk Colwellia psychrerythraea AAZ24463 28 (Vibrio psychroerythus) Q47UB3 Gmk Pseudoalteromonas haloplanktis Q3IJH8 29 Gmk Psychrobacter arcticus WP_011280984.1 30 Q4FQY7 Gmk Psychromonas ingrahamii ABM05306 A1T0P1 Gmk Pseudomonas syringae WP_003392601.1 31 Q4ZZY8

NDP Kinases. A nucleoside diphosphate kinase (NDP kinase) is an enzyme that catalyzes the exchange of terminal phosphate between different NDPs (e.g., ADP, CDP, GDP, UDP) and nucleoside triphosphates (NTP) in a reversible manner to produce NTPs (e.g., ATP, CTP, GTP, UTP). In some embodiments, the NDP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to ADP to produce adenosine triphosphate (ATP). In some embodiments, the NDP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to CDP to produce cytidine triphosphate (CTP). In some embodiments, the NDP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to GDP to produce guanosine triphosphate (GTP). In some embodiments, the NDP kinase catalyzes the transfer of phosphate from a phosphate-donating molecule to UDP to produce uridine triphosphate (UTP). Non-limiting examples of NDP kinases are provided in Table 5. In some embodiments, more than one NDP kinase is used in a reaction mixture. In some embodiments, 2, 3, 4 or 5 different NDP kinases are used in a reaction mixture.

TABLE 5 Examples of NDP Kinases Sequence GenBank # Identification Enzyme Organism UniProt # Number Reference Thermophiles Ndk Aquifex aeolicus O67528 SEQ ID NO: 16 Solvent-tolerant organisms Ndk Pseudomonas putida AFO50002.1 42 DOT-T1E I7C0T7 Ndk Escherichia coli CAA40780.1 53 K-12 P0A763 An09g05870 Aspergillus niger CAK40394.1 45 CBS 513.88 A2QUJ6 YNK1 Saccharomyces cerevisiae AAS56589.1 ATCC 204508/S288c P36010 Ndk Clostridium acetobutylicum ABR36342.1 43 ATCC 824 A6M162 Ndk Halobacterium salinarum BAB17308.1 53 ATCC 700922 P61136 Acidophiles Ndk Acidithiobacillus thiooxidans WP_024892623.1 Ndk Acetobacter aceti WP_042787791.1 Ndk Picrophilus WP_011178084.1 Ndk Thermoplasma acidophilum WP_010901523.1 Ndk Sulfolobus solfataricus WP_009990482.1 Ndk Bacillus acidicola WP_066262668.1 Ndk Ferroplasma WP_009887649.1 Ndk Metallosphaera sedula WP_011921175.1 Psychrophiles Ndk Psychromonas ingrahamii WP_011771565.1 39 A1SZU8 Ndk Colwellia psychrerythraea WP_011044987.1 28 Q47WB6 Ndk Psychrobacter arcticus WP_011279964.1 30 Q4FTX1 Ndk Pseudoalteromonas haloplanktis CAI89189.1 Q3ID15 Halophiles Ndk Halobacterium salinarum WP_010902835.1 40 P61136 Ndk Natrialba magadii WP_004214013.1 41 D3SY02

Non-limiting examples of kinases that convert NDP to NTP include nucleoside diphosphate kinase, polyphosphate kinase, and pyruvate kinase. As discussed herein, thermostable variants of the foregoing enzymes are encompassed by the present disclosure. In some embodiments, the NDP kinase(s) is/are obtained from Aquifex aeolicus.

Phosphorylation of NMPs to NTPs occurs, in some embodiments, through the polyphosphate-dependent kinase pathway, where high-energy phosphate is transferred from polyphosphate to ADP via a polyphosphate kinase (PPK). In some embodiments, the polyphosphate kinase belongs to the polyphosphate kinase 1 (PPK1) family, which transfers high-energy phosphate from polyphosphate to ADP to form ATP. This ATP is subsequently used by NMP kinases (e.g., AMP kinase, UMP kinase, GMP kinase, and CMP kinase) to convert NMPs to their cognate ribonucleotide diphosphates (NDPs). Furthermore, ATP is subsequently used by nucleotide diphosphate kinase to convert NDPs to NTPs.

In some embodiments, the polyphosphate kinase belongs to the polyphosphate kinase 2 (PPK2) family. In some embodiments, the polyphosphate kinase belongs to a Class I PPK2 family, which transfers high-energy phosphate from polyphosphate to NDPs to form NTPs. ATP produced by the system is used as a high-energy phosphate donor to convert NMPs to NDPs. In some embodiments, the polyphosphate kinase belongs to a Class III PPK2 family, which transfers high-energy phosphate from polyphosphate to NMPs and NDPs to form NTPs. In some embodiments, Class III PPK2 is used alone to produce NTPs from NMPs. In other embodiments, Class III PPK2 is used in combination with other kinases. Class III PPK2 produces ATP from ADP, AMP, and polyphosphate, which is subsequently used by NMP and NDP kinases to convert NMPs to NTPs.

Non-limiting examples of PPK2 enzymes for use as provided herein are listed in Table 2. Thus, in some embodiments, the PPK2 enzymes are thermostable. For example, the PPK2 enzymes may be thermostable Class III PPK2 enzymes, which favor ATP synthesis over polyphosphate polymerization, and convert both ADP and AMP to ATP. In some embodiments, the PPK2 enzymes are used to convert a polyphosphate, such as hexametaphosphate to ATP, at rates ranging, for example, from 10 to 800 mM per hour (e.g., 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, or 800 mM per hour).

Polyphosphate and Other High Energy Phosphates. High energy phosphate molecules (phosphate-donating molecules) release energy upon hydrolysis of high energy bond, thereby providing an energy source for biochemical reactions. Polyphosphate (PolyP_(n)) and other high energy phosphate molecules may be used as phosphate sources for production of NTPs, and downstream production of RNA, as described herein. PolyP_(n), for example, comprises repeating units of phosphate (PO₄) linked together by shared oxygen atoms. Phosphorylation of specific substrates/molecules by kinases of the present disclosure involves donation of a phosphate group from PolyP_(n), thereby producing PolyP_(n-1).

The present disclosure is not limited by the number of phosphate groups in the polyphosphate. In some embodiments, PolyP_(n) comprises at least 3 phosphate groups (PolyP₃). In some embodiments, PolyP_(n) comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 phosphate groups. In some embodiments, PolyP_(n) is hexametaphosphate.

Other examples of high energy phosphate molecules include, but are not limited to NTP (e.g., ATP), NDP (e.g., ADP), NMP (e.g., AMP), phosphoenolpyruvate, 1,3-bisphosphoglycerate, phosphocreatine, phosphoenol pyruvate, glucose 1-phosphate, fructose 6-phosphate, and glucose 6-phosphate. In some embodiments, more than one high energy phosphate is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different high energy phosphates are used in a reaction mixture.

Templates. A DNA template includes a promoter, optionally an inducible promoter, operably linked to nucleotide sequence encoding a desired RNA product and, optionally, a transcriptional terminator. A DNA template is typically provided on a vector, such as a plasmid, although other template formats may be used (e.g., linear DNA templates generated by polymerase chain reaction (PCR), chemical synthesis, or other means known in the art). In some embodiments, more than one DNA template is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different DNA templates are used in a reaction mixture.

A promotor or a terminator may be a naturally-occurring sequence or an engineered sequence. In some embodiments, an engineered sequence is modified to enhance transcriptional activity. In some embodiments, the promotor is a naturally-occurring sequence. In other embodiments, the promoter is an engineered sequence. In some embodiments, the terminator is a naturally-occurring sequence. In other embodiments, the terminator is an engineered sequence.

Polymerases. Polymerases are enzymes that synthesize polymers of nucleic acids. Polymerases of the present disclosure include DNA-dependent RNA polymerases and RNA-dependent RNA polymerases. Non-limiting examples of polymerases are provided in Table 6. In some embodiments, a polymerase is a RNA polymerase, such as a T7 RNA polymerase. In some embodiments, more than one polymerase is used in a reaction mixture. In some embodiments, 2, 3, 4, or 5 different polymerases are used in a reaction mixture.

TABLE 6 Examples of RNA Polymerases GenBank # Enzyme Organism UniProt # T7 RNA Bacteriophage T7 NP_041960.1 Polymerase P00573 Φ6 RdRP Bacteriophage Φ6 P11124 T3 RNA Bacteriophage T3 NP_523301.1 polymerase Q778M8 SP6 Bacteriophage SP6 Y00105.1 Polymerase P06221 rpoA Escherichia coli - K12 MG1655 P0A7Z4 rpoB Escherichia coli - K12 MG1655 P0A8V2 rpoC Escherichia coli - K12 MG1655 P0A8T7

RNA Products. RNA produced by the methods provided herein may be any form of RNA, including single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA). Non-limiting examples of single-stranded RNA include messenger RNA (mRNA), micro RNA (miRNA), small interfering RNA (siRNA), and antisense RNA. Double-stranded RNA herein includes wholly double-stranded molecules that do not contain a single-stranded region (e.g., a loop or overhang), as well as partially double-stranded molecules that contain a double-stranded region and a single-stranded region (e.g., a loop or overhang). Thus, short hairpin RNA (shRNA) may be produced by the methods of the present disclosure.

RNA produced by the methods provided herein may be modified as described herein. In some embodiments, RNA is produced according to a method described herein and subsequently modified. In some embodiments, RNA is produced according to a method described herein using a modified starting material. In some embodiments, the modified starting material is a modified nucleobase. In some embodiments, the modified starting material is a modified nucleoside. In some embodiments, the modified starting material is a modified nucleotide.

In some embodiments, modified RNA comprises a backbone modification. In some instances, backbone modification results in a longer half-life for the RNA due to reduced nuclease-mediated degradation. This is turn results in a longer half-life. Examples of suitable backbone modifications include but are not limited to phosphorothioate modifications, phosphorodithioate modifications, p-ethoxy modifications, methylphosphonate modifications, methylphosphorothioate modifications, alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), alkylphosphotriesters (in which the charged oxygen moiety is alkylated), peptide nucleic acid (PNA) backbone modifications, locked nucleic acid (LNA) backbone modifications, and the like. These modifications may be used in combination with each other and/or in combination with phosphodiester backbone linkages.

Alternatively or additionally, RNA may comprise other modifications, including modifications at the base or the sugar moieties. Examples include RNA having sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3′ position and other than a phosphate group at the 5′ position (e.g., a 2′-O-alkylated ribose), RNA having sugars such as arabinose instead of ribose. RNA also embrace substituted purines and pyrimidines such as C-5 propyne modified bases (Wagner et al., Nature Biotechnology 14:840-844, 1996). Other purines and pyrimidines include but are not limited to 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine. Other such modifications are well known to those of skill in the art.

NTP Production Pathways

Provided herein are systems, methods, compositions, and kits for the production of NTPs through various different enzymatic pathways, each of which utilize energy sources as described herein, and low-cost starting materials in the reaction mixture. These enzymatic pathways can be extended, in some embodiments, to the production of RNA (e.g., mRNA or double-stranded RNA) by adding a DNA template and polymerase to the reaction mixture (see, e.g., FIG. 1).

It should be understood that any of the pathway enzymes described herein (e.g., nucleases, kinases, and/or polymerases) may be obtained from unmodified (native) or engineered cells. In some embodiments, the pathway enzyme(s) are secreted from the cells (e.g., the cells are engineered to secrete the enzyme(s)). In other embodiments, the pathway enzymes are obtained from cell lysate(s) of the cells. In some embodiments, the pathway enzymes are components of cell lysate(s) of the cells, in which case, the cell lysate(s) are added to or serve as the reaction mixture in a biosynthetic reaction. In instances where cell lysate(s) is/are used in or serve as the reaction mixture, the cell lysate may be exposed to conditions to eliminate undesired enzymatic activities, as described below, before producing the product (NTP and/or RNA) of interest.

Conversion of NDP to NTP. In some aspects, NTPs are produced using NDPs as substrates, as depicted in FIG. 2A. For example, NTP production methods may include incubating in a reaction mixture NDPs, a (e.g., 1, 2, 3, or 4) polyphosphate kinase, and a (e.g., 1, 2, 3, or 4) polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture for NTP production includes a NDP kinase (see, e.g., Table 5). In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase.

Conversion of NMP to NTP. In some aspects, NTPs are produced using 5′ NMPs as substrates, as depicted in FIG. 2B. For example, NTP production methods may include incubating in a reaction mixture 5′-NMPs, a (e.g., 1, 2, 3, or 4) polyphosphate kinase, and a (e.g., 1, 2, 3, or 4) polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture for NTP production includes a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5). In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase.

Conversion of Nucleosides to NTP. In some aspects, NTPs are produced using nucleosides as substrates, as depicted in FIG. 2C. For example, NTP production methods may include incubating in a reaction nucleosides, a (e.g., 1, 2, 3, or 4) polyphosphate kinase, and a (e.g., 1, 2, 3, or 4) polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase (see, e.g., Table 3) and/or a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5).

Conversion of Nucleobases to NTP. In some aspects, NTPs are produced using nucleobases as substrates, as depicted in FIG. 2D. For example, NTP production methods may include incubating in a reaction mixture nucleobases, a (e.g., 1, 2, 3, or 4) phosphoribosyltransferase, a phosphoribosylpyrophosphate, a (e.g., 1, 2, 3, or 4) polyphosphate kinase, and a (e.g., 1, 2, 3, or 4) polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the NTP production reaction mixture may also include a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5). In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase.

In some embodiments, a biosynthetic pathway for the production of NTPs and/or RNA may use cellular RNA as the substrate, by either first depolymerizing the cellular RNA into NDPs or first depolymerizing the cellular RNA into NMPs.

Conversion of Nucleobases and Ribose to NTP. In some aspects, NTPs are produced using nucleobases as substrates, as depicted in FIG. 2E. For example, NTP production methods may include incubating in a reaction nucleobases, D-ribose, ribokinase, phosphopentomutase, at least one (e.g., 1, 2, 3, or 4) nucleoside phosphorylase, at least one (e.g., 1, 2, 3, or 4) polyphosphate kinase, and at least one (e.g., 1, 2, 3, or 4) polyphosphate under conditions suitable for the production of NTPs. In some embodiments, the NTP production reaction mixture may also include at least one NMP kinase (see, e.g., Table 3) and/or at least one NDP kinase (see, e.g., Table 4) and/or a nucleoside kinase.

Conversion of Cellular RNA into NTP via NDP. In some aspects, NTP is produced using cellular RNA as a substrate by first breaking down (degrading/depolymerizing) the cellular RNA into NDPs and then converting NDPs into NTPs, as depicted in FIG. 3A. For example, NTP production methods may include incubating in a reaction mixture cellular RNA, a polynucleotide phosphorylase (PNPase), and phosphate under conditions suitable for the production of NDPs. To proceed to the production of NTPs, the reaction mixture, in some embodiments, also comprises a polyphosphate kinase and polyphosphate. Thus, the methods further comprise incubating the reaction mixture under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture further comprises a NDP kinase. In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase.

Conversion of Cellular RNA into NTP via NMP. In some aspects, NTP is produced using cellular RNA as a substrate by first breaking down the cellular RNA into 5′-NMPs and then converting NMPs to NDPs and NDPs to NTPs, as depicted in FIG. 3B. For example, NTP production methods may include incubating in a reaction mixture cellular RNA, and a ribonuclease under conditions suitable for the production of 5′-NMPs. To proceed to the production of NTPs, the reaction mixture, in some embodiments, also comprises a polyphosphate kinase, and a polyphosphate. Thus, the methods further comprise incubating the reaction mixture under conditions suitable for the production of NTPs. In some embodiments, the reaction mixture further comprises a NDP kinase. In some embodiments, the NTP production reaction mixture may also include a nucleoside kinase. Alternatively, NTP production methods may include incubating in a reaction mixture cellular RNA, a ribonuclease that cleaves RNA into 3′-NMPs, and an appropriate phosphatase (e.g. alkaline phosphatase or others) under conditions suitable for the production of nucleosides. The phosphatase would then be eliminated before proceeding to the production of NTPs.

RNA Production Pathways

As shown in FIG. 1, RNA (e.g., mRNA or double-stranded RNA) may be produced through various different enzymatic pathways, each of which utilize energy sources as described herein, and low-cost starting materials in the reaction mixture(s). Thus, systems, methods, compositions, and kits for the production of RNA are provided herein.

Conversion of NDP to RNA. In some aspects, RNA is produced using NDPs as substrates, as depicted in FIG. 2A. For examples, RNA production methods may include incubating in a reaction mixture NDPs, a polyphosphate kinase, a polyphosphate, a DNA template, and a RNA polymerase under conditions suitable for the production of RNA. In some embodiments, the RNA production reaction mixture may also include a NDP kinase (see, e.g., Table 5). In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase

Conversion of NMP to RNA. In some aspects, RNA is produced using 5′ NMPs as substrates, as depicted in FIG. 2B. For example, RNA production methods may include incubating in a reaction mixture 5′ NMPs, a polyphosphate kinase, a polyphosphate, a DNA template, and a RNA polymerase under conditions suitable for the production of RNA. In some embodiments, the RNA production reaction mixture may also include a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5). In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase Conversion of Nucleosides to RNA. In some aspects, RNA is produced using nucleosides as substrates, as depicted in FIG. 2C. For example, RNA production methods may include incubating in a reaction mixture nucleosides, a polyphosphate kinase, a polyphosphate, a DNA template, and a RNA polymerase under conditions suitable for the production of RNA. In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase (see, e.g., Table 3) and/or a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5).

Conversion of Cellular RNA into RNA via NDP. In some aspects, RNA is produced using cellular RNA as a substrate by first breaking down the cellular RNA into NDPs, as depicted in FIG. 3A. For example, RNA production methods may include incubating in a reaction mixture cellular RNA, a polynucleotide phosphorylase (PNPase), and phosphate under conditions suitable for the production of NDPs. Before proceeding to the production of RNA, it may be advantageous to eliminate the PNPase to avoid degrading the end product. Thus, the methods may further comprise eliminating the a PNPase, and incubating in the reaction mixture, or in a second reaction mixture, the NDPs, a polyphosphate kinase, a polyphosphate, a DNA template, and a polymerase under conditions suitable for the production of RNA. In some embodiments, the reaction mixture further comprises a NDP kinase. In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase

In some embodiments, these pathway enzymes are capable of withstanding elimination conditions, as discussed below, and, thus, all reaction components are included in a single (one-step) reaction mixture. For example, a RNA production method may comprise (a) incubating in a reaction mixture cellular RNA, a PNPase, phosphate, a polyphosphate kinase, a polyphosphate, a DNA template, and a polymerase under conditions suitable for the production of NDPs (optionally wherein the reaction mixture further comprises a NDP kinase), (b) eliminating the a PNPase, and (c) incubating the reaction mixture under conditions suitable for the production of RNA.

Conversion of Cellular RNA into RNA via NMP. In some aspects, RNA is produced using cellular RNA as a substrate by first breaking down the cellular RNA into 5′ NMPs, as depicted in FIG. 3B. For example, RNA production methods may include incubating in a reaction mixture cellular RNA and a ribonuclease under conditions suitable for the production of 5′ NMPs. Before proceeding to the production of RNA, it may be advantageous to eliminate the ribonuclease to avoid degrading the end product. Thus, the methods may further comprise eliminating the a ribonuclease, and incubating in the reaction mixture, or in a second reaction mixture, the 5′ NMPs, a polyphosphate kinase, a polyphosphate, a DNA template, and a polymerase under conditions suitable for the production of RNA. In some embodiments, the reaction mixture further comprises a NMP kinase and/or a NDP kinase. In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase

In some embodiments, these pathway enzymes are capable of withstanding elimination conditions, as discussed below, and, thus, all reaction components are included in a single (one-step) reaction mixture. For example, a RNA production method may comprise (a) incubating in a reaction mixture cellular RNA, a ribonuclease, a polyphosphate kinase, a polyphosphate, a DNA template, and a polymerase under conditions suitable for the production of NMPs (optionally wherein the reaction mixture further comprises a NMP kinase and/or a NDP kinase), (b) eliminating the a ribonuclease, and (c) incubating the reaction mixture under conditions suitable for the production of RNA.

Conversion of Nucleobases to RNA. In some aspects, RNA is produced using nucleobases as substrates, as depicted in FIG. 2D. For example, RNA production methods may include incubating in a reaction mixture nucleobases, a (e.g., 1, 2, 3, or 4) phosphoribosyltransferase, a phosphoribosylpyrophosphate, a polyphosphate kinase, a polyphosphate, a DNA template, and a RNA polymerase under conditions suitable for the production of RNA. In some embodiments, the RNA production reaction mixture may also include a NMP kinase (see, e.g., Table 4) and/or a NDP kinase (see, e.g., Table 5). In some embodiments, the RNA production reaction mixture may also include a nucleoside kinase

Conversion of Nucleobases and Ribose to RNA. In some aspects, RNA is produced using nucleobases as substrates, as depicted in FIG. 2E. For example, RNA production methods may include incubating in a reaction mixture nucleobases, D-ribose, ribokinase, phosphopentomutase, at least one (e.g., 1, 2, 3, or 4) nucleoside phosphorylase, at least one polyphosphate kinase, at least one polyphosphate, at least one DNA template, and at least one RNA polymerase under conditions suitable for the production of RNA. In some embodiments, the RNA production reaction mixture may also include at least one NMP kinase (see, e.g., Table 3) and/or at least one NDP kinase (see, e.g., Table 4) and/or a nucleoside kinase.

Enzyme Sources

Any (e.g., one, two, three, or more) or all of the pathway enzymes provided herein (e.g., nucleases, kinases, polymerases, etc.) may be endogenous (unmodified) enzymes or recombinant enzymes expressed by a cell. In some embodiments, the pathway enzymes are provided as a component of a cell lysate, which is included in a reaction mixture. In some embodiments, the pathway enzymes are purified from a cell lysate an included in a reaction mixture. In some embodiments, a pathway enzyme is provided as a component of a cell lysate and a pathway enzyme is purified from a cell lysate. In some embodiments, a pathway enzyme is secreted and optionally purified from cell broth.

In some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is an endogenous enzyme purified from a cell and included a reaction mixture as a purified enzyme. In some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is an endogenous enzyme provided as a component of a cell lysate that is included in a reaction mixture. In some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is a recombinant enzyme purified from a cell and included a reaction mixture as a purified enzyme. In some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is a recombinant enzyme provided as a component of a cell lysate that is included in a reaction mixture. In some embodiments, a pathway enzyme is secreted and optionally purified from cell broth.

The present disclosure also encompasses endogenous enzymes and recombinant enzymes secreted by a cell. Thus, in some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is an endogenous enzyme secreted from a cell. In some embodiments, a pathway enzyme (e.g., nucleases, kinases, polymerases, etc.) is a recombinant enzyme secreted from a cell.

Elimination of Undesired Enzymatic Activities

In various embodiments provided herein, enzymes prepared from cells or lysates of cells that express pathway enzymes are used in a reaction mixture for the production of NTP and/or RNA. In these cells or cell lysates, there are enzymes that may have deleterious effects on NTP and/or RNA production. Non-limiting examples of such enzymes include phosphatases, nucleases, proteases, deaminases, oxidoreductases, and/or hydrolases, such as those expressed by Escherichia coli cells. Phosphatases remove phosphate groups (e.g., converting NMPs to nucleosides, converting NDPs to NMPs, or converting NTPs to NDPs), which reduce NTP production due to futile cycles of nucleotide phosphorylation/dephosphorylation. Nucleases cleave nucleic acids into monomers or oligomers, which lead to RNA product degradation (e.g., by RNase) and/or DNA template degradation (e.g., by DNase). Proteases cleave proteins into amino acids or peptides, which degrade pathway enzymes. Deaminases remove amino groups, which reduced NTP concentrations by conversion of pathway intermediates to non-useful substrates (e.g., xanthine and hypoxanthine) and can lead to mutations in RNA products (e.g., C to U). Hydrolases (e.g., nucleoside hydrolase or nucleotide hydrolase) cleave nucleosides or nucleotides into base and sugar moieties, which reduce NTP concentrations due to irreversible degradation of nucleotides. Oxidoreductases catalyze the transfer of electrons from one molecule (the oxidant) to another molecule (the reductant). Oxidation and/or reduction reactions can, for example, damage nucleobases in DNA and/or RNA, leading to errors in transcription and/or translation, or damage proteins or enzymes leading to loss of function.

Thus, it is advantageous in many embodiments to eliminate these native enzymatic activities or other undesired enzymatic activities in an enzyme preparation, a cell lysate, and/or a reaction mixture. Herein, “elimination” of enzymatic activities may be partial (e.g., at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the activity is eliminated) or complete (100% of the activity is eliminated) of an undesired enzymatic activity. As discussed herein, enzymatic activity may be eliminated by genetic modification, conditional inactivation, and/or physical separation. Other elimination methods may also be used. The undesired enzymatic activity may stem from at least one (e.g., 1, 2, 3, 4 or 5) native (endogenous) enzyme, including but not limited to, phosphatases, nucleases, proteases, deaminases, oxidoreductases, and/or hydrolases.

In some embodiments, undesired phosphatase activity is eliminated in an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, undesired nuclease activity is eliminated in an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, undesired protease activity is eliminated in an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, undesired deaminase activity is eliminated in an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, undesired hydrolase activity is eliminated in an enzyme preparation, a cell lysate, and/or a reaction mixture.

Undesired (e.g., native) enzymatic activity(ies) may be eliminated using genetic, conditional, or separation approaches. In some embodiments, a genetic approach is used to remove undesired enzymatic activity. Thus, in some embodiments, cells are modified to reduce or eliminate undesired enzymatic activities. Examples of genetic approaches that may be used to reduce or eliminate undesired enzymatic activity include, but are not limited to, secretion, gene knockouts, and protease targeting. In some embodiments, a conditional approach is used to remove undesired enzymatic activity. Thus, in some embodiments, undesired enzymes exhibiting undesired activities remain in an enzyme preparation, a cell lysate, and/or a reaction mixture and are selectively inactivated. Examples of conditional approaches that may be used to reduce or eliminate undesired enzymatic activity include, but are not limited to, changes in temperature, pH, salt, detergent, organic solvent (e.g., alcohol), and the use of chemical inhibitors. In some embodiments, a separation/purification approach is used to remove undesired enzymatic activity. Thus, in some embodiments, undesired enzymes exhibiting undesired activities are physically removed from an enzyme preparation, a cell lysate, and/or a reaction mixture. Examples of separation approaches that may be used to reduce or eliminate undesired enzymatic activity include, but are not limited to, precipitation, immobilization, filtration, and chromatography.

Genetic Approaches. In some embodiments, cells expressing an enzyme and/or DNA template of a NTP and/or RNA production pathway are modified to reduce or eliminate undesired enzymatic activities. In some embodiments, a gene encoding an enzyme exhibiting an undesired activity is deleted from the cells. In some embodiments, a gene encoding an enzyme exhibiting an undesired activity is mutated such that the resulting gene product is rendered non-functional. In some embodiments, an enzyme exhibiting an undesired activity is modified to include a site-specific protease-recognition sequence in their protein sequence such that the enzyme may be “targeted” and cleaved for inactivation (see, e.g., U.S. Publication No. 2012/0052547 A1, published on Mar. 1, 2012; International Publication No. WO 2015/021058 A2, published Feb. 12, 2015; and International Publication Number WO 2012/030980, published Mar. 8, 2012, each of which is incorporated by reference herein).

Cleavage of an enzyme containing a site-specific protease-recognition sequence results from contact with a cognate site-specific protease that is sequestered in the periplasm of the cell (separate from the target enzyme) during the cell growth phase (e.g., as engineered cells are cultured) and is brought into contact with the enzyme during the ATP production phase (e.g., following cell lysis to produce a cell lysate). Thus, engineered cells of the present disclosure comprise, in some embodiments, (i) an engineered nucleic acid encoding an enzyme exhibiting an undesired activity and includes a site-specific protease-recognition sequence in the protein sequence of the enzyme, and (ii) an engineered nucleic acid encoding a site-specific protease that cleaves the site-specific protease-recognition sequence of the enzyme and includes a periplasmic-targeting sequence. This periplasmic-targeting sequence is responsible for sequestering the site-specific protease to the periplasmic space of the cell until the cell is lysed. Examples of periplasmic-targeting sequences are known.

Examples of proteases that may be used in accordance with the present disclosure include, without limitation, alanine carboxypeptidase, astacin, bacterial leucyl aminopeptidase, cancer procoagulant, cathepsin B, clostripain, cytosol alanyl aminopeptidase, elastase, endoproteinase Brg-C, enterokinase, gastricsin, gelatinase, Gly-X carboxypeptidase, glycyl endopeptidase, human rhinovirus 3C protease, hypodermin C, Iga-specific serine endopeptidase, leucyl aminopeptidase, leucyl endopeptidase, lysC, lysosomal pro-X carboxypeptidase, lysyl aminopeptidase, methionyl aminopeptidase, myxobacter, nardilysin, pancreatic endopeptidase E, picornain 2B, picornain 3C, proendopeptidase, prolyl aminopeptidase, proprotein convertase I, proprotein convertase II, russellysin, saccharopepsin, semenogelase, T-plasminogen activator, thrombin, tissue kallikrein, tobacco etch virus (TEV), togavirin, tryptophanyl aminopeptidase, U-plasminogen activator, V8, venombin B, venombin BB and Xaa-pro aminopeptidase.

Conditional Approaches. In some embodiments, an enzyme preparation, a cell lysate, and/or a reaction mixture includes an enzyme exhibiting undesired activity that is selectively inactivated. In some embodiments, an enzyme exhibiting undesired activity is selectively inactivated by exposing the enzyme to elimination conditions (e.g., high or low temperature, acidic or basic pH value, high salt or low salt, detergent, and/or organic solvent).

In some embodiments, an enzyme preparation, an enzyme preparation, a cell lysate, and/or a reaction mixture is exposed to a temperature that temporarily or irreversibly inactivates the enzyme exhibiting undesired activity. “Temperature inactivation” refers to the process of heating or cooling an enzyme preparation, a cell lysate, and/or a reaction mixture to a temperature sufficient to inactivate (or at least partially inactivate) native target enzyme. Generally, the process of temperature inactivation involves denaturation of (unfolding of) the deleterious enzyme. The temperature at which an enzyme denature varies among organisms. In E. coli, for example, enzymes generally denature at temperatures above 41° C. The denaturation temperature may be higher or lower than 41° C. for other organisms. Enzymes of a cell lysate, as provide here, may be temperature inactivated at a temperature of 0° C.-95° C., or higher. In some embodiments, enzymes of a cell lysate are temperature inactivated at a temperature of 0-90° C., 0-80° C., 0-70° C., 0-60° C., 0-50° C., 0-40° C., 0-30° C., 0-20° C., 0-10° C., or 0-5° C. In some embodiments, enzymes of a cell lysate are temperature inactivated at a temperature of 5-95° C., 10-95° C., 20-95° C., 30-95° C., 40-95° C., 50-95° C., 60-95° C., 70-95° C., 80-95° C., or 90-95° C. For example, enzymes of a cell lysate may be temperature inactivated at a temperature of approximately 40° C., 42° C., 45° C., 50° C., 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., 90° C., or 95° C. In some embodiments, enzymes of a cell lysate are temperature inactivated at a temperature of 50-80° C. In some embodiments, enzymes of a cell lysate are temperature inactivated at a temperature of approximately 70° C. In some embodiments, enzymes of a cell lysate are temperature inactivated at a temperature of approximately 60° C.

In some embodiments, an enzyme preparation, a cell lysate, and/or a reaction mixture is exposed to an acid or base (change in pH) that temporarily or irreversibly inactivates an enzyme exhibiting undesired activity. “Acid or base inactivation” refers to the process of adjusting an enzyme preparation, a cell lysate, and/or a reaction mixture to a pH sufficient to inactivate (or at least partially inactivate) an enzyme. Generally, the process of acid or base inactivation involves denaturation of (unfolding of) the enzyme. The pH at which enzymes denature varies among organisms. In E. coli, for example, native enzymes generally denature at pH above 7.5 or below 6.5. The denaturation pH may be higher or lower than the denaturation pH for other organisms. Enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture, as provide herein, may be base inactivated at a pH of 7.5-14, or higher. In some embodiments, enzymes of a cell lysate is base inactivated at a pH of 8-14, 8.5-14, 9-14, 9.5-14, 10-14, 10.5-14, 11-14, 11.5-14, 12-14, 12.5-14, 13-14, or 13.5-14. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are base inactivated at a pH of 7.5-13.5, 7.5-13, 7.5-12.5, 7.5-12, 7.5-11.5, 7.5-11, 7.5-10.5, 7.5-10, 7.5-9.5, 7.5-9, 7.5-8.5, or 7.5-8. For example, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture may be base inactivated at a pH of approximately 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, or 14. Enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture, as provide herein, may be acid inactivated at a pH of 6.5-0, or lower. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are acid inactivated at a pH of 6.5-0.5, 6.5-1, 6.5-1.5, 6.5-2, 6.5-2.5, 6.5-3, 6.5-3.5, 6.5-4, 6.5-4.5, 6.5-5, or 6.5-6. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are acid inactivated at a pH of 6-0, 5.5-0, 5-0, 4.5-0, 4-0, 3.5-0, 3-0, 2.5-0, 2-0, 1.5-0, 1-0, or 0.5-0. For example, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture may be acid inactivated at a pH of approximately 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.5, or 0.

In some embodiments, an enzyme preparation, a cell lysate, and/or a reaction mixture is exposed to a high salt or low salt (change in salt concentration) that temporarily or irreversibly inactivates an enzyme exhibiting undesired activity. “Salt inactivation” refers to the process of adjusting an enzyme preparation, a cell lysate, and/or a reaction mixture to a salt concentration sufficient to inactivate (or partially inactivate) an enzyme. Generally, the process of salt inactivation involves denaturation of (unfolding of) the enzyme. The salt concentration at which enzymes denature varies among organisms. In E. coli, for example, native enzymes generally denature at a salt concentration above 600 mM. The denaturation salt concentration may be higher or lower than the denaturation salt concentration for other organisms. Salts are combinations of anions and cations. Non-limiting examples of cations include lithium, sodium, potassium, magnesium, calcium and ammonium. Non-limiting examples of anions include acetate, chloride, sulfate, and phosphate. Enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture, as provided herein, may be salt inactivated at a salt concentration of 600-1000 mM, or higher. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are salt inactivated at a salt concentration of 700-1000 mM, 750-1000 mM, 800-1000 mM, 850-1000 mM, 900-1000 mM, 950-1000 mM. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are salt inactivated at a salt concentration of 600-950 mM, 600-900 mM, 600-850 mM, 600-800 mM, 600-750 mM, 600-700 mM, or 600-650 mM. For example, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture may be salt inactivated at a salt concentration of approximately 600 mM, 650 mM, 700 mM, 750 mM, 800 mM, 850 mM, 900 mM, 950 mM, or 1000 mM. Enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture, as provided herein, may be salt inactivated at a salt concentration of 400-0 mM, or lower. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are salt inactivated at a salt concentration of 350-0 mM, 300-0 mM, 250-0 mM, 200-0 mM, 150-0 mM, 100-0 mM, or 50-0 mM. In some embodiments, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are salt inactivated at a salt concentration of 400-50 mM, 400-100 mM, 400-150 mM, 400-200 mM, 400-250 mM, 400-300 mM, or 400-350 mM. For example, enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture may be salt inactivated at a salt concentration of approximately 400 mM, 350 mM, 300 mM, 250 mM, 200 mM, 150 mM, 100 mM, 50 mM, or 0 mM.

In some embodiments, an organic solvent is added to an enzyme preparation, a cell lysate, and/or a reaction mixture to inactivate an enzyme exhibiting undesired activity. Non-limiting examples of organic solvents include ethanol, methanol, ether, dioxane, acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide, and toluene.

In some embodiments, a detergent is added to an enzyme preparation, a cell lysate, and/or a reaction mixture to inactivate an enzyme exhibiting undesired activity. Non-limiting examples of detergents include sodium dodecyl sulfate (SDS), ethyl trimethylammonium bromide (ETMAB), lauryl trimethyl ammonium bromide (LTAB), and lauryl trimethylammonium chloride (LTAC).

In some embodiments, a chemical inhibitor is added to an enzyme preparation, a cell lysate, and/or a reaction mixture to inactivate an enzyme exhibiting undesired activity. Non-limiting examples of chemical inhibitors include sodium orthovanadate (inhibitor of protein phosphotyrosyl phosphatases), sodium fluoride (inhibitor of phosphoseryl and phosphothreonyl phosphatases), sodium pyrophosphate (phosphatase inhibitor), sodium phosphate, and/or potassium phosphate. In some embodiments, chemical inhibitors are selected from a chemical inhibitor library.

For any of the conditional approaches used herein, it should be understood that any of the pathway enzymes present in the cell lysate or reaction mixture may also be exposed to the elimination conditions (e.g., high or low temperature, acidic or basic pH value, high salt or low salt, detergent and/or organic solvent). Thus, in some embodiments, the pathway enzymes (e.g., polyphosphate kinase, NMP kinase, NDP kinase, and/or polymerase) can withstand elimination conditions. An enzyme is considered to withstand elimination conditions if the enzyme, following exposure to the elimination conditions, retains at least 10% (e.g., at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%) of its enzymatic activity (relative to enzymatic activity prior to exposure to the inactivation condition).

For example, when native enzymes of an enzyme preparation, a cell lysate, and/or a reaction mixture are heat-inactivated (e.g., exposed to a temperature of at least 40° C., or 40-95° C., for at least 2 min, or 2-60 min), the pathway enzymes may be thermostable enzymes. Thus, in some embodiments, at least one of a polyphosphate kinase, NMP kinase, NDP kinase, nucleoside kinase, phosphoribosyltransferase, nucleoside phosphorylase, ribokinase, phosphopentomutase, and polymerase is thermostable. An enzyme (e.g., kinase or polymerase) is considered thermostable if the enzyme (a) retains activity after temporary exposure to high temperatures that denature native enzymes or (b) functions at a high rate after temporary exposure to a medium to high temperature where native enzymes function at low rates. Thermostable enzymes are known, and non-limiting examples of thermostable enzymes for use as provided herein. Other non-limiting examples of pathway enzymes that can withstand elimination conditions are also provided herein.

Separation Approaches. In some embodiments, a native enzyme exhibiting undesired activity is physically removed from an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, an enzyme exhibiting undesired activity is precipitated from an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, an enzyme exhibiting undesired activity is filtered (e.g., based on size) from an enzyme preparation, a cell lysate, and/or a reaction mixture. In some embodiments, an enzyme exhibiting undesired activity is removed from an enzyme preparation, a cell lysate, and/or a reaction mixture via capture and/or chromatography (e.g., by differential affinity to a stationary phase).

In some embodiments, an enzyme exhibiting undesired activity is removed from an enzyme preparation, a cell lysate, and/or a reaction mixture via affinity chromatography. Examples of affinity chromatography include, but are not limited to, Protein A chromatography, Protein G chromatography, metal binding chromatography (e.g., nickel chromatography), lectin chromatography, and GST chromatography.

In some embodiments, an enzyme exhibiting undesired activity is removed from an enzyme preparation, a cell lysate, and/or a reaction mixture via ion exchange chromatography. Examples of anion exchange chromatography (AEX) include, but are not limited to, diethylaminoethyl (DEAE) chromatography, quaternary aminoethyl (QAE) chromatography, and quaternary amine(Q) chromatography. Examples of cation exchange chromatography include, but are not limited to, carboxymethyl (CM) chromatography, sulfoethyl (SE) chromatography, sulfopropyl (SP) chromatography, phosphate (P) chromatography, and sulfonate (S) chromatography.

In some embodiments, an enzyme exhibiting undesired activity is removed from an enzyme preparation, a cell lysate, and/or a reaction mixture via hydrophobic interaction chromatography (HIC). Examples of hydrophobic interaction chromatography include, but are not limited to, Phenyl Sepharose chromatography, Butyl Sepharose chromatography, Octyl Sepharose chromatography, Capto Phenyl chromatography, Toyopearl Butyl chromatography, Toyopearl Phenyl chromatography, Toyopearl Hexyl chromatography, Toyopearl Ether chromatography, and Toyopearl PPG chromatography. Any of the chemistries detailed above could be alternatively be used to immobilize or capture pathway enzymes.

Thermostable Enzymes

Any of the pathway enzymes provided herein (e.g., nucleases, kinases, polymerases, etc.) may be thermostable enzymes. Thermostability refers to the quality of enzymes to resist denaturation at relatively high or low temperature. For example, if an enzyme is denatured (inactivated) at a temperature of 42° C., an enzyme having similar activity (e.g., kinase activity) is considered “thermostable” if it does not denature at 42° C.

An enzyme (e.g., kinase or polymerase) is considered thermostable if the enzyme (a) retains activity after temporary exposure to high temperatures that denature other native enzymes or (b) functions at a high rate after temporary exposure to a medium to high temperature where native enzymes function at low rates.

An enzyme (e.g., kinase or polymerase) is also considered thermostable if the enzyme (a) retains activity after temporary exposure to low temperatures that denature other native enzymes or (b) functions at a high rate after temporary exposure to a medium to low temperature where native enzymes function at low rates.

In some embodiments, a thermostable enzyme retains greater than 10% activity following temporary exposure to relatively high temperature (e.g., higher than 41° C. for kinases obtained from E. coli, higher than 37° C. for many RNA polymerases) that would otherwise denature a similar (non-thermostable) native enzyme. In some embodiments, a thermostable enzyme retains 10-100%, 25-100%, or 50-100% activity following temporary exposure to relatively high temperature that would otherwise denature a similar (non-thermostable) native enzyme. For example, a thermostable enzyme may retain 10-90%, 10-85%, 10-80%, 10-75%, 10-70%, 10-65%, 10-60%, 10-55%, 25-90%, 25-85%, 25-80%, 25-75%, 25-70%, 25-65%, 25-60%, 25-55%, 50-90%, 50-85%, 50-80%, 50-75%, 50-70%, 50-65%, 50-60%, or 50-55% temporary exposure to relatively high temperature that would otherwise denature a similar (non-thermostable) native enzyme. In some embodiments, a thermostable enzyme retains 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% activity following temporary exposure to relatively high temperature that would otherwise denature a similar (non-thermostable) native enzyme.

In some embodiments, a thermostable enzyme retains greater than 50% activity following temporary exposure to relatively low temperature (e.g., lower than 32° C. for kinases obtained from E. coli, lower than 32° C. for many RNA polymerases) that would otherwise denature a similar (non-thermostable) native enzyme. In some embodiments, a thermostable enzyme retains 50-100% activity following temporary exposure to relatively low temperature that would otherwise denature a similar (non-thermostable) native enzyme. For example, a thermostable enzyme may retain 50-90%, 50-85%, 50-80%, 50-75%, 50-70%, 50-65%, 50-60%, or 50-55% activity following temporary exposure to relatively low temperature that would otherwise denature a similar (non-thermostable) native enzyme. In some embodiments, a thermostable enzyme retains 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% activity following temporary exposure to relatively low temperature that would otherwise denature a similar (non-thermostable) native enzyme.

In some embodiments, the activity of a thermostable enzyme after temporary exposure to medium to high temperature (e.g., 42-80° C.) is greater than (e.g., 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% greater than) the activity of a similar (non-thermostable) native enzyme.

In some embodiments, the activity of a thermostable enzyme after temporary exposure to medium to low temperature (e.g., 32-0° C.) is greater than (e.g., 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% greater than) the activity of a similar (non-thermostable) native enzyme.

The activity of a thermostable kinase, for example, may be measured by the amount of NMP or NDP the kinase is able to phosphorylate. Thus, in some embodiments, a thermostable kinase, at relatively high temperature (e.g., 42° C.) converts greater than 50% of NMP to NDP, or greater than 50% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively high temperature (e.g., 42° C.) converts greater than 60% of NMP to NDP, or greater than 60% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively high temperature (e.g., 42° C.) converts greater than 70% of NMP to NDP, or greater than 70% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively high temperature (e.g., 42° C.) converts greater than 80% of NMP to NDP, or greater than 80% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively high temperature (e.g., 42° C.) converts greater than 90% of NMP to NDP, or greater than 90% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C.

In some embodiments, a thermostable kinase, at relatively low temperature (e.g., 32° C.) converts greater than 50% of NMP to NDP, or greater than 50% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively low temperature (e.g., 32° C.) converts greater than 60% of NMP to NDP, or greater than 60% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively low temperature (e.g., 32° C.) converts greater than 70% of NMP to NDP, or greater than 70% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively low temperature (e.g., 32° C.) converts greater than 80% of NMP to NDP, or greater than 80% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C. In some embodiments, a thermostable kinase, at relatively low temperature (e.g., 32° C.) converts greater than 90% of NMP to NDP, or greater than 90% of NDP to NTP, in the same amount of time required to complete a similar conversion at 37° C.

The activity of a thermostable polymerase, for example, is assessed based on fidelity and polymerization kinetics (e.g., rate of polymerization). Thus, one unit of a thermostable T7 polymerase, for example, may incorporate 10 nmoles of NTP into acid insoluble material in 30 minutes at temperatures above 37° C. (e.g., at 50° C.). In another example, one unit of a thermostable T7 polymerase may incorporate 10 nmoles of NTP into acid insoluble material in 30 minutes at temperatures below 32° C. (e.g., at 25° C.)

In some embodiments, thermostable enzymes (e.g., kinases or polymerases) may remain active (able to catalyze a reaction) at a temperature of 42° C. to 80° C., or higher. In some embodiments, thermostable enzymes remain active at a temperature of 42-80° C., 42-70° C., 42-60° C., 42-50° C., 50-80° C., 50-70° C., 50-60° C., 60-80° C., 60-70° C., or 70-80° C. For example, thermostable enzymes may remain active at a temperature of 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C., 73° C., 74° C., 75° C., 76° C., 77° C., 78° C., 79° C., or 80° C. Thermostable enzymes may remain active at relatively high temperatures for 15 minutes to 48 hours, or longer. For example, thermostable enzymes may remain active at relatively high temperatures for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 36, 42, or 48 hours.

In some embodiments, thermostable enzymes (e.g., kinases or polymerases) may remain active (able to catalyze a reaction) at a temperature of 32° C. to 0° C., or lower. In some embodiments, thermostable enzymes remain active at a temperature of 32-5° C., 32-10° C., 32-20° C., 32-25° C., 32-30° C., 30-0° C., 25-0° C., 20-0° C., 10-0° C., or 5-0° C. For example, thermostable enzymes may remain active at a temperature of 32° C., 31° C., 30° C., 29° C., 28° C., 27° C., 26° C., 25° C., 24° C., 23° C., 22° C., 21° C., 20° C., 19° C., 18° C., 17° C., 16° C., 15° C., 14° C., 13° C., 12° C., 10° C., 9° C., 8° C., 7° C., 6° C., 5° C., 4° C., 3° C., 2° C., 1° C., or 0° C. Thermostable enzymes may remain active at relatively low temperatures for 15 minutes to 48 hours, or longer. For example, thermostable enzymes may remain active at relatively low temperatures for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 36, 42, or 48 hours.

Non-limiting examples of thermostable NMP kinases are listed in Tables 4A-4D. Other thermostable kinases include thermostable nucleoside diphosphate kinases (see, e.g., Table 5), thermostable pyruvate kinases, and thermostable polyphosphate kinases (see, e.g., Table 2). Other thermostable kinases are encompassed by the present disclosure.

Non-limiting examples of RNA polymerases are listed in Table 6. Other RNA polymerases, including thermostable RNA polymerases, are encompassed by the present disclosure.

Thermostable RNA polymerases may be prepared by modifying wild-type enzymes. Such modifications (e.g., mutations) are known. For example, variant thermostable T7 RNA polymerases may include one or more of the following point mutations: V426 L, A702V, V795I, S430P, F849I, S633P, F880Y, C510R, and S767G (EP2377928 and EP1261696A1, each of which is incorporated herein by reference). In some embodiments, a variant thermostable T7 RNA polymerase includes V426 L, A702V, and V795I mutations. In some embodiments, a variant thermostable T7 RNA polymerase includes S430P, F849I, S633P, and F880Y mutations. In some embodiments, a variant thermostable T7 RNA polymerase includes F880Y, S430P, F849I, S633P, C510R, and S767G mutations. In some embodiments, a variant thermostable T7 RNA polymerase includes Y639V, H784G, E593G, and V685A mutations. In some embodiments, a variant thermostable T7 RNA polymerase includes S430P, N433T, S633P, F849I, and F880Y mutations. Other variant and recombinant thermostable polymerases are encompassed by the present disclosure.

In some embodiments, a thermostable T7 polymerase is used to produce a RNA of interest. For example, a thermostable T7 polymerase (e.g., incubated at a temperature of 37-60° C.) having a concentration of 0.1-5% total protein may be used to synthesize RNA of interest at a rate of greater than 1 g/L/hr (or, e.g., 1 g/L/hr-20 g/L/hr).

It should be understood that while many embodiments of the present disclosure describe the use of thermostable polymerases/enzymes, other enzymes/polymerases may be used. In some embodiments, polymerase may be exogenously added to heat-inactivated cell lysates, for example, to compensate for any reduction or loss of activity of the thermostable enzyme(s).

Fusion Enzymes

Any of the pathway enzymes provided herein (e.g., nucleases, kinases, polymerases, etc.) may be individual enzymes, enzymes with multiple activities, or fusion enzymes. A fusion enzyme may be created by joining two or more gene or gene segments that code for separate proteins. Translation of this fusion gene results in a single or multiple polypeptides with functional properties derived from each of the original proteins, e.g., a fusion protein that acts as a nuclease, acts as a kinase, and/or acts as a polymerase. Other enzymes may also be expressed as a fusion protein.

Some enzymes that exist in nature are multifunctional (e.g., CMP-UMP kinases). Thus, the term “enzyme” encompasses “enzymatic activities,” regardless of how they are supplied.

A fusion enzyme is considered to “act as a nuclease” if the enzyme exhibits nuclease activity (cleaves or depolymerizes a nucleic acid; e.g., RNase R). A fusion enzyme is considered to “act as a kinase” if the enzyme exhibits kinase activity (catalyzes the transfer of a phosphate group from one molecule to another molecule; e.g., polyphosphate kinase). A fusion enzyme is considered to “act as a polymerase” if the enzyme exhibits polymerase activity (assembles nucleotides to produce nucleic acids; e.g., RNA polymerase).

Energy Sources

There are several energy and phosphate sources that may be used, as provided herein, for the production of NTP and/or RNA. Non-limiting examples of sources of phosphate include NTP (e.g., ATP, GTP, UTP, CTP), polyphosphate (e.g., hexametaphosphate), and pyrophosphate (PPi). In some embodiments, NTP, whether chemically synthesized, a product of fermentation, or extracted from a natural source, is included in a reaction mixture for the production of RNA. In some embodiments, polyphosphate and polyphosphate kinase are included in a reaction mixture for the production of NTP and/or RNA. In some embodiments, acetate, ADP, pyrophosphate, and at least two acetate kinases (e.g., acetate kinase (diphosphate) EC 2.7.2.12 and acetate kinase (phosphorylating) EC.7.2.1) are included in a reaction mixture for the production of NTP and/or RNA. In some embodiments, citrate, AMP, pyrophosphate, citrate lyase (the citrate lyase complex), a phosphoenolpyruvate carboxykinase (PEPCK) or a phosphoenolpyruvate carboxylase (PEPC), and a pyruvate phosphate dikinase (PPDK) are included in a reaction mixture for the production of NTP and/or RNA. In some embodiments, sulfite, AMP, pyrophosphate, adenylyl sulfate reductase, and sulfate adenylyltransferase are included in a reaction mixture for the production of NTP and/or RNA. Other energy sources are also encompassed by the present disclosure.

In some embodiments, an energy source is ATP produced from pyrophosphate through cyclical phosphorylation of acetate, from pyrophosphate and citrate, or from pyrophosphate and sulfite. Methods for ATP production from the above pathways are described herein. A summary of the ATP production pathways and pathway enzymes are provided in Table 7 below.

TABLE 7 Summary of Exemplary ATP Production Pathways and Enzymes ATP Production Pathway Enzymes ATP production from acetate kinase (diphosphate) pyrophosphate through (EC 2.7.2.12) the acetate phosphorylation/ acetate kinase (phosphorylating) dephosphorylation cycle (EC 2.7.2.1) ATP production from citrate citrate lyase (EC 4.1.3.6) and pyrophosphate phosphoenolpyruvate carboxykinase (PEPCK) (EC 4.1.1.38) pyruvate phosphate dikinase (PPDK) (EC 2.7.9.1, 2.7.9.2) phosphenolpyruvate carboxylase (PEPC) (EC 4.1.1.31) ATP production from sulfite sulfate adenylytransferase and pyrophosphate (EC 2.7.7.4) adenylyl sulfate reductase (EC 1.8.99.2) ATP Production from Pyrophosphate and ADP Through an Acetate Phosphorylation/Dephosphorylation Cycle

Some aspects of the present disclosure use methods for producing ATP from pyrophosphate (high-energy phosphate donor) and ADP (ultimate energy/phosphate acceptor) through an acetate phosphorylation/dephosphorylation cycle (see, e.g., FIG. 14). The first acetate kinase (AcK1; EC 2.7.2.12) phosphorylates acetate using inorganic pyrophosphate (PP_(i)), which produces acetyl-phosphate and inorganic phosphate (P_(i)). The acetyl-phosphate is then dephosphorylated by a second acetate kinase (AcK2; EC 2.7.2.1), which transfers the high-energy phosphate group from the acetyl-phosphate to ADP and produces ATP and acetate. The resulting acetate is then free to be phosphorylated again by AcK1, thereby completing a reaction cycle.

In some embodiments, the methods of producing ATP from pyrophosphate and ADP include culturing cells engineered to express a first acetate kinase, a second acetate kinase, or two different acetate kinases. In some embodiments, the methods include culturing cells engineered to express a first acetate kinase and a second acetate kinase. In some embodiments, the first acetate kinase and the second acetate kinase are expressed as a single fusion (chimeric) protein.

In some embodiments, at least one of the enzymes is a thermostable enzyme. In some embodiments, at least two of the enzymes are thermostable enzymes. In some embodiments, all of the enzymes are thermostable enzymes. Thus, in some embodiments, the methods include culturing cells engineered to express a thermostable acetate kinase. In other embodiments, the methods include culturing cells engineered to express a first thermostable acetate kinase and a second thermostable acetate kinase.

In some embodiments, the methods of producing ATP from pyrophosphate through the cyclical phosphorylation of acetate include lysing (e.g., thermal, osmotic, mechanical (e.g., sonication), chemical, or enzymatic lysis) the cultured cells to produce at least one (e.g., at least two) cell lysate. It should be understood that multiple cell lysates (and thus multiple cell populations, e.g., from the same organism (e.g., bacteria) or from different organisms (e.g., bacteria, yeast and/or plant) may be used in an enzymatic reaction as provided herein. For example, one cell population may be engineered to express a first acetate kinase of the ATP production pathway, while another cell population may be engineered to express a second acetate kinase of the ATP production pathway. Thus, in some embodiments, the methods comprise culturing a population of cells engineered to express an acetate kinase, and/or culturing a cell population engineered to express at least one additional acetate kinase. Following lysis of the cells, the cell lysates are combined such that the enzymes are present in a single cell lysate/reaction mixture.

In some embodiments, the methods of producing ATP from pyrophosphate through the cyclical phosphorylation of acetate further include heating the cell lysate(s) (or a cell lysate mixture) to a temperature that inactivates native enzymatic activity but does not inactivate any of the thermostable enzymes of the ATP production pathway, to produce a heat-inactivated lysate. The cell lysate(s), in some embodiments, is heated to a temperature of at least 50° C. For example, the cell lysate(s) may be heated to a temperature of at least 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., or 90° C. A native enzyme (or other non-thermostable enzyme) is considered inactive, in some embodiments, when its level of activity is reduced by at least 50%. In some embodiments, a native enzyme (or other non-thermostable enzyme) is considered inactive when its level of activity is reduced by at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

The cell lysate(s) may be heated for a period of time sufficient to inactive native enzymes (or other non-thermostable enzymes) of the cell. For example, the cell lysate(s) may be heated for at least 2, 3, 4, or at least 5 minutes. In some embodiments, the cell lysate(s) are heated for longer than 5 minutes. In some embodiments, the cell lysate(s) is heated for longer than 15 minutes. In some embodiments, the cell lysate(s) is heated for less than 2 minutes. In some embodiments, the cell lysate(s) are heated for a period of time sufficient to reduce activity of native enzymes (or other non-thermostable enzymes) by at least 50% (e.g., at least 60%, 70%, 80%, or 90%).

Following heat inactivation, in some embodiments, at least one (e.g., at least two or at least three) purified enzymes may be added to the cell lysate/reaction mixture. Thus, a reaction mixture, in some embodiments, may include a combination of enzymes present in the cell lysate (expressed by the engineered host cell(s)) and at least one purified enzyme. At least one purified enzyme may be a first acetate kinase and/or a second acetate kinase. In some embodiments, a cell lysate may be cooled (e.g., to 50° C.) following a heat-inactivation step, prior to adding the purified enzyme(s).

In some embodiments, the methods of producing ATP from pyrophosphate through the cyclical phosphorylation of acetate also include incubating the heat-inactivated lysate(s) in the presence of acetate, adenosine diphosphate (ADP), and an inorganic phosphate to produce ATP. The inorganic phosphate may be, for example, pyrophosphate. Other inorganic phosphates and/or orthophosphate polymers, including but not limited to tripolyphosphate, tetrapolyphosphate, pentapolyphosphate, hexametaphosphate and mixtures thereof, may be used.

Also encompassed herein are cells and cell lysates used for the production of ATP from pyrophosphate through the cyclical phosphorylation of acetate. Thus, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure may include at least one (e.g., at least two) acetate kinase. In some embodiments, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure includes at least one (e.g., at least two) thermostable acetate kinase.

TABLE 8 Exemplary Acetate Kinase Enzymes Enzyme Name Reaction catalyzed EC No. Native Organism NCBI No. Acetate Phosphorylates acetate 2.7.2.12 Entamoeba histolytica XP_655990.1 kinase to acetyl-phosphate Acetate Phosphorylates ADP to 2.7.2.1 Cryptococcus neoformans XP_012053491.1 kinase ATP ATP Production from Pyrophosphate, AMP, and Citrate

Some aspects of the present disclosure use methods for producing ATP from pyrophosphate, AMP, and citrate (see, e.g., FIGS. 15A-15B). A three-step enzymatic pathway is shown in FIG. 15A. In the first step, citrate lyase converts citrate to acetate and oxaloacetate. In the second step, phosphoenolpyruvate carboxykinase (PEPCK) converts pyrophosphate and oxaloacetate generated in the first step to phosphoenolpyruvate (PEP), carbon dioxide (CO₂), and inorganic phosphate (P_(i)). In the third step, pyruvate phosphate dikinase (PPDK) converts inorganic pyrophosphate (PP_(i)), AMP, and PEP generated in the second step to pyruvate, P_(i), and ATP. The combined chemical reaction uses one mole of citrate, one mole of AMP, and two moles of PP_(i) to yield one mole of acetate, one mole of pyruvate, one mole of CO₂, two moles of P_(i), and one mole of ATP (FIG. 15B). Alternatively, phosphenolpyruvate carboxylase (PEPC) may be used to catalyze the carboxylation of PEP to oxaloacetate, which may be reversible under certain conditions.

These methods, in some embodiments, include culturing cells engineered to express a citrate lyase, a PEPCK (or at least one PEPC), a PPDK, or a combination of at least two or at least three of the foregoing enzymes. In some embodiments, citrate lyase and PEPCK (or PEPC), PEPCK (or PEPC) and PPDK, or citrate lyase and PPDK are expressed as a single fusion (chimeric) protein.

In some embodiments, at least one of the enzymes is a thermostable enzyme. In some embodiments, at least two or at least three of the enzymes are thermostable enzymes. In some embodiments, all of the enzymes are thermostable enzymes. Thus, in some embodiments, the methods include culturing cells engineered to express a thermostable citrate lyase, a thermostable PEPCK, a PPDK, or a combination of at least two or at least three of the foregoing thermostable enzymes.

In some embodiments, the methods of producing ATP from citrate include lysing (e.g., thermal, osmotic, mechanical (e.g., sonication), chemical, or enzymatic lysis) the cultured cells to produce at least one (e.g., at least two, or three) cell lysate. It should be understood that multiple cell lysates (and thus multiple cell populations, e.g., from the same organism (e.g., bacteria) or from different organisms (e.g., bacteria, yeast and/or plant cells) may be used in an enzymatic reaction as provided herein. For example, one cell population may be engineered to express one or more enzymes of the ATP production pathway, while another cell population (or several other cell populations) may be engineered to express another (at least one other) enzyme of the ATP production pathway. Thus, in some embodiments, the methods comprise culturing a population of cells engineered to express a citrate lyase, culturing a cell population engineered to express a PEPCK (a thermostable PEPCK), and/or culturing a cell population engineered to express a PPDK. Following lysis of the cells, the cell lysates are combined such that the enzymes are present in a single cell lysate/reaction mixture.

In some embodiments, the methods of producing ATP from citrate further include heating the cell lysate(s) (or a cell lysate mixture) to a temperature that inactivates native enzymatic activity but does not inactivate any of the thermostable enzymes of the ATP production pathway, to produce a heat-inactivated lysate. The cell lysate(s), in some embodiments, is heated to a temperature of at least 50° C. For example, the cell lysate(s) may be heated to a temperature of at least 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., or 90° C. A native enzyme (or other non-thermostable enzyme) is considered inactive, in some embodiments, when its level of activity is reduced by at least 50%. In some embodiments, a native enzyme (or other non-thermostable enzyme) is considered inactive when its level of activity is reduced by at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

The cell lysate(s) may be heated for a period of time sufficient to inactive native enzymes (or other non-thermostable enzymes) of the cell. For example, the cell lysate(s) may be heated for at least 2, 3, 4, or at least 5 minutes. In some embodiments, the cell lysate(s) are heated for longer than 5 minutes. In some embodiments, the cell lysate(s) are heated for a period of time sufficient to reduce activity of native enzymes (or other non-thermostable enzymes) by at least 50% (e.g., at least 60%, 70%, 80%, or 90%).

Following heat inactivation, in some embodiments, at least one (e.g., at least two or at least three) purified enzymes may be added to the cell lysate/reaction mixture. Thus, a reaction mixture, in some embodiments, may include a combination of enzymes present in the cell lysate (expressed by the engineered host cell(s)) and at least one purified enzyme. At least one purified enzyme may be selected from the group consisting of citrate lyase, PEPCK (or PEPC), and PPDK. In some embodiments, a cell lysate may be cooled (e.g., to 50° C.) following a heat-inactivation step, prior to adding the purified enzyme(s).

In some embodiments, the methods of producing ATP from citrate also include incubating the heat-inactivated lysate(s) in the presence of citrate, adenosine monophosphate (AMP), and inorganic phosphate to produce ATP. The inorganic phosphate may be, for example, pyrophosphate. Other inorganic phosphates and/or orthophosphate polymers, including but not limited to tripolyphosphate, tetrapolyphosphate, pentapolyphosphate, hexametaphosphate and mixtures thereof, may be used.

Also encompassed herein are cells and cell lysates used for the production of ATP from citrate. Thus, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure may include at least one (e.g., at least two or at least three) enzyme selected from the group consisting of citrate lyase, PEPCK (or PEPC), and PPDK. In some embodiments, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure includes at least one (e.g., at least two or at least three) enzyme selected from the group consisting of thermostable citrate lyase, thermostable PEPCK (or thermostable PEPC), and thermostable PPDK.

TABLE 9 Exemplary ATP Production from Pyrophosphate and Citrate Pathway Enzymes Pathway Step Enzyme Name EC No. Native Organism NCBI No. 1 Citrate lyase 4.1.3.6 Escherichia coli AAC28949.1; AAC73717.2; AAC73716.1 Caloramator australicus CCJ33900.1; CCJ33901.1; CCJ33902.1 2 phosphoenolpyruvate 4.1.1.38 Propionibacterium freudenreichii AJQ89945.1 carboxykinase (PEPCK); LC062511.1 also known as Entamoeba histolytica XP_654765.1 phosphoenolpyruvate XP_650862.1 carboxytransphosphorylase phosphenolpyruvate 4.1.1.31 Pseudomonas fluorescens ABA72812.1 carboxylase (PEPC) 3 pyruvate phosphate 2.7.9.1 Clostridium symbiosum AAA22917.1 dikinase (PPDK) ATP Production from Pyrophosphate, AMP, and Sulfite

Some aspects of the present disclosure use methods for producing ATP from pyrophosphate, AMP, and sulfite (see, e.g., FIG. 16). In the first step, adenylyl sulfate reductase converts adenosine monophosphate (AMP) to adenosine 5′-phosphosulfate (APS) with consumption of sulfite. In the second step, sulfate adenylyltransferase catalyzes the conversion of APS to sulfate with generation of ATP and consumption of pyrophosphate.

In some embodiments, the methods of producing ATP from pyrophosphate, AMP, and sulfite include culturing cells engineered to express a adenylyl sulfate reductase, a sulfate adenylyltransferase, or a combination of a adenylyl sulfate reductase and a sulfate adenylyltransferase. In some embodiments, the adenylyl sulfate reductase and the sulfate adenylyltransferase are expressed as a single fusion (chimeric) protein or a bifunctional protein.

In some embodiments, reducing agents may be added that serve as electron sinks. Examples of such reducing agents include but are not limited to the following: dithiothreitol (DTT) or glutathione or ferricyanide or dithioerythritol or Tris-2-carboxyethylphosphine hydrochloride (TCEP). While individual enzymes will differ in their cofactor preferences, there may be instances where biological cofactors such as NAD⁺, NADP⁺, NADH, or NADPH may be used by an enzyme to absorb these electrons. In these instances, cofactors such as these may also be included.

In some embodiments, at least one of the enzymes is a thermostable enzyme. In some embodiments, at least two (of the enzymes are thermostable enzymes. In some embodiments, all of the enzymes are thermostable enzymes. Thus, in some embodiments, the methods include culturing cells engineered to express a thermostable adenylyl sulfate reductase and a thermostable sulfate adenylyltransferase.

In some embodiments, the methods of producing ATP from sulfite include lysing (e.g., thermal, osmotic, mechanical (e.g., sonication), chemical, or enzymatic lysis) the cultured cells to produce at least one (e.g., 2, 3, 4 or 5) cell lysate. It should be understood that multiple cell lysates (and thus multiple cell populations, e.g., from the same organism (e.g., bacteria) or from different organisms (e.g., bacteria, yeast, and/or plant) may be used in an enzymatic reaction as provided herein. For example, one cell population may be engineered to express an adenylyl sulfate reductase, while another cell population (or several other cell populations) may be engineered to express a sulfate adenylyltransferase. Thus, in some embodiments, the methods comprise culturing a population of cells engineered to express an adenylyl sulfate reductase, and/or culturing a cell population engineered to express a sulfate adenylyltransferase. Following lysis of the cells, the cell lysates are combined such that the enzymes are present in a single cell lysate/reaction mixture.

In some embodiments, the methods of producing ATP from sulfite further include heating the cell lysate(s) (or a cell lysate mixture) to a temperature that inactivates native enzymatic activity but does not inactivate any of the thermostable enzymes of the ATP production pathway, to produce a heat-inactivated lysate. The cell lysate(s), in some embodiments, is heated to a temperature of at least 50° C. For example, the cell lysate(s) may be heated to a temperature of at least 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., or 90° C. A native enzyme (or other non-thermostable enzyme) is considered inactive, in some embodiments, when its level of activity is reduced by at least 50%. In some embodiments, a native enzyme (or other non-thermostable enzyme) is considered inactive when its level of activity is reduced by at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

The cell lysate(s) may be heated for a period of time sufficient to inactive native enzymes (or other non-thermostable enzymes) of the cell. For example, the cell lysate(s) may be heated for at least 2, 3, 4, or at least 5 minutes. In some embodiments, the cell lysate(s) are heated for longer than 5 minutes. In some embodiments, the cell lysate(s) are heated for a period of time sufficient to reduce activity of native enzymes (or other non-thermostable enzymes) by at least 50% (e.g., at least 60%, 70%, 80%, or 90%).

Following heat inactivation, in some embodiments, at least one (e.g., at least two or at least three) purified enzymes may be added to the cell lysate/reaction mixture. Thus, a reaction mixture, in some embodiments, may include a combination of cell lysate, enzymes present in the cell lysate (expressed by the engineered host cell(s)), and at least one purified enzyme. At least one purified enzyme may be a first acetate kinase and/or a second acetate kinase. In some embodiments, a cell lysate may be cooled (e.g., to 50° C.) following a heat-inactivation step, prior to adding the purified enzyme(s).

In some embodiments, the methods of producing ATP from sulfite also include incubating the heat-inactivated lysate(s) in the presence of sulfite, adenosine monophosphate (AMP), and inorganic phosphate to produce ATP. The inorganic phosphate may be, for example, pyrophosphate. Other inorganic phosphates and/or orthophosphate polymers, including but not limited to tripolyphosphate, tetrapolyphosphate, pentapolyphosphate, hexametaphosphate and mixtures thereof, may be used.

Also encompassed herein are cells and cell lysates used for the production of ATP. Thus, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure may include at least one (e.g., at least two) adenylyl sulfate reductase and/or at least one sulfate adenylyltransferase. In some embodiments, an engineered cell (e.g., bacterial cell, yeast cell, and/or plant cell) or cell lysate(s) of the present disclosure includes at least one (e.g., at least two, at least three, or at least four) thermostable adenylyl sulfate reductase and/or at least one thermostable sulfate adenylyltransferase.

TABLE 10 Exemplary ATP Production from Pyrophosphate, AMP, and Sulfite Pathway Enzymes Pathway Uniprot Step Enzyme Name EC No. Native Organism NCBI No. ID 1 Adenylyl sulfate 1.8.99.2 Archaeoglobus fulgidus CAA45030.1, Q59115, reductase CAA45029.1 Q59116 Archaeoglobus profundus WP_012940649.1, WP_012940650 Thermodesulforhabdus SFM96889.1 norvegica Thiobacillus denitrificans AAQ18138.1, Q5VLA6, AAQ18139.1 Q5VLA7 Desulfovibrio vulgaris YP_010068.1, Q59339, YP_010067.1 Q59338 2 Sulfate 2.7.7.4 Archaeoglobus fulgidus KUJ93479.1 A0A124 adenylyltransferase FBI0 Archaeoglobus profundus WP_012940652.1 Thermodesulforhabdus WP_093395234.1, norvegica SFM89448.1 Thiobacillus denitrificans AAQ18137.1 Desulfovibrio vulgaris WP_012611243.1, WP_010938590.1 Escherichia coli ANO79304.1

Depolymerization of Cellular RNA

In some embodiments, cellular RNA serves as the substrate for the production of NTP and/or RNA. Depolymerization (degradation) of cellular RNA results in a pool comprising nucleoside diphosphates (NDPs) or 5′-nucleoside monophosphates (5′-NMPs), depending on the enzymes used for depolymerization.

Cellular RNA, in some embodiments, is depolymerized into NDPs using, for example, a polynucleotide phosphorylase (PNPase) (see, e.g., Table 1). In some embodiments, the concentration of PNPase used in a reaction mixture is 0.001-10 mg/mL (e.g., 0.001, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 5, or 10 mg/mL). In some embodiments, the concentration of PNPase is a reaction mixture is 0.5-5 mg/mL. In some embodiments, the concentration of PNPase is a reaction mixture is 5 mg/mL. In some embodiments, the concentration of PNPase is a reaction mixture is greater than 10 mg/mL.

Cellular RNA, in other embodiments, is depolymerized into NMPs using, for example, a nuclease (e.g., RNase R or P1 nuclease) (see, e.g., Table 1). Depending on the enzyme, enzymatic depolymerization of RNA may yield 3′-NMPs, 5′-NMPs or a combination of 3′-NMPs and 5′-NMPs. Because it is not possible to polymerize 3′-NTPs (converted from 3′-NDPs, which are converted from 3′-NMPs), enzymes (e.g., RNase R and/or P1 nuclease) that yield 5′-NMPs (which are then converted to 5′-NDPs, and then 5′-NTPs) are preferred. In some embodiments, the concentration of nuclease (e.g., RNase R and/or P1 nuclease) used in a reaction mixture is 0.001-10 mg/mL (e.g., 0.001, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 5, or 10 mg/mL). In some embodiments, the concentration of nuclease in a reaction mixture is 0.0.5-5 mg/mL. In some embodiments, the concentration of nuclease in a reaction mixture is 5 mg/mL. In some embodiments, the concentration of nuclease in a reaction mixture is greater than 10 mg/mL.

The PNPase and/or the RNase, in some embodiments, is obtained from or is a component of a cell lysate of cells that express the PNPase and/or the RNase.

The amount of cellular RNA required to synthesize a RNA product of interest may vary, depending on, for example, the desired length and yield of the RNA product as well as the nucleotide composition of the RNA product relative to the nucleotide composition of the cellular RNA starting material. Typically, for a bacterial cell or a yeast cell, for example, cellular RNA content ranges from 5-50% of the total cell mass. The percent of total cell mass can be calculated, for example, using the following equation: (kilogram (kg) of RNA/kilogram of dry cell weight)×100%.

Conditions suitable for the production of NMPs and conditions suitable for the production of NDPs are known in the art or may be determined by one of ordinary skill in the art, taking into consideration, for example, optimal conditions for nuclease (e.g., RNase) activity, including pH (e.g., pH 3-8), temperature (e.g., 15° C. to 70° C.), length of time (e.g., 5 min-72 hrs), and salt concentration (e.g., sodium chloride, potassium chloride, sodium acetate, potassium acetate at a concentration of 5 mM to 1 M) of the reaction mixture as well as any exogenous cofactors. In some embodiments, buffer is added to a cell lysate, for example, to achieve a particular pH value and/or salt concentration. Examples of buffers include, without limitation, phosphate buffer, Tris buffer, MOPS buffer, HEPES buffer, citrate buffer, acetate buffer, malate buffer, MES buffer, histidine buffer, PIPES buffer, bis-tris buffer, and ethanolamine buffer.

In some embodiments, a reaction mixture during a RNA depolymerization reaction is incubated for 24 hours at a temperature of 37° C. In some embodiments, a reaction mixture during a RNA depolymerization reaction is incubated for 5-30 min at a temperature of 37° C. In some embodiments, a reaction mixture during a RNA depolymerization reaction has a pH of 7.0 and is incubated for 15 minutes at a temperature of 37° C. In some embodiments, a reaction mixture during a RNA depolymerization reaction may be incubated under conditions that result in greater than 65% conversion of RNA to NDP or RNA to 5′-NMPs. In some embodiments, RNA is converted to NDP or 5′-NMPs at a rate of (or at least) 50 mM/hr, 100 mM/hr or 200 mM/hr. In other embodiments, a reaction mixture during an RNA depolymerization reaction is incubated at a higher temperature (for example, 50° C.-70° C.), as in Example 5.

Polymerization of RNA Product

In some embodiments, NTPs, either produced by a method provided herein or supplied from commercial sources, are used in a biosynthetic pathway for the production of a RNA product of interest. A DNA designed to encode the RNA product serves as the template for the synthesis of the RNA. The DNA template may be engineered, in some instances, to have a transcriptional promoter that selectively drives transcription of the RNA of interest. Polymerization of RNA requires NTPs, a DNA template comprising a transcriptional promoter, and a polymerase (e.g., RNA polymerase) specific to the transcriptional promoter. Typically, a polymerase for use as provided herein is a single subunit polymerase, is highly selective for its cognate transcriptional promoters, has high-fidelity, and is highly efficient.

In some embodiments, the concentration of the DNA template in a reaction mixture is 0.001-10 μg/μl. In some embodiments, the concentration of the DNA template in a reaction mixture is 0.001 μg/μl, 0.05 μg/μl, 0.1 μg/μl, 0.5 μg/μl, 1.0 μg/μl, 5 μg/μl, or 10 μg/μl.

Conditions suitable for the production of RNA are known in the art or may be determined by one of ordinary skill in the art, taking into consideration, for example, optimal conditions for polymerase (e.g., T7 RNA polymerase) activity, including pH (e.g., pH 3-8), temperature (e.g., 15° C. to 70° C.), length of time (e.g., 5 min-72 hrs), and salt concentration (e.g., sodium chloride, potassium chloride, sodium acetate, potassium acetate at a concentration of 5 mM to 1 M) of the reaction mixture as well as any exogenous cofactors. In some embodiments, buffer is added to a cell lysate, for example, to achieve a particular pH value and/or salt concentration. Examples of buffers include, without limitation, phosphate buffer, Tris buffer, MOPS buffer, HEPES buffer, citrate buffer, acetate buffer, malate buffer, MES buffer, histidine buffer, PIPES buffer, bis-tris buffer, and ethanolamine buffer.

In some embodiments, a reaction mixture during a RNA polymerization reaction is incubated for 0.5-24 hours at a temperature of 37° C. In some embodiments, a reaction mixture during a RNA polymerization reaction is incubated for 0.5-24 hours at a temperature of 50° C.

Cells and Cell Lysates

Cells of the present disclosure, in some embodiments, express cellular RNA, enzymes that depolymerizes RNA (e.g., RNases), pathway enzymes (e.g., recombinant enzymes such as polyphosphate kinase), and/or polymerases (e.g., RNA polymerases). In some embodiments, the engineered cells include a DNA template containing a promoter, and optionally a transcriptional terminator, operably linked to a nucleotide sequence encoding a RNA product of interest.

In some embodiments, the cells are engineered cells. Engineered cells are cells that comprise a engineered (e.g., recombinant or synthetic) nucleic acid, or are otherwise modified such that they are structurally and/or functionally distinct from their naturally-occurring counterparts. Thus, a cell that contains an engineered nucleic acid is considered an “engineered cell.”

A cell “expresses” a product if the product, encoded by a nucleic acid (e.g., an engineered nucleic acid), is produced in the cell. It is known in the art that gene expression refers to the process by which genetic instructions in the form of a nucleic acid are used to synthesize a product, such as a protein (e.g., an enzyme).

Cells may be prokaryotic cells or eukaryotic cells. In some embodiments, cells are bacterial cells, yeast cells, insect cells, mammalian cells, plant cells, or other types of cells.

Bacterial cells of the present disclosure include, without limitation, Escherichia spp., Streptomyces spp., Zymomonas spp., Acetobacter spp., Citrobacter spp., Synechocystis spp., Rhizobium spp., Clostridium spp., Corynebacterium spp., Streptococcus spp., Xanthomonas spp., Lactobacillus spp., Lactococcus spp., Bacillus spp., Alcaligenes spp., Pseudomonas spp., Aeromonas spp., Azotobacter spp., Comamonas spp., Mycobacterium spp., Rhodococcus spp., Gluconobacter spp., Ralstonia spp., Acidithiobacillus spp., Microlunatus spp., Geobacter spp., Geobacillus spp., Arthrobacter spp., Flavobacterium spp., Serratia spp., Saccharopolyspora spp., Thermus spp., Stenotrophomonas spp., Chromobacterium spp., Sinorhizobium spp., Saccharopolyspora spp., Agrobacterium spp., Pantoea spp, and Vibrio natriegens.

Yeast cells of the present disclosure include, without limitation, engineered Saccharomyces spp., Schizosaccharomyces, Hansenula, Candida, Kluyveromyces, Yarrowia and Pichia.

In some embodiments, cells of the present disclosure are Escherichia coli cells, Bacillus subtilis cells, Pseudomonas putida cells, Saccharomyces cerevisiae cells, or Lactobacillus brevis cells. In some embodiments, cells of the present disclosure are Escherichia coli cells.

Typically, cells are cultured. Culturing is the process by which cells are grown under controlled conditions, typically outside of their natural environment. For example, cells, such as bacterial cells, may be grown as a cell suspension in liquid nutrient broth, also referred to as liquid culture medium.

Examples of commonly used bacterial Escherichia coli growth media include, without limitation, LB (Lysogeny Broth) Miller broth (1% NaCl): 1% peptone, 0.5% yeast extract, and 1% NaCl; LB (Lysogeny Broth) Lennox Broth (0.5% NaCl): 1% peptone, 0.5% yeast extract, and 0.5% NaCl; SOB medium (Super Optimal Broth): 2% peptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄; SOC medium (Super Optimal broth with Catabolic repressor): SOB+20 mM glucose; 2×YT broth (2× Yeast extract and Tryptone): 1.6% peptone, 1% yeast extract, and 0.5% NaCl; TB (Terrific Broth) medium: 1.2% peptone, 2.4% yeast extract, 72 mM K₂HPO₄, 17 mM KH₂PO₄ and 0.4% glycerol; and SB (Super Broth) medium: 3.2% peptone, 2% yeast extract, and 0.5% NaCl and or Korz medium (Korz, D J et al. 1995).

Examples of high density bacterial Escherichia coli growth media include, but are not limited to, DNAGro™ medium, ProGro™ medium, AutoX™ medium, DetoX™ medium, InduX™ medium, and SecPro™ medium.

In some embodiments, cells are cultured under conditions that result in expression of enzymes or nucleic acids. Such culture conditions may depend on the particular product being expressed and the desired amount of the product.

In some embodiments, cells are cultured at a temperature of 30° C. to 40° C. For example, engineered cells may be cultured at a temperature of 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C. or 40° C. Typically, cells, such as engineered E. coli cells, are cultured at a temperature of 37° C.

In some embodiments, cells are cultured for a period of time of 12 hours to 72 hours, or more. For example, engineered cells may be cultured for a period of time of 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, or 72 hours. Typically, cells, such as engineered bacterial cells, are cultured for a period of time of 12 to 24 hours. In some embodiments, cells are cultured for 12 to 24 hours at a temperature of 37° C.

In some embodiments, cells are cultured (e.g., in liquid cell culture medium) to an optical density, measured at a wavelength of 600 nm (OD₆₀₀), of 5 to 200. In some embodiments, cells are cultured to an OD₆₀₀ of 5, 10, 15, 20, 25, 50, 75, 100, 150, or 200.

In some embodiments, cells are cultured to a density of 1×10⁸ (OD₆₀₀<1) to 2×10¹¹ (OD˜200) viable cells/ml cell culture medium. In some embodiments, cells are cultured to a density of 1×10⁸, 2×10⁸, 3×10⁸, 4×10⁸, 5×10⁸, 6×10⁸, 7×10⁸, 8×10⁸, 9×10⁸, 1×10⁹, 2×10⁹, 3×10⁹, 4×10⁹, 5×10⁹, 6×10⁹, 7×10⁹, 8×10⁹, 9×10⁹, 1×10¹⁰, 2×10¹⁰, 3×10¹⁰, 4×10¹⁰, 5×10¹⁰, 6×10¹⁰, 7×10¹⁰, 8×10¹⁰, 9×10¹⁰, 1×10¹¹, or 2×10¹¹ viable cells/ml. (Conversion factor: OD 1=8×10⁸ cells/ml).

In some embodiments, cells are cultured in a bioreactor. A bioreactor refers simply to a container in which cells are cultured, such as a culture flask, a dish, or a bag that may be single-use (disposable), autoclavable, or sterilizable. The bioreactor may be made of glass, or it may be polymer-based, or it may be made of other materials.

Examples of bioreactors include, without limitation, stirred tank (e.g., well mixed) bioreactors and tubular (e.g., plug flow) bioreactors, airlift bioreactors, membrane stirred tanks, spin filter stirred tanks, vibromixers, fluidized bed reactors, and membrane bioreactors. The mode of operating the bioreactor may be a batch or continuous processes and will depend on the engineered cells being cultured. A bioreactor is continuous when the feed and product streams are continuously being fed and withdrawn from the system. A batch bioreactor may have a continuous recirculating flow, but no continuous feeding of nutrient or product harvest. For intermittent-harvest and fed-batch (or batch fed) cultures, cells are inoculated at a lower viable cell density in a medium that is similar in composition to a batch medium. Cells are allowed to grow exponentially with essentially no external manipulation until nutrients are somewhat depleted and cells are approaching stationary growth phase. At this point, for an intermittent harvest batch-fed process, a portion of the cells and product may be harvested, and the removed culture medium is replenished with fresh medium. This process may be repeated several times. For production of recombinant proteins and antibodies, a fed-batch process may be used. While cells are growing exponentially, but nutrients are becoming depleted, concentrated feed medium (e.g., 10-15 times concentrated basal medium) is added either continuously or intermittently to supply additional nutrients, allowing for further increase in cell concentration and the length of the production phase. Fresh medium may be added proportionally to cell concentration without removal of culture medium (broth). To accommodate the addition of medium, a fedbatch culture is started in a volume much lower that the full capacity of the bioreactor (e.g., approximately 40% to 50% of the maximum volume).

Some methods of the present disclosure are directed to large-scale (commercial-scale) production of RNA (e.g., mRNA). For large-scale production methods, cells may be grown in liquid culture medium in a volume of 5 liters (L) to 250,000 L, or more. In some embodiments, cells may be grown in liquid culture medium in a volume of greater than (or equal to) 10 L, 100 L, 1000 L, 10000 L, or 100000 L. In some embodiments, cells are grown in liquid culture medium in a volume of 5 L, 10 L, 15 L, 20 L, 25 L, 30 L, 35 L, 40 L, 45 L, 50 L, 100 L, 500 L, 1000 L, 5000 L, 10000 L, 100000 L, 150000 L, 200000 L, 250000 L, or more. In some embodiments, cells may be grown in liquid culture medium in a volume of 5 L to 10 L, 5 L to 15 L, 5 L to 20 L, 5 L to 25 L, 5 L to 30 L, 5 L to 35 L, 5 L to 40 L, 5 L to 45 L, 10 L to 15 L, 10 L to 20 L, 10 L to 25 L, 20 L to 30 L, 10 L to 35 L, 10 L to 40 L, 10L to 45 L, 10 L to 50 L, 15 L to 20 L, 15 L to 25 L, 15 L to 30 L, 15 L to 35 L, 15 L to 40 L, 15 L to 45 L, or 15 to 50 L. In some embodiments, cells may be grown in liquid culture medium in a volume of 100 L to 300000 L, 100 L to 200000 L, or 100 L to 100000 L.

Typically, culturing of cells is followed by lysing the cells. Lysing is the process by which cells are broken down, for example, by viral, heat, chemical, enzymatic, mechanical, or osmotic mechanisms. A cell lysate is a fluid containing the contents of lysed cells (e.g., lysed engineered cells), including, for example, organelles, membrane lipids, proteins, nucleic acids and inverted membrane vesicles. Cell lysates of the present disclosure may be produced by lysing any population of engineered cells, as provided herein.

Cell lysis can disturb carefully controlled cellular environments, resulting in protein degradation and modification by unregulated endogenous proteases and phosphatases. Thus, in some embodiments, protease inhibitors and/or phosphatase inhibitors and/or nuclease inhibitors and/or hydrolase inhibitors and/or deaminase inhibitors may be added to the cell lysate or cells before lysis, or these activities may be removed by heat inactivation, gene inactivation, or protease targeting.

Cell lysates, in some embodiments, may be combined with a nutrient. For example, cell lysates may be combined with Na₂HPO₄, KH₂PO₄, NH₄Cl, NaCl, MgSO₄, CaCl₂. Examples of other nutrients include, without limitation, magnesium sulfate, magnesium chloride, magnesium orotate, magnesium citrate, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, ammonium phosphate monobasic, ammonium phosphate dibasic, ammonium sulfate, ammonium chloride, and ammonium hydroxide.

Cell lysates, in some embodiments, may be combined with a cofactor. For example, cell lysates may be combined with adenosine diphosphate (ADP), adenosine triphosphate (ATP), nicotinamide adenine dinucleotide (NAD+), or other non-protein chemical compounds required for activity of an enzyme (e.g., inorganic ions and coenzymes).

The volume of cell lysate used for a single reaction may vary. In some embodiments, the volume of a cell lysate is 0.001 to 250 m³.

Nucleic Acids

A “nucleic acid” is at least two nucleotides covalently linked together, and in some instances, may contain phosphodiester bonds (e.g., a phosphodiester “backbone”). Nucleic acids (e.g., components, or portions, of nucleic acids) may be naturally occurring or engineered. “Naturally occurring” nucleic acids are present in a cell that exists in nature in the absence of human intervention. “Engineered nucleic acids” include recombinant nucleic acids and synthetic nucleic acids. A “recombinant nucleic acid” refers to a molecule that is constructed by joining nucleic acid molecules (e.g., from the same species or from different species) and, typically, can replicate in a living cell. A “synthetic nucleic acid” refers to a molecule that is biologically synthesized, chemically synthesized, or by other means synthesized or amplified. A synthetic nucleic acid includes nucleic acids that are chemically modified or otherwise modified but can base pair with naturally-occurring nucleic acid molecules. Recombinant and synthetic nucleic acids also include those molecules that result from the replication of either of the foregoing. Engineered nucleic acids may contain portions of nucleic acids that are naturally occurring, but as a whole, engineered nucleic acids do not occur naturally and require human intervention. In some embodiments, a nucleic acid encoding a product of the present disclosure is a recombinant nucleic acid or a synthetic nucleic acid. In other embodiments, a nucleic acid encoding a product is naturally occurring.

An engineered DNA template encoding RNA, as provided herein, may be operably linked to a promoter, which is a control region of a nucleic acid at which initiation and rate of transcription of the remainder of a nucleic acid are controlled. A promoter drives expression or drives transcription of the nucleic acid that it regulates.

A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5′ non-coding sequences located upstream of the coding segment of a given gene or sequence. Such a promoter may be endogenous.

In some embodiments, a coding nucleic acid sequence may be positioned under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with the encoded sequence in its natural environment. Such promoters may include promoters of other genes; promoters isolated from any other cell; and synthetic promoters or enhancers that are not “naturally occurring” such as, for example, those that contain different elements of different transcriptional regulatory regions and/or mutations that alter expression through methods of genetic engineering that are known in the art. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including polymerase chain reaction (PCR).

A promoter is considered to be operably linked to a nucleotide sequence when it is in a correct functional location and orientation in relation to the nucleotide sequence it regulates to control (“drive”) transcriptional initiation and/or expression of that nucleotide sequence.

Engineered nucleic acids of the present disclosure may contain a constitutive promoter or an inducible promoter. In some embodiments, the constitutive promotor or the inducible promoter is operably linked to a coding sequence, and optionally one or more transcriptional terminators. In some embodiments, the coding sequence encodes a protein or a RNA product. A “constitutive promoter” refers to a promoter that is constantly active in a cell. An “inducible promoter” refers to a promoter that initiates or enhances transcriptional activity when in the presence of, influenced by, or contacted by an inducer or inducing agent, or activated in the absence of a factor that causes repression. Inducible promoters for use in accordance with the present disclosure include any inducible promoter described herein or known to one of ordinary skill in the art. Examples of inducible promoters include, without limitation, chemically/biochemically-regulated and physically-regulated promoters such as organic solvent-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature/heat-inducible, phosphate-regulated (e.g., PhoA), and light-regulated promoters.

An engineered DNA template encoding RNA, as provided herein, may also be operably linked to one or more transcriptional terminators, which are control regions of a nucleic acid which cause a polymerase to stop transcribing and dissociate from the DNA template.

A terminator may be one or more sequences naturally associated with a gene or sequence, as may be obtained by isolating the 3′-non-coding sequences located downstream of the coding segment of a given gene or sequence. Such a terminator may be endogenous or engineered for improved termination efficiency. Endogenous and/or engineered terminator sequences from one or more sources can be added in series for improved termination efficiency.

Circular DNA templates encoding RNA may include one or more transcriptional terminators to minimize or prevent transcription of non-template DNA sequence, for example, a sequence that is part of a plasmid backbone.

Engineered nucleic acids may be introduced into host cells using any means known in the art, including, without limitation, transformation, transfection (e.g., chemical (e.g., calcium phosphate, cationic polymers, or liposomes) or non-chemical (e.g., electroporation, sonoporation, impalefection, optical transfection, hydrodynamic transfection)), and transduction (e.g., viral transduction).

Enzymes or other proteins encoded by a naturally-occurring, intracellular nucleic acid may be referred to as “endogenous enzymes” or “endogenous proteins.”

Compositions

In some embodiments, a reaction mixture for the production of nucleoside triphosphates (NTPs) comprises nucleoside diphosphates (NDPs), a polyphosphate kinase, and a polyphosphate. In some embodiments, the reaction mixture further comprises a nucleoside kinase and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of NTPs comprises 5′ nucleoside monophosphates, a polyphosphate kinase, and polyphosphate. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of NTPs comprises nucleosides, a polyphosphate kinase, and a polyphosphate. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of NTPs comprises nucleobases, a phosphoribosyltransferase, a phosphoribosylpyrophosphate, a polyphosphate kinase, and a polyphosphate. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of NTPs comprises nucleobases, D-ribose, a ribokinase, a phosphopentomutase, a nucleoside phosphorylase, a polyphosphate kinase, and a polyphosphate. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of ribonucleic acid (RNA) comprises nucleoside diphosphates (NDPs), a polyphosphate kinase, a polyphosphate, a deoxyribonucleic acid (DNA) template, and a polymerase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMO kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of RNA comprises 5′ nucleoside monophosphates, a polyphosphate kinase, a polyphosphate, a deoxyribonucleic acid (DNA) template, and a polymerase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of RNA comprises nucleosides, a nucleoside kinase, a polyphosphate kinase, a polyphosphate, a deoxyribonucleic acid (DNA) template, and a polymerase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of RNA comprises nucleobases, a phosphoribosyltransferase, a phosphoribosylpyrophosphate, a polyphosphate kinase, a polyphosphate, a deoxyribonucleic acid (DNA) template, and a polymerase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

In some embodiments, a reaction mixture for the production of RNA comprises nucleobases, D-ribose, a ribokinase, a phosphopentomutase, a nucleoside phosphorylase, a polyphosphate kinase, a polyphosphate, a deoxyribonucleic acid (DNA) template, and a polymerase. In some embodiments, the reaction mixture further comprises a nucleoside kinase, a NMP kinase, and/or a NDP kinase.

Additional Embodiments

Additional embodiments of the present disclosure are encompassed by the following numbered paragraphs.

1. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture nucleoside diphosphates (NDPs),         a polyphosphate kinase, and a polyphosphate under conditions         appropriate for the production of NTPs, optionally wherein the         reaction mixture further comprises a nucleoside kinase and/or a         NDP kinase.

2. The method of paragraph 1, wherein the NDPs comprise ADP, GDP, CDP, and/or UDP.

3. The method of paragraph 1 or 2, wherein the NDPs are chemically synthesized, a product of fermentation, or extracted from a natural source.

4. The method of any one of paragraphs 1-3, wherein the a polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

5. The method of paragraph 4, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

6. The method of any one of paragraphs 1-5, wherein the polyphosphate comprises hexametaphosphate.

7. The method of any one of paragraphs 1-6, wherein the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase.

8. The method of any one of paragraphs 1-7, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase.

9. The method of paragraph 8, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated.

10. The method of paragraph 9, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

11. The method of paragraph 9 or 10, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

12. The method of any one of paragraphs 9-11, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

13. The method of any one of paragraphs 9-12, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

14. The method of any one of paragraphs 1-13, wherein the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase can withstand elimination conditions.

15. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture 5′ nucleoside monophosphates         (5′ NMPs), a polyphosphate kinase, and a polyphosphate under         conditions appropriate for the production of NTPs, optionally         wherein the reaction mixture further comprises a nucleoside         kinase, a NMP kinase, and/or a NDP kinase.

16. The method of paragraph 15, wherein the 5′ NMPs comprise 5′ AMP, 5′ GMP, 5′ CMP and/or 5′ UMP.

17. The method of paragraph 15 or 16, wherein the 5′ NMPs are chemically synthesized, a product of fermentation, or extracted from a natural source.

18. The method of any one of paragraphs 15-17, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

19. The method of paragraph 18, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

20. The method of any one of paragraphs 15-19, wherein the polyphosphate comprises hexametaphosphate.

21. The method of any one of paragraphs 15-20, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

22. The method of any one of paragraphs 15-21, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

23. The method of paragraph 22, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

24. The method of paragraph 23, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

25. The method of paragraph 23 or 24, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

26. The method of any one of paragraphs 23-25, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

27. The method of any one of paragraphs 23-26, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

28. The method of any one of paragraphs 15-27, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase can withstand elimination conditions.

29. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture nucleosides, a polyphosphate         kinase, and a polyphosphate under conditions appropriate for the         production of NTPs, optionally wherein the reaction mixture         further comprises a nucleoside kinase, a NMP kinase, and/or a         NDP kinase.

30. The method of paragraph 29, wherein the nucleosides comprise adenosine, guanosine, cytidine, and/or uridine.

31. The method of paragraph 29 or 30, wherein the nucleosides are chemically synthesized, a product of fermentation, or extracted from a natural source.

32. The method of any one of paragraphs 29-31, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

33. The method of paragraph 32, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

34. The method of any one of paragraphs 29-33, wherein the polyphosphate comprises hexametaphosphate.

35. The method of any one of paragraphs 29-34, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase and/or the NDP kinase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

36. The method of any one of paragraphs 29-35, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

37. The method of paragraph 36, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

38. The method of paragraph 37, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

39. The method of paragraph 37 or 38, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

40. The method of any one of paragraphs 37-39, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

41. The method of any one of paragraphs 37-40, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

42. The method of any one of paragraphs 29-41, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase can withstand elimination conditions.

43. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture nucleobases, a         phosphoribosyltransferase, a phosphoribosylpyrophosphate, a         polyphosphate kinase, and a polyphosphate under conditions         appropriate for the production of NTPs, optionally wherein the         reaction mixture further comprises a nucleoside kinase, a NMP         kinase, and/or a NDP kinase.

44. The method of paragraph 43, wherein the nucleobases comprise adenine, guanidine, cytosine, and/or uracil.

45. The method of paragraph 43 or 44, wherein the nucleobases are chemically synthesized, a product of fermentation, or extracted from a natural source.

46. The method of any one of paragraphs 43-45, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

47. The method of paragraph 46, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

48. The method of any one of paragraphs 43-47, wherein the polyphosphate comprises hexametaphosphate.

49. The method of any one of paragraphs 43-48, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase and/or the NDP kinase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

50. The method of any one of paragraphs 43-49, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

51. The method of paragraph 50, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

52. The method of paragraph 51, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

53. The method of paragraph 51 or 52, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

54. The method of any one of paragraphs 51-53, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

55. The method of any one of paragraphs 51-54, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

56. The method of any one of paragraphs 43-55, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase can withstand elimination conditions.

57. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture nucleobases, ribose,         ribokinase, phosphopentomutase, a nucleoside phosphorylase, a         polyphosphate kinase, and a polyphosphate under conditions         appropriate for the production of NTPs, optionally wherein the         reaction mixture further comprises a nucleoside kinase, a NMP         kinase, and/or a NDP kinase.

58. The method of paragraph 57, wherein the nucleobases comprise adenine, guanidine, cytosine, and/or uracil.

59. The method of paragraph 57 or 58, wherein the nucleobases are chemically synthesized, a product of fermentation, or extracted from a natural source.

60. The method of any one of paragraphs 57-59, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

61. The method of paragraph 60, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

62. The method of any one of paragraphs 57-61, wherein the polyphosphate comprises hexametaphosphate.

63. The method of any one of paragraphs 57-62, wherein the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase is prepared from cells that express the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

64. The method of any one of paragraphs 57-63, wherein the reaction mixture comprises a lysate prepared from cells that express the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

65. The method of paragraph 64, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

66. The method of paragraph 65, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

67. The method of paragraph 65 or 66, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, organic solvent, and/or chemical inhibitors.

68. The method of any one of paragraphs 65-67, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

69. The method of any one of paragraphs 65-68, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

70. The method of any one of paragraphs 57-69, wherein the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the NMP kinase, the NDP kinase, and/or the nucleoside kinase is modified to withstand elimination conditions.

71. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   incubating in a reaction mixture cellular ribonucleic acid         (RNA), a polynucleotide phosphorylase (PNPase), inorganic         phosphate, a polyphosphate kinase, and a polyphosphate under         conditions appropriate for the production of NDPs and NTPs,         optionally wherein the reaction mixture further comprises a         nucleoside kinase and/or a NDP kinase.

72. The method of paragraph 71, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

73. The method of paragraph 61 or 72, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

74. The method of any one of paragraphs 71-73, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

75. The method of paragraph 74, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

76. The method of any one of paragraphs 71-75, wherein the polyphosphate comprises hexametaphosphate.

77. The method of any one of paragraphs 71-76, wherein the PNPase, the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase is prepared from cells that express the PNPase, the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase.

78. The method of any one of paragraphs 71-77, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the PNPase, the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase.

79. The method of paragraph 78, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

80. The method of paragraph 79, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

81. The method of paragraph 79 or 80, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

82. The method of any one of paragraphs 79-81, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

83. The method of any one of paragraphs 79-82, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

84. The method of any one of paragraphs 79-83, wherein the PNPase, the polyphosphate kinase, the nucleoside kinase, and/or the NDP kinase can withstand elimination conditions.

85. A method for producing nucleoside triphosphates (NTPs), comprising:

-   -   (a) incubating in a reaction mixture cellular ribonucleic acid         (RNA), a ribonuclease, a polyphosphate kinase, and a         polyphosphate under conditions appropriate for the production of         5′ NMPs and NTPs, optionally wherein the reaction mixture         further comprises a nucleoside kinase, a NMP kinase, and/or a         NDP kinase.

86. The method of paragraph 85, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

87. The method of paragraph 85 or 86, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

88. The method of any one of paragraphs 85-87, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

89. The method of paragraph 88, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

90. The method of any one of paragraphs 85-89, wherein the polyphosphate comprises hexametaphosphate.

91. The method of any one of paragraphs 85-90, wherein the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase is prepared from cells that express the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

92. The method of any one of paragraphs 85-91, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase.

93. The method of paragraph 92, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

94. The method of paragraph 93, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

95. The method of paragraph 93 or 94, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

96. The method of any one of paragraphs 93-95, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

97. The method of any one of paragraphs 93-96, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

98. The method of any one of paragraphs 93-97, wherein the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, and/or the NDP kinase can withstand elimination conditions.

99. A method for producing ribonucleic acid (RNA), comprising:

-   -   incubating in a reaction mixture nucleoside diphosphates (NDPs),         a polyphosphate kinase, a polyphosphate, a DNA template encoding         a RNA of interest, and a RNA polymerase under conditions         appropriate for the production of the RNA of interest,         optionally wherein the reaction mixture further comprises a         nucleoside kinase and/or a NDP kinase.

100. The method of paragraph 99, wherein the NDPs comprise ADP, GDP, CDP, and/or UDP.

101. The method of paragraph 99 or 100, wherein the NDPs are chemically synthesized, a product of fermentation, or extracted from a natural source.

102. The method of any one of paragraphs 99-101, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

103. The method of paragraph 102, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

104. The method of any one of paragraphs 99-103, wherein the polyphosphate comprises hexametaphosphate.

105. The method of any one of paragraphs 99-104, wherein the polyphosphate kinase, the DNA template, the polymerase, the nucleoside kinase, and/or the NDP kinase is prepared from cells that express the polyphosphate kinase, the DNA template, the polymerase, the nucleoside kinase, and/or the NDP kinase.

106. The method of any one of paragraphs 99-105, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the DNA template, the polymerase, the nucleoside kinase, and/or the NDP kinase.

107. The method of paragraph 106, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated.

108. The method of paragraph 107, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

109. The method of paragraph 107 or 108, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

110. The method of any one of paragraphs 107-109, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

111. The method of any one of paragraphs 107-110, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

112. The method of any one of paragraphs 99-111, wherein the polyphosphate kinase, the polymerase, the nucleoside kinase, and/or the NDP kinase can withstand elimination conditions.

113. The method of any one of paragraphs 99-112, wherein the polymerase comprises a RNA polymerase.

114. A method for producing ribonucleic acid (RNA), comprising:

-   -   incubating in a reaction mixture 5′ nucleoside monophosphates         (5′ NMPs), a polyphosphate kinase, a polyphosphate, a DNA         template encoding a RNA of interest, and a polymerase under         conditions appropriate for the production of the RNA of         interest, optionally wherein the reaction mixture further         comprises a nucleoside kinase, a NMP kinase, and/or a NDP         kinase.

115. The method of paragraph 114, wherein the 5′ NMPs comprise 5′ AMP, 5′ GMP, 5′ CMP and/or 5′ UMP.

116. The method of paragraph 114 or 115, wherein the 5′ NMPs are chemically synthesized, a product of fermentation, or extracted from a natural source.

117. The method of any one of paragraphs 114-116, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

118. The method of paragraph 117, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

119. The method of any one of paragraphs 114-118, wherein the polyphosphate comprises hexametaphosphate.

120. The method of any one of paragraphs 114-119, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

121. The method of any one of paragraphs 114-120, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

122. The method of paragraph 121, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

123. The method of paragraph 122, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

124. The method of paragraph 122 or 123, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

125. The method of any one of paragraphs 122-124, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

126. The method of any one of paragraphs 122-125, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

127. The method of any one of paragraphs 114-126, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

128. The method of any one of paragraphs 114-127, wherein the polymerase comprises a RNA polymerase.

129. A method for producing ribonucleic acid (RNA), comprising:

-   -   incubating in a reaction mixture nucleosides, a polyphosphate         kinase, a polyphosphate, a DNA template encoding a RNA of         interest, and/or a polymerase under conditions appropriate for         the production of the RNA of interest, optionally wherein the         reaction mixture further comprises a nucleoside kinase, a NMP         kinase, and/or a NDP kinase.

130. The method of paragraph 129, wherein the nucleosides comprise adenosine, guanosine, cytidine, and/or uridine.

131. The method of paragraph 129 or 130, wherein the nucleosides are chemically synthesized, a product of fermentation, or extracted from a natural source.

132. The method of any one of paragraphs 129-131, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

133. The method of paragraph 132, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

134. The method of any one of paragraphs 129-133, wherein the polyphosphate comprises hexametaphosphate.

135. The method of any one of paragraphs 129-134, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the least one polyphosphate kinase, the nucleoside kinase, the polyphosphate, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

136. The method of any one of paragraphs 129-135, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the least one polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

137. The method of paragraph 136, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

138. The method of paragraph 137, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

139. The method of paragraph 137 or 138, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

140. The method of any one of paragraphs 137-139, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

141. The method of any one of paragraphs 137-140, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

142. The method of any one of paragraphs 129-141, wherein the least one polyphosphate kinase, the polyphosphate, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

143. The method of any one of paragraphs 129-142, wherein the polymerase comprises a RNA polymerase.

144. A method for producing ribonucleic acid (RNA), comprising:

-   -   incubating in a reaction mixture nucleobases, a         phosphoribosyltransferase, a phosphoribosylpyrophosphate, a         polyphosphate kinase, and a polyphosphate, a DNA template         encoding a RNA of interest, and/or a polymerase under conditions         appropriate for the production of the RNA of interest,         optionally wherein the reaction mixture further comprises a         nucleoside kinase, a NMP kinase, and/or a NDP kinase.

145. The method of paragraph 144, wherein the nucleobases comprise adenine, guanidine, cytosine, and/or uracil.

146. The method of paragraph 144 or 145, wherein the nucleobases are chemically synthesized, a product of fermentation, or extracted from a natural source.

147. The method of any one of paragraphs 144-146, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

148. The method of paragraph 148, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

149. The method of any one of paragraphs 144-148, wherein the polyphosphate comprises hexametaphosphate.

150. The method of any one of paragraphs 144-149, wherein the phosphoribosyltransferase, the polyphosphate kinase, the nucleoside kinase, a NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the phosphoribosyltransferase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

151. The method of any one of paragraphs 144-150, wherein the reaction mixture comprises a cell lysate or an enzyme preparation from cells that express the phosphoribosyltransferase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

152. The method of paragraph 151, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

153. The method of paragraph 152, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

154. The method of paragraph 152 or 153, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

155. The method of any one of paragraphs 152-154, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

156. The method of any one of paragraphs 152-155, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

157. The method of any one of paragraphs 144-156, wherein the phosphoribosyltransferase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

158. The method of any one of paragraphs 144-157, wherein the polymerase comprises a RNA polymerase.

159. A method for producing ribonucleic acid (RNA), comprising:

-   -   incubating in a reaction mixture nucleobases, a ribose, a         ribokinase, a phosphopentomutase, a nucleoside phosphorylase, a         polyphosphate kinase, a polyphosphate, a DNA template encoding a         RNA of interest, and a polymerase under conditions appropriate         for the production of the RNA of interest, optionally wherein         the reaction mixture further comprises a nucleoside kinase, a         NMP kinase, and/or at least one NDP kinase.

160. The method of paragraph 159, wherein the nucleobases comprise adenine, guanidine, cytosine, and/or uracil.

161. The method of paragraph 159 or 160, wherein the nucleobases are chemically synthesized, a product of fermentation, or extracted from a natural source.

162. The method of any one of paragraphs 159-161, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

163. The method of paragraph 162, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

164. The method of any one of paragraphs 159-163, wherein the polyphosphate comprises hexametaphosphate.

165. The method of any one of paragraphs 159-164, wherein the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is from at least one lysate prepared from engineered cells modified to express the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

166. The method of any one of paragraphs 159-165, wherein the reaction mixture a lysate prepared from cells that express the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

167. The method of paragraph 166, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated.

168. The method of paragraph 167, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

169. The method of paragraph 167 or 168, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, organic solvent, and/or chemical inhibitors.

170. The method of any one of paragraphs 167-169, wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

171. The method of any one of paragraphs 167-170, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

172. The method of any one of paragraphs 159-171, wherein the ribokinase, the phosphopentomutase, the nucleoside phosphorylase, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase is modified to withstand elimination conditions.

173. The method of any one of paragraphs 159-172, wherein the at least one polymerase comprises at least one RNA polymerase.

174. A method for producing ribonucleic acid (RNA), comprising:

-   -   (a) incubating in a reaction mixture cellular ribonucleic acid         (RNA), a polynucleotide phosphorylase (PNPase), and inorganic         phosphate under conditions appropriate for the production of         nucleoside diphosphates (NDPs);     -   (b) eliminating the PNPase; and     -   (c) incubating in the reaction mixture, or in a second reaction         mixture, the NDPs, a polyphosphate kinase, a polyphosphate, a         DNA template encoding a RNA of interest, and a polymerase under         conditions appropriate for the production of the RNA of         interest, optionally wherein the reaction mixture of step (c)         further comprises a nucleoside kinase and/or a NDP kinase.

175. The method of paragraph 174, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

176. The method of paragraph 174 or 175, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

177. The method of any one of paragraphs 174-176, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

178. The method of paragraph 177, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

179. The method of any one of paragraphs 174-178, wherein the polyphosphate comprises hexametaphosphate.

180. The method of any one of paragraphs 174-179, wherein the PNPase is prepared from cells that express the PNPase.

181. The method of any one of paragraphs 174-180, wherein the reaction mixture of (a) comprises a cell lysate prepared from cells that express the PNPase.

182. The method of paragraph 181, wherein step (b) comprises eliminating the PNPase via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

183. The method of paragraph 181 or 182, wherein step (b) comprises eliminating the PNPase via wherein native enzymatic activity of enzymes in the cell lysate or enzyme preparation have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

184. The method of any one of paragraphs 174-183, wherein the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase.

185. The method of any one of paragraphs 174-183, wherein the reaction mixture of step (c) comprises a cell lysate prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase.

186. The method of paragraph 185, wherein native enzymatic activity of enzymes in the cell lysate of step (c) have been eliminated.

187. The method of paragraph 186, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

188. The method of paragraph 186 or 187, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

189. The method of any one of paragraphs 186-188, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

190. The method of any one of paragraphs 186-189, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

191. The method of any one of paragraphs 186-190, wherein the polyphosphate kinase, the nucleoside kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

192. The method of any one of paragraphs 174-191, wherein the polymerase comprises a RNA polymerase.

193. A method for producing ribonucleic acid (RNA), comprising:

-   -   (a) incubating in a reaction mixture cellular ribonucleic acid         (RNA), a polynucleotide phosphorylase (PNPase), inorganic         phosphate, a polyphosphate kinase, a polyphosphate, a DNA         template encoding a RNA of interest, and a polymerase under         conditions appropriate for the production of nucleoside         diphosphates, optionally wherein the reaction mixture further         comprises a nucleoside kinase and/or a NDP kinase;     -   (b) eliminating the PNPase; and     -   (c) incubating the reaction mixture under conditions appropriate         for the production of the RNA of interest.

194. The method of paragraph 193, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

195. The method of paragraph 193 or 194, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

196. The method of any one of paragraphs 193-195, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

197. The method of paragraph 196, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

198. The method of any one of paragraphs 193-197, wherein the polyphosphate comprises hexametaphosphate.

199. The method of any one of paragraphs 193-198, wherein the PNPase, the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the PNPase, the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase.

200. The method of any one of paragraphs 193-199, wherein the reaction mixture of (a) comprises a cell lysate prepared from cells that express the PNPase, the polyphosphate kinase, the nucleoside kinase, the NDP kinase, the DNA template, and/or the polymerase.

201. The method of paragraph 200, wherein step (b) comprises eliminating the PNPase and native enzymatic activities in the cell lysate via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

202. The method of paragraph 200 or 201, wherein step (b) comprises eliminating the PNPase and native enzymatic activities in the cell lysate via separation, precipitation, filtration, capture, and/or chromatography.

203. The method of any one of paragraphs 200-202, wherein step (b) comprises eliminating native enzymatic activities in the cell lysate via genetic modification, enzyme secretion from a cell, and/or protease targeting.

204. The method of any one of paragraphs 201-203, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

205. The method of any one of paragraphs 201-204, wherein the polyphosphate kinase, the nucleoside kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

206. The method of any one of paragraphs 193-205, wherein the polymerase comprises a RNA polymerase.

207. A method for producing ribonucleic acid (RNA), comprising:

-   -   (a) incubating in a reaction mixture cellular ribonucleic acid         (RNA) and a ribonuclease under conditions appropriate for the         production of 5′ nucleoside monophosphates (5′ NMPs);     -   (b) eliminating the ribonuclease; and     -   (c) incubating in the reaction mixture, or in a second reaction         mixture, the 5′ NMPs, a polyphosphate kinase, a polyphosphate, a         DNA template encoding a RNA of interest, and a polymerase under         conditions appropriate for the production of the RNA of         interest, optionally wherein the reaction mixture of step (c)         further comprises a nucleoside kinase, a NMP kinase, and/or a         NDP kinase.

208. The method of paragraph 207, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

209. The method of paragraph 207 or 208, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

210. The method of any one of paragraphs 207-209, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

211. The method of paragraph 210, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

212. The method of any one of paragraphs 207-211, wherein the polyphosphate comprises hexametaphosphate.

213. The method of any one of paragraphs 207-212, wherein the ribonuclease is prepared from cells that express the ribonuclease.

214. The method of any one of paragraphs 207-213, wherein the reaction mixture of (a) comprises a cell lysate prepared from cells that express the ribonuclease.

215. The method of paragraph 214, wherein step (b) comprises eliminating the ribonuclease via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

216. The method of paragraph 214 or 215, wherein step (b) comprises eliminating the ribonuclease via separation, precipitation, filtration, capture, and/or chromatography.

217. The method of any one of paragraphs 207-216, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

218. The method of any one of paragraphs 207-216, wherein the reaction mixture of step (c) comprises a cell lysate prepared from cells that express the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

219. The method of paragraph 218, wherein native enzymatic activity of enzymes in the cell lysate of step (c) have been eliminated.

220. The method of paragraph 219, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via genetic modification, enzyme secretion from a cell, and/or protease targeting.

221. The method of paragraph 219 or 220, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

222. The method of any one of paragraphs 219-221, wherein native enzymatic activity of enzymes in the cell lysate have been eliminated via separation, precipitation, filtration, capture, and/or chromatography.

223. The method of any one of paragraphs 219-222, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

224. The method of any one of paragraphs 219-223, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

225. The method of any one of paragraphs 207-224, wherein the polymerase comprises at least on RNA polymerase.

226. A method for producing ribonucleic acid (RNA), comprising:

-   -   (a) incubating in a reaction mixture cellular ribonucleic acid         (RNA), a ribonuclease, a polyphosphate kinase, a polyphosphate,         a DNA template encoding a RNA of interest, and a polymerase         under conditions appropriate for the production of 5′ nucleoside         monophosphates (5′ NMPs);     -   (b) eliminating the ribonuclease; and     -   (c) incubating the reaction mixture under conditions appropriate         for the production of the RNA of interest.

227. The method of paragraph 226, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.

228. The method of paragraph 226 or 214, wherein the cellular RNA is from a unicellular organism or a multicellular organism.

229. The method of any one of paragraphs 226-228, wherein the polyphosphate kinase is selected from PPK1 family enzymes and PPK2 family enzymes.

230. The method of paragraph 229, wherein the polyphosphate kinase comprises a Class III polyphosphate kinase 2 from Deinococcus geothermalis.

231. The method of any one of paragraphs 226-230, wherein the polyphosphate comprises hexametaphosphate.

232. The method of any one of paragraphs 226-231, wherein the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase is prepared from cells that express the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

233. The method of any one of paragraphs 227-232, wherein the reaction mixture of (a) comprises a cell lysate prepared from cells that express the ribonuclease, the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, the DNA template, and/or the polymerase.

234. The method of paragraph 233, wherein step (b) comprises eliminating the ribonuclease and native enzymatic activities in the cell lysate via temperature, pH, salt, detergent, alcohol, and/or chemical inhibitors.

235. The method of paragraph 233 or 234, wherein step (b) comprises eliminating the ribonuclease and native enzymatic activities in the cell lysate via separation, precipitation, filtration, capture, and/or chromatography.

236. The method of any one of paragraphs 233-235, wherein step (b) comprises eliminating native enzymatic activities in the cell lysate via genetic modification, enzyme secretion from a cell, and/or protease targeting.

237. The method of any one of paragraphs 234-236, wherein the native enzymatic activities are selected from phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.

238. The method of any one of paragraphs 234-237, wherein the polyphosphate kinase, the nucleoside kinase, the NMP kinase, the NDP kinase, and/or the polymerase can withstand elimination conditions.

239. The method of any one of paragraphs 226-238, wherein the polymerase comprises a RNA polymerase.

Examples Example 1—Cell-Free Synthesis of RNA Starting from Either Lysate RNA or Purified E. coli RNA

Materials and Methods

Strains and Lysates

E. coli strain BL21(DE3) was transformed with pETDuet-1 vectors encoding codon-optimized versions of the following enzymes: RNase R (K544R) from E. coli (EcRNR), UMP kinase from Pyrococcus furiosus (PfPyrH), CMP kinase from Thermus thermophilus (TthCmk), GMP kinase from Thermotoga maritima (TmGmk), NDP kinase from Aquifex aeolicus (AaNdk), and Class III polyphosphate kinase 2 from Deinococcus geothermalis (DgPPK2). All enzymes, except for DgPPK2, contained N-terminal hexahistidine tags. The resulting strains were grown in a 37° C. batch fermentation process in Korz media supplemented with 40 g/L glucose and 50 mg/L carbenicillin until OD₆₀₀=20, induced with 0.8 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and grown for an additional 1 hour before harvest via centrifugation. After harvest, biomass pellets were stored at −80° C.

Biomass pellets were then used to prepare cell lysates. Lysates were prepared by thawing biomass pellets on ice, then resuspending in 1.5 volumes resuspension buffer. For the strain expressing EcRNR, biomass was resuspended in 58.8 mM potassium phosphate dibasic. For strains expressing PfPyrH, TthCmk, TmGmk, and AaNdk, biomass was resuspended in 50 mM Tris-HCl (pH 8.5) with 50 mM NaCl. For the strain expressing DgPPK2, biomass was resuspended in 100 mM MOPS-NaOH (pH 7.0). For all strains, biomass was lysed by 2-3 passes of mechanical homogenization at 15,000 psi at 4° C. Lysates were then clarified by centrifugation at 16,000×g for 1 hour at 4° C.

Extraction and Purification of E. coli RNA

RNA was extracted and purified from high-density E. coli lysates (protein concentration: 40-50 mg/mL) according to established protocols (Mohanty, B. K., Giladi, H., Maples, V. F., & Kushner, S. R. (2008). Analysis of RNA decay, processing, and polyadenylation in Escherichia coli and other prokaryotes. Methods in Enzymology, 447, 3-29).

Protein Expression and Purification

E. coli strain BL21(DE3) was transformed with a pBAD24 vector encoding a thermostable mutant T7 RNA polymerase with an N-terminal hexahistidine tag. The resulting strain was cultivated in baffled shake flasks using lysogeny broth (LB) media supplemented with 50 mg/L carbenicillin. Cultures were grown at 37° C. with shaking until OD600=0.6, then induced with 0.2% (w/v) L-arabinose and grown for an additional 4 hours. Biomass was then harvested by centrifugation and stored at −80° C. prior to lysis. Lysates were prepared by thawing biomass pellets on ice, resuspending in 1.5 volumes equilibration/wash buffer (20 mM sodium phosphate pH 7.4, 500 mM sodium chloride, 30 mM imidazole), and 2-3 passes of mechanical homogenization at 15,000 psi and 4° C. Lysates were then clarified by centrifugation. Recombinant protein was purified by fast protein liquid chromatography (FPLC) using an AKTAPrime Plus equipped with a HisTrap HP column (GE Healthcare Life Sciences) following standard protocols. Fractions containing recombinant protein were then combined and buffer exchanged by dialysis into 2× phosphate buffered saline (PBS) supplemented with 5 mM DTT and 0.01% Triton X-100. Post-dialysis, protein stocks were diluted with an equal volume of glycerol and stored at −20° C.

For E. coli RNase R, cultures were grown, expression was induced, and lysates were prepared following the protocols described herein. The enzyme was then purified following the protocols described herein, except that the purified enzyme was buffer-exchanged by dialysis into 2×PBS supplemented with 500 mM NaCl prior to mixing with glycerol.

DNA Template Preparation

Linear DNA templates were amplified from synthetic DNA by PCR and purified using solid-phase reversible immobilization (SPRI) on paramagnetic beads. Plasmid DNA templates were prepared by cloning the sequence of interest into a suitable plasmid vector, transforming the resulting plasmid into E. coli strain DH10b, culturing the transformants in LB media, and purifying the plasmids using Plasmid Maxi or Giga kits (Qiagen).

Cell-Free RNA Synthesis from Lysate RNA

Lysates expressing EcRNR, TthCmk, PfPyrH, TmGmk, AaNdk, and DgPPK2 were each diluted to 42 mg/mL in 50 mM Tris, 50 mM NaCl (pH 7.0), then combined in equal proportion. Depolymerization of RNA in the lysates was initiated by adding an equal volume of 3 mM ethylenediaminetetraacetic acid (EDTA) in 50 mM Tris, 50 mM NaCl (pH 7.0) and incubating at 37° C. for 15 minutes. Depolymerization was monitored by quantifying acid-soluble nucleotides by absorbance at 260 nm. Magnesium sulfate and sodium hexametaphosphate were added to the lysates to final concentrations of 30 mM and 1 mM, respectively, then the lysates were incubated at 70° C. for 15 minutes to inactivate EcRNR and endogenous E. coli enzymes. After 15 minutes, the temperature was reduced to 50° C. and the reaction was assembled with the following composition:

TABLE 11 Reaction Conditions Magnesium sulfate 30 mM Sodium hexametaphosphate 4 mM Kinase lysates 21 g/L total protein Spermidine 2 mM Template DNA 25 mg/L RNA polymerase 0.3 g/L

Reactions were incubated at 50° C. for 2 hours, treated with TURBO DNase (Thermo Fisher), and analyzed by agarose gel electrophoresis.

Cell-Free RNA Synthesis from Purified E. coli RNA

Purified E. coli RNA (approximately 8 g/L) was depolymerized by incubating with 1 g/L purified E. coli RNase R in a buffer containing 50 mM Tris-HCl (pH 7.0), 50 mM sodium chloride, and 2 mM magnesium sulfate. The depolymerization reaction was incubated at 37° C. for 30 minutes and monitored by quantifying acid-soluble nucleotides by absorbance at 260 nm. After 30 minutes, the depolymerization reaction was combined with the TthCmk, TmGmk, PfPyrH, AaNdk, and DgPPK2 lysates each diluted in 50 mM Tris-HCl (pH 7.0), 50 mM NaCl, and mixed in equal proportion. Magnesium sulfate and sodium hexametaphosphate were then added to final concentrations of 30 mM and 1 mM, respectively, and the reaction heated to 70° C. for 15 minutes. After heat inactivation, reactions were assembled as described herein with the following composition:

TABLE 12 Reaction Conditions Magnesium sulfate 30 mM Sodium hexametaphosphate 4 mM Kinase lysates 13 g/L total protein Spermidine 2 mM Template DNA 25 mg/L RNA polymerase 0.3 g/L

Results

Cell-free synthesis of RNA was performed using lysate RNA as a substrate. RNA from pooled lysates overexpressing pathway enzymes was first depolymerized by overexpressed E. coli RNase R (EcRNR), an exonuclease that produces 5′ NMPs. Depolymerization was rapid, producing approximately 14 mM acid-soluble nucleotides after 15 minutes (FIG. 8A). The lysate mix containing pathway enzymes and 5′ NMPs was then heat treated to inactivate EcRNR and endogenous E. coli enzymes, while the thermostable pathway enzymes remained active. After heat inactivation, the RNA synthesis reaction was assembled, incubated at 50° C., and visualized on an agarose gel (FIG. 8B). Reactions with two different templates, including a linear PCR product (Template 1) and a hairpin template encoded on a plasmid (Template 2), yielded distinct bands on an agarose gel (FIG. 8B). No bands were observed in the conditions without RNA polymerase. As a positive control, reactions were performed where purified 5′ NMPs (4 mM each AMP, CMP, GMP, and UMP) were added. These reactions produced products that migrated at the same size as reactions using NMPs produced by depolymerizing RNA.

Cell-free synthesis of RNA was also performed using purified E. coli RNA as substrate. RNA was first incubated with purified E. coli RNase R (K544R) to release 5′ NMPs (FIG. 9A). After 30 minutes, the depolymerization reaction was combined with a lysate mix containing pathway enzymes and heat treated to inactivate EcRNR and endogenous E. coli enzymes, while the thermostable pathway enzymes remained active. After heat inactivation, the RNA synthesis reaction was assembled, incubated at 50° C., and visualized on an agarose gel (FIG. 9B). Reactions with two different templates, including a linear PCR product (Template 1) and a hairpin template encoded on a plasmid (Template 2), yielded defined bands on an agarose gel, though yields appeared lower for Template 2 (FIG. 9B). Again, no bands were observed in the conditions without RNA polymerase.

Taken together, these results demonstrate that cell-free RNA synthesis can be used to produce an RNA of interest from a variety of NMP source material, including high-purity purchased NMPs, NMPs produced by enzymatic depolymerization of lysate RNA, and NMPs produced by enzymatic depolymerization of purified RNA.

Example 2—Cell-Free Synthesis of RNA Using a Non-Thermostable Wild-Type Polymerase or a Thermostable Polymerase Mutant, and Purified NMPs as a Substrate

Materials and Methods

Biomass, lysates, purified proteins, and DNA template were prepared as described herein. Cell-free synthesis of RNA was performed essentially as described in Example 1, except that EcRNR was omitted and 4 mM each AMP, CMP, GMP, and UMP were added to the reaction.

Results

Cell-free synthesis of RNA was performed using purified NMPs as a substrate at a 37° C. reaction temperature. Lysates containing pathway enzymes were assembled and heat treated to inactivate endogenous E. coli enzymes, while the thermostable pathway enzymes remained active. After heat inactivation, the reaction was assembled using either wild-type T7 RNA polymerase or a thermostable mutant, incubated at 37° C. for 2 hours, and visualized on an agarose gel (FIG. 10). Reactions with two different templates, including a linear PCR product (Template 1) and a hairpin template encoded on a plasmid (Template 2), yielded distinct bands with both polymerases. At 37° C., RNA yield (based on gel band intensity) appeared greater with the wild-type polymerase than the thermostable mutant, especially with Template 2. No bands were observed in the conditions without RNA polymerase.

These results demonstrate that the RNA polymerase used for cell-free RNA synthesis does not need to be thermostable, and that RNA can be produced using a wild-type T7 RNA polymerase in a 37° C. reaction.

Example 3—Cell-Free Synthesis of RNA Using a Class III Polyphosphate Kinase 2 from Deinococcus geothermalis (DgPPK2) and NMPs as a Substrate

Materials and Methods

Cell-free RNA synthesis reactions were assembled essentially as described in Example 2, with the following composition:

TABLE 13 Reaction Conditions Magnesium sulfate 45 mM Sodium hexametaphosphate 13 mM DgPPK2 lysate 7 g/L total protein Template DNA 50 mg/L Spermidine 2 mM RNA polymerase 0.3 g/L As a positive control, a 5-enzyme lysate system containing uridylate kinase, cytidylate kinase, guanylate kinase, nucleotide diphosphate kinase and a polyphosphate kinase was used in the reaction according to Examples 1-2. The dsRNA synthesized in the reactions was purified via an adapted RNASwift extraction protocol and quantitated using a reverse phase ion pair chromatography as described herein (Nwokeji, A. O., Kilby, P. M., Portwood, D. E., & Dickman, M. J. (2016). RNASwift: A rapid, versatile RNA extraction method free from phenol and chloroform. Analytical Biochemistry, 512, 36-46).

Results

Cell-free synthesis of RNA was performed in reactions comprising DgPPK2 as the sole kinase in the reaction, and NMPs as a substrate. As a positive control, RNA was synthesized in the presence of the 5-enzyme lysate system containing uridylate kinase, cytidylate kinase, guanylate kinase, nucleotide diphosphate kinase, and polyphosphate kinase. Control reaction were performed in the absence of polymerase.

The response factor for each reaction was determined. The response factor was calculated as ratio of area of the dsRNA of interest to that of a commercially-available dsRNA internal standard. Comparison of the response factors demonstrated that reactions containing DgPPK2 as the sole kinase synthesized ˜48% of the dsRNA synthesized that was synthesized in reactions containing the 5-enzyme lysate system (FIG. 11A). The dsRNA product synthesized in the DgPPK2 reaction and the 5-enzyme lysate system reaction were analyzed by HPLC. The HPLC chromatograms of the dsRNA product from the reactions were similar demonstrating that the dsRNA product produced by the DgPPK2-only system was similar to the product produced by the 5-enzyme system (FIG. 11B).

Taken together, these results demonstrate that the DgPPK2 could be used as a sole kinase to synthesize cell-free dsRNA from NMPs or NDPs.

Example 4—Depolymerization of RNA from Various Sources Using Purified RNase R or Purified Nuclease P1

Materials and Methods

Extraction and Purification of RNA and Nuclease

RNA was extracted and purified from high-density E. coli lysates (protein concentration: 40-50 mg/mL) according to established protocols (Mohanty, B. K., Giladi, H., Maples, V. F., & Kushner, S. R. (2008). Analysis of RNA decay, processing, and polyadenylation in Escherichia coli and other prokaryotes. Methods in Enzymology, 447, 3-29).

RNA from Vibrio was purified from V. natriegens cell broth using RNASwift Protocol (Nwokeji, A. O., Kilby, P. M., Portwood, D. E., & Dickman, M. J. (2016). RNASwift: A rapid, versatile RNA extraction method free from phenol and chloroform. Analytical Biochemistry, 512, 36-46).

Yeast derived RNA extract was purchased from commercial sources. The RNA powder was ˜85% to ˜90% pure and required no further purification. RNase R was purified from an E. coli strain overexpressing RNase R and grown to high cell density. Proteins were purified by immobilized metal affinity chromatography using HisTrap HP columns connected to an AKTAPrime Plus FPLC system (GE Healthcare). Purified Nuclease P1, a 5′ phosphodiesterase, was obtained from commercial sources.

Depolymerization of RNA with Exogenous Nuclease

E. coli RNA, V. natriegens RNA, Yeast derived RNA powder resuspended in nuclease-free water (RNA content of 11 mg/mL), RNase R solution (1 mg/mL in 300 mM potassium phosphate buffer pH 7.4, 200 mM KCl, 2 mM MgCl₂) and Purified Nuclease P1 (also referred 5′ phosphodiesterase) (1-2 mg/mL in 100 mM potassium phosphate buffer pH 7.4, 1 mM ZnCl₂, 10 mM MgCl₂) were pre-equilibrated at 2° C. before initiating the reaction. At time t=0, 50 μL, of RNA and 50 μL nuclease solution were mixed and the reaction initiated by transferring to a preheated 37° C. block. After initiation, reactions were incubated at 37° C. and periodically sampled by transferring 10 μL to acid quench solution (90 μL of 0.2M sulfuric acid) on ice. After completion of the time course, quenched samples were clarified by centrifugation at 3,200×g for 20 minutes at 2° C. Depolymerization was first quantified by absorbance of acid-soluble nucleotides at 260 nm. The total nucleotide pool (e.g., 100% depolymerization) was determined by alkaline hydrolysis of RNA: 50 μL RNA was combined with 150 μL of 0.2M potassium hydroxide, then heated to 99° C. for 20 minutes. Alkaline-hydrolyzed samples were then quenched and analyzed as described above. Depolymerization was also quantified by LC-MS analysis of 5′, 2′, and 3′ NMPs: 10 μL of sample was quenched in 30 μL 100% acetonitrile and diluted into 500 μL of deionized water containing 10 μM adipic acid used as internal standard. The sample was then centrifuged and passed through a 0.2 μm filter before LC-MS analysis.

Nucleotide Analysis

Analysis of 2′, 3′, and 5′ NMPs was performed by mass spectrometry and liquid chromatography using an ABSCIEX API 5000 Mass spectrometer and a standard Agilent 1200 HPLC equipped with Sequant Zinc-hilic column (2.1×50 mm, 3 μm i.d.). The mobile phases consisted of 20 mM ammonium acetate in 90% acetonitrile (A) and 20 mM ammonium acetate in 10% acetonitrile (B). The separation method consisted of the following: starting gradient of 6% B followed by a gradient to 8.5% B over 600 seconds, a gradient to 13% B over 400 seconds, followed by a gradient from to 20% B over 60 seconds, a wash at 50% B for 60 seconds, and finally, re-equilibration at 6% B for 220 seconds. Quantitation was performed in negative mode electro-spray ionization (ESI) using the following mass spec transitions: 2′3′5′ AMP: 346.1-134.1, 2′3′5′ UMP: 323.0—97, 2′3′5′ CMP: 322—97, 2′3′5′ GMP: 362.1—211. Peak areas were compared to standard curves consisting of purified compounds (purchased from Sigma-Aldrich except for 2′ and 3′ CMP, UMP, and GMP which were purchased from Biolog Life Science Institute) and normalized to an internal standard (adipic acid) that was spiked into the samples prior to analysis. For analysis of samples, standard curves were prepared in deionized water, diluted with internal standard and filtered as in the sample preparation steps described herein.

Results

V. natriegens RNA was digested using purified E. coli RNase R, and E. coli RNA and yeast-derived RNA extract were digested using both E. coli RNase R and Nuclease P1. Depolymerization was monitored by release of acid-soluble nucleotides. Treatment of E. coli and V. natriegens RNA with RNase R showed a time-dependent conversion of RNA to acid-soluble nucleotides reaching ˜98 to ˜100% depolymerization after 30 minutes of incubation (FIG. 12A). Treatment of yeast-derived RNA extract reached ˜94% depolymerization with Nuclease P1 (FIG. 12A). Also, treatment of E. coli RNA with Nuclease P1 resulted in ˜90% depolymerization (FIG. 12A). Subsequent analyses by LC-MS revealed release of 5′ NMPs in E. coli RNA and yeast-derived RNA extract treated with Nuclease P1 (FIG. 12B)

These results demonstrate that varying sources of RNA (e.g., Vibrio RNA, E. coli RNA, and yeast RNA) can be digested to 5′ NMP using different nucleases (e.g., RNase R and Nuclease P1).

Example 5—Effects of Temperature and Lysate Inactivation on RNA Depolymerization

Materials and Methods

Strains and Lysates

Strain GL17-086 (BL21(DE3).ΔtolC.Δph[DE3]1+2*.Δph[285p]*.ΔfhuA*.ΔlamB*rna::tolC) and strain GL17-109 (BL21(DE3). ΔtolC.Δph[DE3]1+2*.Δph[285p]*.ΔfhuA*.ΔlamB*Δrna*. ΔphoA*.ΔappA*.Δamn*.ΔnagD*.ΔushA::tolC) were used in the study described herein. For both strains, 1L cultures were grown under batch-growth conditions in KORZ media (5 g/L (NH₄)₂SO₄, 15.7 g/L K₂HPO₄, 4.2 g/L KH₂PO₄, 1.7 g/L citric acid, 0.6 g/L MgSO₄, 0.1% Thiamine-HCl, 0.01% Pluronic, trace metals, and 40 g/L glucose) for approximately seven hours. After growth the cells were centrifuged at 6000 g for 20 minutes and then stored at −80° C. Frozen biomass was thawed in 1.5× volumes of a 58.8 mM dibasic potassium phosphate solution and lysed by passing through an EmulsiFlex C3 homogenizer (Avestin) for 3 passes, recirculating, with pulses of 15000-20000 psi. Lysate was clarified by spinning at 15000 g for 1 hour at 4° C. The lysate was then stored at −80° C. in single-use aliquots.

Analysis of RNA Polymerization Products at Various Temperatures

Frozen lysates for both strains (086 and 109) were incubated at varying temperatures to profile the RNA depolymerization products and their potential degradation. Lysate aliquots were thawed on ice and then dispensed into PCR strip-tubes. Tubes were then incubated at 40° C., 50° C., 60° C., and 70° C. up to an hour with intermittent sampling. The initial to timepoint was taken by quenching while the lysates were still on ice. For all other times, samples were quenched in 5× volumes of acetonitrile with 60 μl diluted into 500 μl of a 50 μM adipic acid solution in 50 mM ammonium acetate, and then run on an LC-QQQ. Using MRM, all four main nucleotides and their associated derivates (ATP, ADP, AMP, adenine, adenosine, GTP, GDP, GMP, guanine, guanosine, CTP, CDP, CMP, cytidine, cytosine, UTP, UDP, UMP, uridine, and uracil) were quantified at each timepoint. Base hydrolysis of lysates, where RNA is completely hydrolyzed down to NMPs, was performed by incubating the lysate in 3× volumes of 0.2M NaOH at 99° C. for 20 minutes. It was then neutralized with an equal volume of 150 mM HCl and 20 μl of this solution was diluted into 200 μl of a 50 mM ammonium acetate solution with 50 μM adipic acid. Base hydrolyzed lysate values represent 100% depolymerization. Under some conditions these lysates were incubated as-is, and in others conditions the lysates were mixed with either 0.5 mg/ml Nuclease P1 (Sigma N8630) or RNase R. RNase R was prepared as follows: cells were resuspended in 1.5× volumes of lysis buffer (50 mM potassium phosphate, pH=7.4, 500 mM NaCl, 20 mM imidazole), lysed in an EmulsiFlex C3 Homogenizer (Avestin) for three passes at 15000-25000 psi, clarified for one hour at 16000 g, 4° C. The supernatant was then purified via FPLC, then dialyzed overnight in 2×PBS. Precipitated protein post-dialysis was recovered by adding 500 mM NaCl, mixed with glycerol to yield a 50% glycerol solution for aliquoting and storing at −20° C.

Analysis of Dilution Effects and Pre-Heat-Kill Effects on RNA Depolymerization

Experiments were performed with the lysate of GL17-109, prepared as described herein. Lysates were prepared under a wide range of conditions. Common across all conditions, reactions received an added 150 mM potassium phosphate (pH=7.4), 100 mM KCl, and 0.1 mM ZnCl₂, and all of the following conditions were tested with RNase R, Nuclease P1, or no exogenous nuclease added. Both nuclease stock solutions were made as described previously. Depolymerization reactions were carried out under 80% and 50% lysate dilutions into water. These were screened with 0.5 or 0.31 mg/ml, respectively, of exogenous nuclease spiked in. Lysate mixtures were also prepared by making a 1 mg/ml nuclease lysate and mixing it into a non-spiked lysate yielding 0.064 and 0.04 mg/ml nuclease in 80% dilution conditions, or 0.04 and 0.025 mg/ml nuclease in 50% dilution conditions. Lastly, conditions were tested where lysates that did not contain added nuclease were heat killed at 70° C. for 15 minutes and then mixed with either purified nuclease, or the still-active 1 mg/ml nuclease lysate. Samples were incubated at 37° C. for 30 minutes and sampled by quenching in 5× volumes of acetonitrile, and diluting into 1 ml of a 50 μM adipic acid solution in 50 mM ammonium acetate. The quench solution was then spun down, filtered through a 0.2 μm filter plate, and the filtrate was run on an LC-QQQ to measure NMPs, nucleosides, and nucleobases.

Results

RNA nucleases (RNases) are known to have activity profiles that span temperature profiles more broadly than many other enzymes from mesophilic sources, occasionally showing activity up to 60° C. despite originating from an organism evolved to grow at 37° C. To evaluate the impact of elevated temperatures on RNA depolymerization in an E. coli lysate, two separate studies were conducted. First, lysates from two separate strains were incubated at temperatures greater than 37° C. over the course of an hour, with or without the addition of one of two RNases—RNase R or RNase P1. The second study involved eliminating a lysate to remove deleterious enzymatic activities and mixing this inactive lysate with an active lysate to study potential impacts on RNA depolymerization, or mixing exogenous nucleases into the inactivated lysate.

Improved depolymerization was observed when lysates were incubated at 60° C. and 70° C. (FIG. 13). Depolymerization improved in several ways. When RNA depolymerizes, it predominantly produces NMPs. In an active lysate, however, theses NMPs continue to be degraded by other enzymes, with a very large accumulation of two main products—guanosine and uracil. Incubating lysates at 60° C. and 70° C. significantly decreased the accumulation of these nucleobases, even in lysates that did not receive exogenous RNase R or Nuclease P1 (FIG. 13). As each mole of nucleobase correlates to an irreversible loss of NMPs from RNA, this demonstrated improved NMP stability in lysates. Additionally, when exogenous nuclease is added under these temperature conditions, dramatic improvement in net NMP accumulation is seen, as shown in FIG. 13 at 70° C. with RNase R added. Base hydrolysis of the GL17-109 lysate showed a maximum concentration of 32.6 mM NMPs. Correcting for dilution of the added nuclease, the accumulation of ˜22 mM NMPs seen at 70° C. with RNase R is a 75% yield. Assuming that tRNA represents about 15% of the total RNA pool and that it is inaccessible to these nucleases, this would represent a 94% yield of all accessible RNA. Depolymerization in GL17-086 was poorer across the board than GL17-109, likely due to the greater phosphorylytic activity (data not shown).

The impacts of pre-heat kill and lysate dilutions showed a small benefit, but only under a more heavily diluted lysate. In this study, two types of lysates were made—a “reagent” lysate, which contains the RNA to be depolymerized, and the “catalyst” lysate, containing exogenous nuclease (RNase R or Nuclease P1). Many different conditions were evaluated, as shown in Table 14 below, to determine their impact on RNA depolymerization. Lysates that were diluted to only 80% showed similar depolymerization performance, regardless of whether portions of the lysate were heat-killed or not. However, lysates that were diluted to 50% performed slightly better when a large portion of the RNA was in an inactivated lysate. Across all of the conditions tested at this dilution, an average depolymerization yield improvement of 2.7% was observed. The performance of the depolymerization reaction under these conditions does not show a dramatic improvement, but by performing equivalently or only slightly better, this does leave the possibility open for implementing a pre-depolymerization heat kill should other parts of the process require it, for example halting growth of any unlysed cells that may remain in the culture or reducing the protein content of the lysate if a pelleting step is included after heat-treatment.

TABLE 14 Summary of RNA depolymerization yields across varying mixtures of lysates, nucleases, and inactivated lysates. Percent yields are based on a basis of 32.6 mM NMPs, as quantified through lysate base hydrolysis of RNA. No Pre-Heat Kill Pre-Heat Kill % Depol. % Depol. % Depol. Yield % Depol. Yield Yield (Nuclease Yield (Nuclease Reaction (RNase R) P₁) (RNase R) P₁) 80% background lysate + 0.5 26 40 27 40 mg/mL Nuclease 72% background lysate + 8% of 1 26 33 22 30 mg/mL nuclease lysate (0.064 mg/mL nuclease final) 75% background lysate + 5% of 1 29 31 24 29 mg/mL nuclease lysate (0.04 mg/mL nuclease final) 80% background lysate - no 18 23 10 10 nuclease control 50% background lysate + 0.31 41 49 44 56 mg/mL Nuclease 46% background lysate + 4% of 1 33 41 40 36 mg/mL nuclease lysate (0.04 mg/mL nuclease final) 47.5% background lysate + 2.5% of 27 37 27 41 1 mg/mL nuclease lysate (0.025 mg/mL nuclease final) 50% background lysate - no 20 34 10 12 nuclease control

Example 6: Cell-Free Production of RNA Using Various Nucleotide Sources

Materials and Methods

Yeast RNA powder obtained from commercial sources was dissolved in water at 45-60 g/L and depolymerized using 1.2 g/L P1 nuclease at 70° C., pH 5.5-5.8 for 1 hour in the presence of 0.05 mM zinc chloride. The resulting depolymerized material was clarified by centrifugation and filtered using a 10 kDa MWCO filter. The resulting stream contained 5′ nucleotide monophosphates (NMPs) at a total concentration of ˜90-100 mM (˜20-25 mM each AMP, CMP, GMP, and UMP).

E. coli BL21(DE3) derivatives carrying pBAD24-derived vectors encoding individual kinase enzymes (TthCmk, PfPyrH, TmGmk, AaNdk, and DgPPK2) were cultivated in fermentations with Korz media supplemented with 50 mg/L carbenicillin using standard techniques [Korz, D. J., Rinas, U., Hellmuth, K., Sanders, E. A., & Deckwer, W. D. (1995). Simple fed-batch technique for high cell density cultivation of Escherichia coli. Journal of biotechnology, 39(1), 59-65.]. Protein expression was induced by adding L-arabinose. After harvest, lysates were prepared in 60 mM phosphate buffer using high-pressure homogenization, resulting in mixtures of approximately 40 g/L total protein.

E. coli BL21(DE3) derivatives carrying pUC19-derived vectors containing one or more transcriptional templates (each consisting of a T7 promoter, target sequence, and one or more transcriptional terminators) encoding a 524 bp double-stranded RNA sequence. Cells were cultivated in fermentations in Korz media using standard techniques [Phue, J. N., Lee, S. J., Trinh, L., & Shiloach, J. (2008). Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5alpha). Biotechnology and bioengineering, 101(4), 831.]. After harvest, lysates were created by high pressure homogenization, diluted, and heat-treated following similar procedures.

E. coli BL21(DE3) derivatives carrying pBAD24-derived vectors encoding thermostable T7 RNA polymerase enzymes were cultivated, enzyme expression was induced, and lysates were prepared using similar procedures. Polymerase enzymes were partially purified using two steps of ammonium sulfate fractionation.

Reactions were assembled in 30 mM phosphate buffer, pH 7 according to Table 15.

TABLE 15 Reaction Conditions Depolymerized Nucleotide source cellular RNA NMPs NDPs Nucleotides 15% v/v 4 mM each 4 mM each Magnesium sulfate 45 mM Sodium hexametaphosphate 13 mM Kinase lysates 2 g/L total protein Template DNA lysate 5.4% v/v RNA polymerase 0.1 g/L

In assembling the cell-free reactions, lysates containing kinase enzymes and template DNA were diluted, combined in equal proportion, and mixed with reaction additives such as magnesium sulfate and sodium hexametaphosphate. Lysates were incubated at 70° C. for 15 minutes to inactivate other enzymatic activities while preserving the activities of the overexpressed kinases. Cell-free reactions were initiated by the addition of RNA polymerase, incubated at 48° C. for 1 hour, and analyzed according to established protocols [Nwokeoji, A. O., Kilby, P. M., Portwood, D. E., & Dickman, M. J. (2016). RNASwift: A rapid, versatile RNA extraction method free from phenol and chloroform. Analytical biochemistry, 512, 36].

Results

Cell-free RNA synthesis reactions were performed using cellular RNA, an equimolar mix of nucleoside 5′-monophosphates (AMP, CMP, GMP, UMP), or an equimolar mix of 5′ nucleoside diphosphates (ADP, CDP, GDP, UDP). Similar titers of dsRNA product were produced for each nucleotide source (FIG. 17).

These results demonstrate that the cell-free reactions described herein can be used to synthesize RNA from multiple sources of nucleotides, including cellular RNA, nucleoside 5′-monophosphates, and nucleoside diphosphates.

Example 7: Cell-Free Production of RNA Using Wild-Type RNA Polymerase

Materials and Methods

E. coli BL21(DE3) derivatives carrying pBAD24-derived vectors encoding hexahistidine-tagged thermostable or wild-type T7 RNA polymerase enzymes were cultivated, enzyme expression was induced, and lysates were prepared using procedures described herein. Polymerase enzymes were purified by fast protein liquid chromatography (FPLC) as described herein. Cell-free reactions were performed as described herein except that reactions were performed at a range of temperatures (37-48° C.) for 2 hours. Titers of dsRNA product were quantified as described herein.

Results

Cell-free RNA synthesis reactions were performed using wild-type T7 RNA polymerase or a thermostable mutant (FIG. 18). Reactions performed with the thermostable mutant produced dsRNA product at 37° C. and 48° C. In contrast, reactions performed with the wild-type polymerase produced product at 37° C. but not 48° C.

These results demonstrate that the cell-free reactions described herein do not require thermostable RNA polymerases provided they are incubated at appropriate temperatures.

Example 8: Cell-Free Production of NTPs Using Various Nucleotide Sources

Materials and Methods

Cell-free reactions were performed as described in Example 6, except the template DNA lysate and RNA polymerase were omitted. Nucleotides were analyzed by HPLC using an adaptation of published methods [de Korte, D., Haverkort, W. A., Roos, D., & van Gennip, A. H. (1985). Anion-exchange high performance liquid chromatography method for the quantitation of nucleotides in human blood cells. Clinica chimica acta; international journal of clinical chemistry, 148(3), 185.]

Results

Cell-free reactions to produce nucleotide 5′-triphosphates (NTPs: ATP, CTP, GTP and UTP) were performed using cellular RNA, an equimolar mix of nucleoside 5′-monophosphates (AMP, CMP, GMP, UMP), or an equimolar mix of 5′ nucleoside diphosphates (ADP, CDP, GDP, UDP). Similar titers of each NTP were produced for each nucleotide source (FIG. 19).

These results demonstrate that the cell-free reactions described herein can also be used to produce NTPs simply by omitting the RNA polymerase and DNA template. Similarly to the cell-free reactions producing RNA described in Example 6, cell-free reactions producing NTPs can utilize multiple sources of nucleotides, including cellular RNA, nucleoside 5′-monophosphates, and nucleoside diphosphates.

REFERENCES

-   1. Maekewa K., Tsunasawa S., Dibo G., Sakiyama F. 1991. Primary     structure of nuclease P1 from Penicillium citrinum. Eur. J. Biochem.     200:651-661. -   2. Volbeda A., Lahm A., Sakiyama F., Suck D. 1991. Crystal structure     of Penicillium citrinum P1 nuclease at 2.8-A resolution. EMBO J.     10:1607-1618(1991) -   3. Romier C., Dominguez R., Lahm A., Dahl O., Suck D. 1998.     Recognition of single-stranded DNA by nuclease P1: high resolution     crystal structures of complexes with substrate analogs. Proteins     32:414-424 -   4. Cheng Z. F., Deutscher M. P. 2002. Purification and     characterization of the Escherichia coli exoribonuclease RNase R.     Comparison with RNase II. J. Biol. Chem. 277:21624-21629. -   5. Zilhao R., Camelo L., Arraiano C. M. 1993. DNA sequencing and     expression of the gene rnb encoding Escherichia coli     ribonuclease II. Mol. Microbiol. 8:43-51 -   6. March P. E., Ahnn J., Inouye M. 1985. The DNA sequence of the     gene (mc) encoding ribonuclease III of Escherichia coli. Nucleic     Acids Res. 13:4677-4685 -   7. Chen S. M., Takiff H. E., Barber A. M., Dubois G. C., Bardwell J.     C., Court D. L. 1990. Expression and characterization of RNase III     and Era proteins. Products of the mc operon of Escherichia coli. J.     Biol. Chem. 265:2888-2895 -   8. Robertson H. D., Webster R. E., Zinder N. D. 1968. Purification     and properties of ribonuclease III from Escherichia coli. J. Biol.     Chem. 243:82-91. -   9. Molina L., Bernal P., Udaondo Z., Segura A., Ramos J. L. 2013.     Complete Genome Sequence of a Pseudomonas putida Clinical Isolate,     Strain H8234. Genome Announc. 1:E00496-13; and Cheng, Z. F.     and M. P. Deutscher. 2002. Purification and characterization of the     Escherichia coli exoribonuclease RNAse R. Comparison with RNAse II.     J Biol Chem. 277(24). -   10. Even S., Pellegrini O., Zig L., Labas V., Vinh J.,     Brechemmier-Baey D., Putzer H. 2005. Ribonucleases J1 and J2: two     novel endoribonucleases in B. subtilis with functional homology     to E. coli RNase E. Nucleic Acids Res. 33:2141-2152. -   11. Li de la Sierra-Gallay I., Zig L., Jamalli A., Putzer H. 2008.     Structural insights into the dual activity of RNase J. Nat. Struct.     Mol. Biol. 15:206-212. -   12. Ball T. K., Saurugger P. N., Benedick M. J. 1987. The     extracellular nuclease gene of Serratia marcescens and its secretion     from Escherichia coli. Gene 57:183-192. -   13. Biedermann K., Jepsen P. K., Riise E., Svendsen I. 1989.     Purification and characterization of a Serratia marcescens nuclease     produced by Escherichia coli. Carlsberg Res. Commun. 54:17-27. -   14. Shlyapnikov S. V., Lunin V. V., Perbandt M., Polyakov K. M.,     Lunin V. Y., Levdikov V. M., Betzel C., Mikhailov A. M. 2000. Atomic     structure of the Serratia marcescens endonuclease at 1.1 A     resolution and the enzyme reaction mechanism. Acta Crystallogr. D     56:567-572. -   15. Zuo Y., Deutscher M. P. 2002. Mechanism of action of RNase T. I.     Identification of residues required for catalysis, substrate     binding, and dimerization. J. Biol. Chem. 277:50155-50159. -   16. Zuo Y., Zheng H., Wang Y., Chruszcz M., Cymborowski M., Skarina     T., Savchenko A., Malhotra A., Minor W. 2007. Crystal structure of     RNase T, an exoribonuclease involved in tRNA maturation and end     turnover. Structure 15:417-428. -   17. Huang S., Deutscher M. P. 1992. Sequence and transcriptional     analysis of the Escherichia coli rnt gene encoding RNase T. J. Biol.     Chem. 267:25609-25613. -   18. Chauhan A. K., Miczak A., Taraseviciene L., Apirion D. 1991.     Sequencing and expression of the me gene of Escherichia coli.     Nucleic Acids Res. 19:125-129. -   19. Cormack R. S., Genereaux J. L., Mackie G. A. 1993. RNase E     activity is conferred by a single polypeptide: overexpression,     purification, and properties of the ams/rne/hmp1 gene product. Proc.     Natl. Acad. Sci. U.S.A. 90:9006-9010. -   20. Motomura., K., Hirota, R., Okada, M., Ikeda, T., Ishida, T., &     Kuroda, A, (2014), A New Subfamily of Polyphosphate Kinase 2 (Class     III PPK2) Catalyzes both Nucleoside Monophosphate Phosphorylation     and Nucleoside Diphosphate Phosphorylation, Applied and     Environmental Microbiology, 80(8), 2602-2608.     http://doi.org/10.1128/AEM 0.03971-13 -   21. Elkin, S. R., Kumar, A., Price, C. W., & Columbus, L. (2013). A     Broad Specificity Nucleoside Kinase from Thermoplasma acidophilum.     Proteins, 81(4), 568-582. doi.org/10.1002/prot.24212 -   22. Hansen, T., Arnfors, L., Ladenstein, R., & Schönheit, P. (2007).     The phosphofructokinase-B (MJ0406) from Methanocaldococcus     jannaschii represents a nucleoside kinase with a broad substrate     specificity. Extremophiles, 11(1), 105. -   23. Ota, H., Sakasegawa, S., Yasuda, Y., Imamura, S., & Tamura, T.     (2008). A novel nucleoside kinase from Burkholderia thailandensis: a     member of the phosphofructokinase B-type family of enzymes. The FEBS     journal, 275(23), 5865. -   24. Tomoike, F., Nakagawa, N., Kuramitsu, S., & Masui, R. (2011). A     single amino acid limits the substrate specificity of Thermus     thermophilus uridine-cytidine kinase to cytidine. Biochemistry,     50(21), 4597. -   25. Henne A., Brueggemann H., Raasch C., Wiezer A., Hartsch T.,     Liesegang H., Johann A., Lienard T., Gohl O., Martinez-Arias R.,     Jacobi C., Starkuviene V., Schlenczeck S., Dencker S., Huber R.,     Klenk H.-P., Kramer W., Merkl R., Gottschalk G., Fritz H.-J. 2004.     The genome sequence of the extreme thermophile Thermus thermophilus.     Nat. Biotechnol. 22:547-553. -   26. Tan Z W, Liu J, Zhang X F, Meng F G, Zhang Y Z. Nan Fang Yi Ke     Da Xue Xue Bao. 2010. Expression, purification and enzymatic     characterization of adenylate kinase of Thermus thermophilus HB27 in     Escherichia coli. January; 30(1):1-6 -   27. Maeder D. L., Weiss R. B., Dunn D. M., Cherry J. L., Gonzalez J.     M., DiRuggiero J., Robb F. T. 1999. Divergence of the     hyperthermophilic archaea Pyrococcus furiosus and P. horikoshii     inferred from complete genomic sequences. Genetics 152:1299-1305. -   28. Methé, B. A., Nelson, K. E., Deming, J. W., Momen, B., Melamud,     F., Zhang, X., Fraser, C. M. (2005). The psychrophilic lifestyle as     revealed by the genome sequence of Colwellia psychrerythraea 34H     through genomic and proteomic analyses. Proceedings of the National     Academy of Sciences of the United States of America, 102(31),     10913-10918. doi.org/10.1073/pnas.0504766102 -   29. Médigue, C., Krin, E., Pascal, G., Barbe, V., Bernsel, A.,     Bertin, P. N., . . . Danchin, A. (2005). Coping with cold: The     genome of the versatile marine Antarctica bacterium     Pseudoalteromonas haloplanktis TAC125. Genome Research, 15(10),     1325-1335. doi.org/10.1101/gr.4126905 -   30. Ayala-del-Rio, H. L., Chain, P. S., Grzymski, J. J., Ponder, M.     A., Ivanova, N., Bergholz, P. W., . . . Tiedje, J. M. (2010). The     Genome Sequence of Psychrobacter arcticus 273-4, a Psychroactive     Siberian Permafrost Bacterium, Reveals Mechanisms for Adaptation to     Low-Temperature Growth. Applied and Environmental Microbiology,     76(7), 2304-2312. doi.org/10.1128/AEM.02101-09 -   31. Feil, H., Feil, W. S., Chain, P., Larimer, F., DiBartolo, G.,     Copeland, A., . . . Lindow, S. E. (2005). Comparison of the complete     genome sequences of Pseudomonas syringae pv. syringae B728a and pv.     tomato DC3000. Proceedings of the National Academy of Sciences of     the United States of America, 102(31), 11064-11069.     doi.org/10.1073/pnas.0504930102 -   32. Song, S., Inouye, S., Kawai, M., Fukami-Kobayashi, K., Gō, M., &     Nakazawa, A. (1996). Cloning and characterization of the gene     encoding Halobacterium halobium adenylate kinase. Gene, 175(1),     65-70. -   33. Masui R., Kurokawa K., Nakagawa N., Tokunaga F., Koyama Y.,     Shibata T., Oshima T., Yokoyama S., Yasunaga T., Kuramitsu S.     Complete genome sequence of Thermus thermophilus HB8. Submitted     (November 2004) to the EMBL/GenBank/DDBJ databases. -   34. Ng, W. V., Kennedy, S. P., Mahairas, G. G., Berquist, B., Pan,     M., Shukla, H. D., . . . DasSarma, S. (2000). Genome sequence of     Halobacterium species NRC-1. Proceedings of the National Academy of     Sciences of the United States of America, 97(22), 12176-42181. -   35. Marco-Marin C., Escamilla-Honrubia J. M., Rubio V. 2005.     First-time crystallization and preliminary X-ray crystallographic     analysis of a bacterial-archaeal type UMP kinase, a key enzyme in     microbial pyrimidine biosynthesis. Biochim. Biophys. Acta     1747:271-275. -   36. Marco-Marin C., Escamilla-Honrubia J. M., Rubio V. 2005.     First-time crystallization and preliminary X-ray crystallographic     analysis of a bacterial-archaeal type UMP kinase, a key enzyme in     microbial pyrimidine biosynthesis. Biochim. Biophys. Acta     1747:271-275. -   37. Jensen, K. S., Johansson, E., &. Jensen, K. F. (2007).     Structural and enzymatic investigation of the Sulfolobus     solfataricus uridylate kinase shows competitive UTP inhibition and     the lack of GTP stimulation. Biochemistry, 46(10), 2745-2757. -   38. Nelson K. E., Clayton R. A., Gill S. R., Gwinn M. L., Dodson R.     J., Haft D. H., Hickey E. K., Peterson J. D., Nelson W. C.,     Ketchum K. A., McDonald L. A., Utterback T. R., Malek J. A.,     Linher K. D., Garrett M. M., Stewart A. M., Cotton M. D.,     Pratt M. S. Fraser C. M. 1999. Evidence for lateral gene transfer     between Archaea and Bacteria from genome sequence of Thermotoga     maritima. Nature 399:323-329. -   39. Riley, M., Staley, J. T., Danchin, A., Wang, T. Z., Brettin, T.     S., Hauser, L. J., . . . Thompson, L. S. (2008). Genomics of an     extreme psychrophile, Psychromonas ingrahamii. BMC Genomics, 9, 210.     doi.org/10.1186/1471-2164-9-210 -   40. Ishibashi, M., Tokunaga, H., Hiratsuka, K., Yonezawa, Y.,     Tsurumaru, H., Arakawa, T., & Tokunaga, M. (2001). NaCl-activated     nucleoside diphosphate kinase from extremely halophilic archaeon,     Halobacterium salinarum, maintains native conformation without salt.     FEBS letters, 493(2-3), 134. -   41. Polosina, Y. Y., Zamyatkin, D. F., Kostyukova, A. S.,     Filimonov, V. V., & Fedorov, O. V. (2002). Stability of Natrialba     magadii NDP kinase: comparisons with other halophilic proteins.     Extremophiles: life under extreme conditions, 6(2), 135. -   42. Polosina, Y. Y., Zamyatkin, D. F., Kostyukova, A. S.,     Filimonov, V. V., & Fedorov, O. V. (2002), Stability of Natrialba     magadii NDP kinase: comparisons with other halophilic proteins.     Extremophiles: life under extreme conditions, 6(2), 135. -   43. Udaondo, Z., Molina, L, Daniels, C., Gomez, M. J.,     Molina-Henares, M. A., Matilla, M. A., . . . Ramos, J. L. (2013).     Metabolic potential of the organic-solvent tolerant Pseudomonas     putida DOT-T1E deduced from its annotated genome. Microbial     Biotechnology, 6(5), 598-611, http://doi.org/10.1111/1751-7915.12061 -   44. Nölling, J., Breton, G., Omelchenko, Ni. V., Makarova, K. S.,     Zeng, Q., Gibson, R., Smith, D. R. (2001). Genome Sequence and     Comparative Analysis of the Solvent-Producing Bacterium Clostridium     acetobutylicum. Journal of Bacteriology, 183(16), 4823-4838.     http://doi.org/10.1128/JB.183.16.4823-4838.2001 -   45. Brune, M., Schumann, R., & Wittinghofer, F. (1985). Cloning and     sequencing of the adenylate kinase gene (adk) of Escherichia coli.     Nucleic Acids Research, 13(19), 7139-7151. -   46. Pel, H. J., de Winde., J. H., Archer, D. B., Dyer, P. S.,     Hofmann, G., Schaap, P. J., . . . & Andersen, M. R. (2007). Genome     sequencing and analysis of the versatile cell factory Aspergillus     niger CBS 513, 88. Nature biotechnology, 25(2), 221. -   47. Magdolen, V., Ochsner, U., & Bandlow, W. (1987). The complete     nucleotide sequence of the gene coding for yeast adenylate kinase.     Current genetics, 12(6), 405. -   48. Pedersen, S., Skouv, J., Kajitani, M., & Ishihama. (1984).     Transcriptional organization of the rpsA operon of Escherichia coli.     Molecular & general genetics: MGG, 196(1), 135. -   49. Smallshaw, J., & Kelln, R. A. (1992). Cloning, nucleotide     sequence and expression of the Escherichia coli K-12 pyrH gene     encoding UMP kinase. Genetics (Life Sci. Adv.), 11, 59-65, -   50. Liljelund, P., Sanni, A., Friesen, J. D., & Lacroute, F. (1989).     Primary structure of the S. cerevisiae gene encoding uridine     monophosphokinase. Biochemical and biophysical research     communications, 165(1), 464. -   51. Gentry, D., Bengra, C., Ikehara, K., & Cashel, M. (1993).     Guanylate kinase of Escherichia coli K-12. The Journal of biological     chemistry, 268(19), 14316. -   52. Konrad, M. (1992). Cloning and expression of the essential gene     for guanylate kinase from yeast. The Journal of biological     chemistry, 267(36), 25652. -   53. Hama, H., Almaula, N., Lerner, C. G., Inouye, S., & Inouye, M.     (1991). Nucleoside diphosphate kinase from Escherichia coli; its     overproduction and sequence comparison with eukaryotic enzymes.     Gene, 105(1), 31. -   54. Besir, H., Zeth, K., Bracher, A., Heider, U., Iishibashi, M.,     Tokunaga, M., & Oesterhelt, D. (2005). Structure of a halophilic     nucleoside diphosphate kinase from Halobacterium salinarum. FEBS     letters, 579(29), 6595. -   55. Deutscher, M. & Reuven N. (1991). Enzymatic basis for hydrolytic     versus phosphorolytic mRNA degradation in Escherichia coli and     Bacillus subtilis. PNAS, 88, 3277-3280, -   56. Nwokeji, A. O., Kilby, P. M., Portwood, D. E., & Dickman, M. J.     (2016). RNASwift: A rapid, versatile RNA extraction method free from     phenol and chloroform. Analytical Biochemistry, 512, 36-46. -   57. Mohanty, B. K., Giladi, H., Maples, V. F., & Kushner, S. R.     (2008). Analysis of RNA decay, processing, and polyadenylation in     Escherichia coli and other prokaryotes. Methods in Enzymology, 447,     3-29. -   58. Korz, D. J., Rinas, U., Hellmuth, K., Sanders, E. A., &     Deckwer, W. D. (1995). Simple fed-batch technique for high cell     density cultivation of Escherichia coli. Journal of biotechnology,     39(1), 59-654 -   59. Phue, J. N., Lee, S. J., Trinh, L., & Shiloach, J. (2008).     Modified Escherichia coli B (BL21), a superior producer of plasmid     DNA compared with Escherichia coli K (DH5alpha). Biotechnology and     bioengineering, 101(4), 831. -   60. de Korte, D., Haverkort, W. A., Roos, D., & van Gennip, A. H.     (1985). Anion-exchange high performance liquid chromatography method     for the quantitation of nucleotides in human blood cells. Clinica     chimica acta; international journal of clinical chemistry, 148(3),     185.]

Sequences Deinococcus geothermalis DSM 11300 PPK2 (SEQ ID NO: 1) MQLDRYRVPPGQRVRLSNWPTDDDGGLSKAEGEALLPDLQQRLANLQERL YAESQQALLIVLQARDAGGKDGTVKHVIGAFNPSGVQVSNFKVPTEEERA HDFLWRIHRQTPRLGMIGVFNRSQYEDVLVTRVHHLIDDQTAQRRLKHIC AFESLLTDSGTRIVKFYLHISPEEQKKRLEARLADPSKHWKFNPGDLQER AHWDAYTAVYEDVLTTSTPAAPWYVVPADRKWFRNLLVSQILVQTLEEMN PQFPAPAFNAADLRIV Meiothermus ruber DM 1279 PPK2 (SEQ ID NO: 2) MGFCSIEFLMGAQMKKYRVQPDGRFELKRFDPDDTSAFEGGKQAALEALA VLNRRLEKLQELLYAEGQHKVLVVLQAMDAGGKDGTIRVVFDGVNPSGVR VASFGVPTEQELARDYLWRVHQQVPRKGELVIFNRSHYEDVLVVRVKNLV PQQVWQKRYRHIREFERMLADEGTTILKFFLHISKDEQRQRLQERLDNPE KRWKFRMGDLEDRRLWDRYQEAYEAAIRETSTEYAPWYVIPANKNWYRNW LVSHILVETLEGLAMQYPQPETASEKIVIE Meiothermus silvanus DSM 9946 PPK2 (SEQ ID NO: 3) MAKTIGATLNLQDIDPRSTPGFNGDKEKALALLEKLTARLDELQEQLYAE HQHRVLVILQGMDTSGKDGTIRHVFKNVDPLGVRVVAFKAPTPPELERDY LWRVHQHVPANGELVIFNRSHYEDVLVARVHNLVPPAIWSRRYDHINAFE KMLVDEGTTVLKFFLHISKEEQKKRLLERLVEADKHWKFDPQDLVERGYW EDYMEAYQDVLDKTHTQYAPWHVIPADRKWYRNLQVSRLLVEALEGLRMK YPRPKLNIPRLKSELEKM Thermosynechococcus elongatus BP-1 PPK2 (SEQ ID NO: 4) MIPQDFLDEINPDRYIVPAGGNFHWKDYDPGDTAGLKSKVEAQELLAAGI KKLAAYQDVLYAQNIYGLLIIFQAMDAAGKDSTIKHVMSGLNPQACRVYS FKAPSAEELDHDFLWRANRALPERGCIGIFNRSYYEEVLVVRVHPDLLNR QQLPPETKTKHIWKERFEDINHYERYLTRNGILILKFFLHISKAEQKKRF LERISRPEKNWKFSIEDVRDRAHWDDYQQAYADVFRHTSTKWAPWHIIPA NHKWFARLMVAHFIYQKLASLNLHYPMLSEAHREQLLEAKALLENEPDED Anaerolinea thermophila UNI-1 PPK2 (SEQ ID NO: 5) MGEAMERYFIKPGEKVRLKDWSPDPPKDFEGDKESTRAAVAELNRKLEVL QERLYAERKHKVLVILQGMDTSGKDGVIRSVFEGVNPQGVKVANFKVPTQ EELDHDYLWRVHKVVPGKGEIVIFNRSHYEDVLVVRVHNLVPPEVWKKRY EQINQFERLLHETGTTILKFFLFISREEQKQRLLERLADPAKHWKFNPGD LKERALWEEYEKAYEDVLSRTSTEYAPWILVPADKKWYRDWVISRVLVET LEGLEIQLPPPLADAETYRRQLLEEDAPESR Caldilinea aerophila DSM 14535 PPK2 (SEQ ID NO: 6) MDVDRYRVPPGSTIHLSQWPPDDRSLYEGDKKQGKQDLSALNRRLETLQE LLYAEGKHKVLIILQGMDTSGKDGVIRHVFNGVNPQGVKVASFKVPTAVE LAHDFLWRIHRQTPGSGEIVIFNRSHYEDVLVVRVHGLVPPEVWARRYEH INAFEKLLVDEGTTILKFFLHISKEEQRQRLLERLEMPEKRWKFSVGDLA ERKRWDEYMAAYEAVLSKTSTEYAPWYIVPSDRKWYRNLVISHVIINALE GLNMRYPQPEDIAFDTIVIE Chlorobaculum tepidum TLS PPK2 (SEQ ID NO: 7) MKLDLDAFRIQPGKKPNLAKRPTRIDPVYRSKGEYHELLANHVAELSKLQ NVLYADNRYAILLIFQAMDAAGKDSAIKHVMSGVNPQGCQVYSFKHPSAT ELEHDFLWRTNCVLPERGRIGIFNRSYYEEVLVVRVHPEILEMQNIPHNL AHNGKVWDHRYRSIVSHEQHLHCNGTRIVKFYLHLSKEEQRKRFLERIDD PNKNWKFSTADLEERKFWDQYMEAYESCLQETSTKDSPWFAVPADDKKNA RLIVSRIVLDTLESLNLKYPEPSPERRKELLDIRKRLENPENGK Oceanithermus profundus DSM 14977 PPK2 (SEQ ID NO: 8) MDVSRYRVPPGSGFDPEAWPTREDDDFAGGKKEAKKELARLAVRLGELQA RLYAEGRQALLIVLQGMDTAGKDGTIRHVFRAVNPQGVRVTSFKKPTALE LAHDYLWRVHRHAPARGEIGIFNRSHYEDVLVVRVHELVPPEVWGRRYDH INAFERLLADEGTRIVKFFLHISKDEQKRRLEARLENPRKHWKFNPADLS ERARWGDYAAAYAEALSRTSSDRAPWYAVPADRKWQRNRIVAQVLVDALE AMDPRFPRVDFDPASVRVE Roseiflexus castenholzii DSM 13941 PPK2 (SEQ ID NO: 9) MYAQRVVPGMRVRLHDIDPDANGGLNKDEGRARFAELNAELDVMQEELYA AGIHALLLILQGMDTAGKDGAIRNVMLNLNPQGCRVESFKVPTEEELAHD FLWRVHRVVPRKGMVGVFNRSHYEDVLVVRVHSLVPESVWRARYDQINAF ERLLADTGTIIVKCFLHISKEEQEQRLLARERDVSKAWKLSAGDWRERAF WDDYMAAYEEALTRCSTDYAPWYIIPANRKWYRDLAISEALVETLRPYRD DWRRALDAMSRARRAELEAFRAEQHAMEGRPQGAGGVSRR Roseiflexus sp. RS-1 PPK2 (SEQ ID NO: 10) MHYAHTVIPGTQVRLRDIDPDASGGLTKDEGRERFASFNATLDAMQEELY AAGVHALLLILQGMDTAGKDGAIRNVMHNLNPQGCRVESFKVPTEEELAH DFLWRVHKVVPRKGMVGVFNRSHYEDVLVVRVHSLVPEHVWRARYDQINA FERLLTDTGTIIVKCFLHISKDEQEKRLLAREQDVTKAWKLSAGDWRERE RWDEYMAAYEEALTRCSTEYAPWYIIPANRKWYRDLAISEVLVETLRPYR DDWQRALDAMSQARLAELKAFRHQQTAGATRL Truepera radiovictrix DSM 17093 PPK2 (SEQ ID NO: 11) MSQGSAKGLGKLDKKVYARELALLQLELVKLQGWIKAQGLKVVVLFEGRD AAGKGSTITRITQPLNPRVCRVVALGAPTERERTQWYFQRYVHHLPAAGE MVLFDRSWYNRAGVERVMGFCTEAEYREFLHACPTFERLLLDAGIILIKY WFSVSAAEQERRMRRRNENPAKRWKLSPMDLEARARWVAYSKAKDAMFYH TDTKASPWYVVNAEDKRRAHLSCIAHLLSLIPYEDLTPPPLEMPPRDLAG ADEGYERPDKAHQTWVPDYVPPTR Thermus thermophilus Adk (SEQ ID NO: 12) MDVGQAVIFLGPPGAGKGTQASRLAQELGFKKLSTGDILRDHVARGTPLG ERVRPIMERGDLVPDDLILELIREELAERVIFDGFPRTLAQAEALDRLLS ETGTRLLGVVLVEVPEEELVRRILRRAELEGRSDDNEETVRRRLEVYREK TEPLVGYYEARGVLKRVDGLGTPDEVYARIRAALGI Thermus thermophilus Cmk (SEQ ID NO: 13) MRGIVTIDGPSASGKSSVARRVAAALGVPYLSSGLLYRAAAFLALRAGVD PGDEEGLLALLEGLGVRLLAQAEGNRVLADGEDLTSFLHTPEVDRVVSAV ARLPGVRAWVNRRLKEVPPPFVAEGRDMGTAVFPEAAHKFYLTASPEVRA WRRARERPQAYEEVLRDLLRRDERDKAQSAPAPDALVLDTGGMTLDEVVA WVLAHIRR Pyrococcus furiosus PyrH (SEQ ID NO: 14) MRIVFDIGGSVLVPENPDIDFIKEIAYQLTKVSEDHEVAVVVGGGKLARK YIEVAEKFNSSETFKDFIGIQITRANAMLLIAALREKAYPVVVEDFWEAW KAVQLKKIPVMGGTHPGHTTDAVAALLAEFLKADLLVVITNVDGVYTADP KKDPTAKKIKKMKPEELLEIVGKGIEKAGSSSVIDPLAAKIIARSGIKTI VIGKEDAKDLFRVIKGDHNGTTIEP Thermotoga maritima Gmk (SEQ ID NO: 15) MKGQLFVICGPSGAGKTSIIKEVLKRLDNVVFSVSCTTRPKRPHEEDGKD YFFITEEEFLKRVERGEFLEWARVHGHLYGTLRSFVESHINEGKDVVLDI DVQGALSVKKKYSNTVFIYVAPPSYADLRERILKRGTEKEADVLVRLENA KWELMFMDEFDYIVVNENLEDAVEMVVSIVRSERAKVTRNQDKIERFKME VKGWKKL Aquifex aeolicus Ndk (SEQ ID NO: 16) MAVERTLIIVKPDAMEKGALGKILDRFIQEGFQIKALKMFRFTPEKAGEF YYVHRERPFFQELVEFMSSGPVVAAVLEGEDAIKRVREIIGPTDSEEARK VAPNSIRAQFGTDKGKNAIHASDSPESAQYEICFIFSGLEIV

All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.

The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

The terms “about” and “substantially” preceding a numerical value mean±10% of the recited numerical value.

Where a range of values is provided, each value between the upper and lower ends of the range are specifically contemplated and described herein. 

1. A method for producing one or more nucleoside triphosphates (NTPs), comprising: incubating in a reaction mixture one or more nucleoside monophosphates (NMPs), at least one polyphosphate kinase (PPK), and polyphosphate.
 2. (canceled)
 3. The method of claim 1 further comprising: incubating in a reaction mixture cellular ribonucleic acid (RNA) and (a) a polynucleotide phosphorylase (PNPase) and inorganic phosphate; and/or (b) a ribonuclease. 4.-8. (canceled)
 9. The method of claim 1, wherein the polyphosphate kinase is selected from PPK1 and PPK2 family enzymes. 10-26. (canceled)
 27. The method of claim 1 further comprising at least one NMP kinase and/or NDP kinase.
 28. The method of claim 1, wherein the at least one PPK is a Class III PPK2 enzyme from Deinococcus geothermalis (SEQ ID NO: 1).
 29. The method of claim 1, wherein the method is a cell-free method.
 30. The method of claim 1, wherein the one or more NMPs comprise AMP, GMP, CMP, and/or UMP.
 31. The method of claim 1, wherein the one or more NMPs comprise modified nucleoside monophosphates.
 32. The method of claim 1, wherein the polyphosphate is selected from the group consisting of tetrapolyphosphates, pentapolyphosphates, and hexametaphosphates.
 33. The method of claim 27, wherein: (i) the at least one NMP kinase is an AMP kinase, a GMP kinase, a CMP kinase, and/or a UMP kinase; and/or (ii) the at least one NDP kinase is an ADP kinase, a GDP kinase, a CDP kinase, or a UDP kinase.
 34. The method of claim 27, wherein: (i) the at least one NMP kinase is AMP kinase from Thermus thermophilus (SEQ ID NO: 12), CMP kinase from Thermus thermophilus (SEQ ID NO: 13), UMP kinase from Pyrococcus furiosus (SEQ ID NO: 14), and/or GMP kinase from Thermotoga maritima (SEQ ID NO: 15); and/or (ii) the at least one NDP kinase is from Aquifex aeolicus (SEQ ID NO: 16).
 35. A method for producing one or more nucleoside triphosphates (NTPs), comprising: incubating in a reaction mixture one or more nucleoside diphosphates (NDPs), at least one polyphosphate kinase, and polyphosphate.
 36. A method for producing nucleoside triphosphates (NTPs) comprising: (a) incubating (i) cellular RNA and (ii) a ribonuclease to produce 5′ nucleoside monophosphates (NMPs); (b) eliminating the ribonuclease; and (c) incubating the 5′ NMPs with at least one polyphosphate kinase (PPK), and polyphosphate to produce NTPs.
 37. The method of claim 36, wherein step (c) further comprises at least one NMP kinase and/or at least one NDP kinase.
 38. The method of claim 36, wherein the cellular RNA comprises ribosomal RNA, messenger RNA, and/or transfer RNA.
 39. The method of claim 36, wherein the ribonuclease is Nuclease P1 or RNase R.
 40. The method of claim 36, wherein the ribonuclease is eliminated via temperature, pH, salt, detergent, alcohol, chemical inhibitors, separation, precipitation, filtration, capture, and/or chromatography.
 41. The method of claim 37, wherein: (i) the at least one NMP kinase is an AMP kinase, a GMP kinase, a CMP kinase, and/or a UMP kinase; and/or (ii) the at least one NDP kinase is an ADP kinase, a GDP kinase, a CDP kinase, or a UDP kinase.
 42. The method of claim 37, wherein: (i) the at least one NMP kinase is AMP kinase from Thermus thermophilus (SEQ ID NO: 12), CMP kinase from Thermus thermophilus (SEQ ID NO: 13), UMP kinase from Pyrococcus furiosus (SEQ ID NO: 14), and/or GMP kinase from Thermotoga maritima (SEQ ID NO: 15); and/or (ii) the at least one NDP kinase is from Aquifex aeolicus (SEQ ID NO: 16).
 43. The method of claim 36, wherein the at least one PPK is a PPK1 family enzyme or a PPK2 family enzyme.
 44. The method of claim 36, wherein the at least one PPK is a Class III PPK2 enzyme from Deinococcus geothermalis (SEQ ID NO: 1).
 45. The method of claim 36, wherein the polyphosphate is selected from the group consisting of tertapolyphosphates, pentapolyphosphates, and hexametaphosphates.
 46. The method of claim 37, wherein step (c) comprises an enzyme preparation or cell lysate obtained from cells that produce the PPK, the NMP kinase, and/or the NDP kinase.
 47. The method of claim 46, wherein the activity of native enzymes in the cells has been eliminated via genetic modification, enzyme secretion from a cell, protease targeting, temperature, pH, salt, detergent, alcohol, chemical inhibitors, separation, precipitation, filtration, capture, and/or chromatography.
 48. The method of claim 47, wherein the native enzymes are selected from the group consisting of phosphatases, nucleases, proteases, deaminases, oxidoreductases, and hydrolases.
 49. The method of claim 1, further comprising: incubating in a reaction mixture cellular ribonucleic acid (RNA), a polynucleotide phosphorylase (PNPase), inorganic phosphate, and a helicase. 